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1. Introduction
1.1 About DANMAP
 
Antimicrobial resistance is considered a major threat to 
human health. While antimicrobial agents are essential for 
treating disease in humans and in animals, they are also the 
main contributors to the selection and spread of antimicro-
bial  resistance. It is, therefore, essential to monitor trends in 
consumption of antimicrobial agents and antimicrobial resis-
tance in order to identify the risk factors that contribute to the 
dissemination of resistance as well as the interaction between 
the risk factors.
Humans and animals constitute overlapping reservoirs of 
resistance and an integrated approach that takes this into ac-
count is therefore needed. The Danish Integrated Antimicrobial 
Resistance Monitoring and Research Programme, DANMAP, has 
implemented the One Health approach, comprising the entire 
chain from farm to fork to sickbed, since 1995. The organisa-
tion and collection of DANMAP data is presented in Figure 1.1.
DANMAP was established at the initiative of the Danish 
Ministry of Health and the Danish Ministry of Food, Agriculture 
and Fisheries. The programme participants are the National 
Food Institute and the National Veterinary Institute, both at 
the Technical University of Denmark (DTU), as well as Statens 
Serum Institut (SSI). The DANMAP programme is funded jointly 
by the Ministry of Health, the Ministry of Higher Education and 
Science, and the Ministry of Environment and Food.
The objectives of DANMAP are:
• to monitor the consumption of antimicrobial agents in food 
animals and humans;
• to monitor the occurrence of antimicrobial resistance in bac-
teria isolated from food animals, food of animal origin (e.g. 
meat) and humans;
• to study associations between antimicrobial consumption 
and antimicrobial resistance; and
• to identify routes of transmission and areas for further 
research studies. 
The monitoring of antimicrobial resistance is based on three 
categories of bacteria:
• Human and animal pathogens that cause infections and are 
thought to reflect resistance caused by the use of antimicro-
bial agents in the respective reservoirs;
• Zoonotic bacteria that can develop resistance in the animal 
reservoir, which may subsequently compromise treatment 
outcome when causing infection in humans;
• Indicator bacteria (enterococci and E. coli) due to their ubiq-
uitous nature in animals, food and humans, and their ability 
to readily develop or transfer antimicrobial resistance in 
response to selective pressure in both reservoirs.
 
All pathogens may be considered reservoirs of resistance de-
terminants – genes – that may be disseminated independently 
of the bacterial hosts.
Public health risks
Bacteria become resistant either by spontaneous mutation or by transfer of resistance genes from other bacteria. Resistant 
strains are favoured when use of antimicrobial agents provide a selective pressure. This occurs in humans as well as in animals 
undergoing antimicrobial treatment. Resistant bacteria can spread between humans in the community, at healthcare centres 
and at hospitals. Furthermore, resistant bacteria from animals can be transmitted to humans either through direct contact with 
animals and their environment or through ingestion of contaminated food or other contaminated vehicles.
Antimicrobial treatment failure may occur if the ingested resistant bacteria are a direct cause of disease, or if resistance 
determinants are transferred to pathogenic bacteria causing the disease. Bacteria may be resistant to several – sometimes all – 
antimicrobial agents available for treatment, leading to life-threatening illness.
Currently, there is only a limited number of antimicrobial agents, with novel modes of actions, under development by the phar-
maceutical industry. Therefore, it is vital for public health organisations to ensure the continued effectiveness of compounds 
considered critically important to human treatment by ensuring prudent use for both humans and animals.
Prudent use should include the restriction of critical antimicrobial agents for use in humans only, as well as the elimination of 
overuse, i.e. only humans and animals suffering from an infection responsive to antimicrobial treatment should be exposed to 
antimicrobial agents.
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A web annex presenting minimum inhibitory concentration 
(MIC) distributions, detailed tables of antimicrobial consump-
tion and other additional data are available for download at 
www.danmap.org. Current and previous DANMAP reports are 
also available at the website (PDF versions).
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2. Summary
2.1 Sammendrag
 
DANMAP (Danish Antimicrobial Resistance Monitoring and 
Research Program) har siden 1995 beskrevet det årlige forbrug 
af antibiotika og forekomsten af antibiotikaresistens hos dyr 
og mennesker i Danmark. Denne udgave beskriver udviklingen 
i 2014.
Antibiotikaforbrug til dyr
Siden 2001 er al anvendelse af receptordineret medicin til dyr 
registreret i det offentlige register VetStat.
I 2014 blev der brugt 114 ton antibiotika (aktivt stof) til 
dyr i Danmark. Fordelt på dyrearter stod svin for ca. 76 % af 
 antibiotikaforbruget, kvæg for 11 %, akvakultur for 4 %, pels-
dyr for 4 %, fjerkræ for 1 % og kæledyr, heste og andre dyr for 
de resterende 4 %. Det totale forbrug (kg aktivt stof) til dyr var 
2 % lavere i 2014 end i 2013.
De overordnede ændringer i antibiotikaforbruget til dyr styres 
primært af ændringer i forbrugsmønstret til svin. Svineproduk-
tionen står for 86 % af den danske kødproduktion, men kun  
43 % af den totale levende biomasse.
Svin. Det totale antibiotikaforbrug til svin i 2014 var på ca. 86 
ton aktivt stof, hvilket i forhold til 2013 udgør et fald på næ-
sten 5 ton. Dette svarer til et fald på 5 % når forbruget udreg-
nes i DAPD og der justeres for eksport. Enheden DAPD anslår 
andelen af en population (i tusinder), som dagligt behandles 
med en standarddosis antibiotikum. Reduktionen i antibio-
tikaforbrug (DAPD) til svin skyldtes især et fald i forbruget af 
tetracykliner, men også i forbruget af pleuromutiliner og ma-
krolider. Pleuromutiliner og tetracykliner tilsættes primært til 
foder eller vand i forbindelse med mave-tarm lidelser. I svin var 
forbruget af 3. og 4. generations cefalosporiner fortsat meget 
lavt (4 kg), hvilket er et resultat af, at svinebranchen i 2010 
frivilligt indførte stop for brugen af disse stoffer. Forbruget af 
fluorkinoloner var også meget lavt (4 kg), hvilket det har været 
siden 2003, hvor lovgivning om begrænsning af fluorkinolon-
forbruget trådte i kraft. 
Kvæg. Forbruget til kvæg har været faldende i nogle år (14 % 
i perioden 2010 til 2013), men i 2014 steg forbruget med 8 % 
fra 12 ton i 2013 til 13 ton i 2014. Målt i standard doser (DADD) 
steg forbruget til golddyrsbehandling med 12 %, hvorimod 
antallet af DADD til behandling af klinisk mastitis faldt med  
2 % i forhold til 2013. Forbruget af beta-laktamase følsomme 
penicilliner udgjorde som tidligere år størstedelen af forbruget. 
Forbruget af fluorkinoloner, som er et af de kritisk vigtige anti-
biotika til human behandling, har siden 2003 været stort set nul. 
Sammenlignet med 2013 faldt forbruget af 3. og 4. generations 
cefalosporiner til systemisk behandling med 27%. 
Fjerkræ. Antibiotikaforbruget til fjerkræ var cirka 1.548 kg 
aktivt stof i 2014, hvilket er 22 % højere end i 2013. Stig-
ningen i antibiotikaforbrug skyldtes især en stigning i forbru-
get af tetracykliner, men også i forbruget af bredspektrede 
penicilliner. Der er flere forklaringer på stigningen i forbruget, 
herunder øget forekomst af diarre og ledinfektioner i slagte-
kyllingeproduktionen, og en fortsat høj forekomst af luftvejsli-
delser i kalkunflokke. Forbruget af fluorkinoloner i den danske 
fjerkræproduktion, inklusiv avl og opdræt, har været meget 
lavt siden 2006, og der er ikke rapporteret brug af cefalospori-
ner til fjerkræ i over 10 år.
Fisk. Det totale antibiotikaforbrug til fisk i akvakultur var på 
5.116 kg aktivt stof i 2014, en generel stigning på 43 % i 
forhold til 2013. Som i 2013, var sommeren 2014 også præget 
af ekstraordinært høje vandtemperaturer, hvilket igen med-
førte øget forekomst af bakterielle infektioner i forhold til de 
foregående år. Branchen har fortsat fokus på udvikling af nye 
vacciner og forbedrede vaccinationsstrategier for at begrænse 
brugen af antibiotika.
Pelsdyr. I både 2013 og 2014 er forbruget af antibiotika til 
pelsdyr (mink) faldet. I 2014 blev der brugt 4.202 kg aktivt 
stof, hvilket var 14 % mindre end året før. Forbruget af fluo-
rkinoloner og cephalosporiner har været tæt på nul i flere år. 
En mulig forklaring på faldet i antibiotikaforbrug kan være det 
øgede fokus branche, dyrlæger og producenter har haft på at 
forbedre foderkvalitet og dyrevelfærd samt at reducere 
antibiotikaforbruget. 
Kæledyr og heste. Oplysningerne i VetStat om antibiotikafor-
brug til kæledyr og heste er mindre detaljerede end oplysnin-
gerne vedrørende produktionsdyr. I 2014 var forbruget stort 
set på samme niveau som i 2013 (1.989 kg i 2013, 2.017 kg i 
2014). Forbruget af kritisk vigtige antibiotika som cefalospori-
ner og fluorkinoloner faldt igen i 2014. Derimod steg forbruget 
af flere grupper af antibiotika, herunder aminoglycosider, ma-
krolider, penicilliner (beta-laktamase følsomme), sulfonamider, 
trimethoprim og tetracykliner. Det let ændrede forbrugsmøn-
ster til kæledyr kan være et resultat af den antibiotikavejled-
ning for familiedyr, som blev udgivet af Dyrlægeforeningen 
i 2012. Forbruget af kritisk vigtige antibiotika er dog stadig 
relativt højt i kæledyr sammenlignet med forbruget i produkti-
onsdyr og giver fortsat anledning til øget bevågenhed.
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Antibiotikaforbrug til mennesker 
Forbruget af receptordineret medicin på patientniveau er ble-
vet overvåget siden begyndelsen af 1990erne med etablering 
af Lægemiddelstyrelsens Lægemiddelstatistikregister i 1994.
I DANMAP rapporten 2014 er for første gang medtaget det 
perorale forbrug af metronidazol (P01AB01) og vancomycin 
(A07AA09). Totale forbrugstal samt forbrug i henholdsvis 
hospitals- og primærsektor er samtidig justeret fra 2005 og 
frem.  Disse antibiotika har ikke tidligere været medtaget da 
forbruget ikke klassificeres i ATC-gruppen systemiske anti-
infektiva (J01), men som henholdsvis antiparasitære (P01) 
og intestinale (A07) midler. Peroral metronidazol udgør en 
væsentlig del af den anaerobe antibiotiske behandling og af 
behandlingen af infektioner med Clostridium difficile. Peroral 
vancomycin anvendes ligeledes til behandlingen af infektioner 
med Clostridium difficile.
Totalforbrug. I 2014 faldt det totale humane forbrug af 
antibiotika til systemisk brug (primærsektoren og hospitalssek-
toren sammenlagt) med 3 % eller 0,5 DDD pr 1000 indbyggere 
pr dag (DID), 18,58 DID i 2014 sammenholdt med 19,10 DID i 
2013. Primærsektoren udgjorde 90 % af forbruget og faldet i 
det totale forbrug skyldtes især et fald i forbruget af tetracyk-
liner på 0,3 DID (se nedenfor). I 2011, hvor det højeste totale 
forbrug nogensinde blev observeret, var forbruget på 19,31 
DID, en stigning fra 1997 på næsten 40 %.
Fra 2005 til 2014 er det totale forbrug af antibiotika i Dan-
mark steget med 1,86 DID (11 %). Samlet set blev der i 2014 
brugt 52.819 kg aktiv substans.
Primærsektor. Det totale antibiotikaforbrug i primærsektoren 
udgjorde i 2014 16,40 DID (16,95 DID i 2013). Det mest mar-
kante fald i forbrug var som anført blandt tetracyklinerne (fra 
1,96 DID i 2013 til 1,66 DID i 2014); dette fald skyldes dog 
primært store ændringer i forbruget af doxycyklin, der havde 
en uventet top i 2013 men i 2014 faldt tilbage til tidligere 
niveau. 
Som i de tidligere år udgjorde beta-laktamase følsomme peni-
cilliner den største gruppe af antibiotika (27 %), efterfulgt af 
penicilliner med udvidet spektrum (22 %), makrolider (11 %), 
tetracykliner (10 %) og kombinationspenicilliner og beta-lakta-
mase resistente penicilliner (begge 8 %). Penicilliner udgjorde 
samlet 65 % af forbruget. Fluorkinoloner (primært ciprofloxa-
cin) udgjorde 3 % af forbruget. 
Fra 2013 til 2014 faldt forbruget af beta-laktamase sensitive 
penicilliner fra 4,65 DID til 4.38 DID (6 %). Forbruget af kom-
binationspenicilliner og beta-laktamase resistente penicil-
liner øgedes i samme periode, fra hhv. 1,22 DID til 1,30 DID (7 
%) og fra 1,30 DID til 1,36 DID (5 %), hvilket ligger i tråd med 
det stigende forbrug, der er observeret over de sidste 10 år. 
Stigninger i forbruget af kombinationspenicilliner kan forkla-
res med ændrede retningslinjer for behandling af lungein-
fektioner hos patienter med kronisk obstruktiv lungesygdom 
(KOL), men der ses et samlet øget forbrug, også blandt andre 
patient- og aldersgrupper. Dette forsøges nærmere belyst 
over de næste år. 
Forbruget af fluorquinoloner fortsatte den svagt faldende 
tendens, der er observeret over de sidste 3 år (fra 0,57 DID i 
2011 til 0,50 DID i 2014). 
Forbruget af trimethoprim, sulfonamider og nitrofurantoin 
forblev uændret. 
I det seneste årti er forbruget af antibiotika i primærsektoren 
steget med 10 %, fra 14,96 DID i 2005 til 16,40 DID i 2014, 
dog kan denne udvikling opdeles i et støt stigende forbrug 
frem til 2011, hvorefter forbruget nu er stagneret. Stigningen 
skyldes sandsynligvis til dels et øget antal DDD (definerede 
dagsdoser) pr behandlet patient og et øget antal DDD pr 
udskrevet medicinpakning. Sidstnævnte kan afspejle ændrede 
retningslinjer for behandling af infektioner gående mod kor-
tere behandlingstider med højere doser. 
Hospitaler. På somatiske hospitaler steg antibiotikaforbruget 
når det blev opgjort i DDD pr 100 sengedage (DBD): fra 99,88 
DBD i 2013 til 104,30 i 2014 (4 %). Fra 2005 til 2014 steg 
det totale antibiotikaforbrug med 57 % (fra 66,32 DBD). Denne 
stigning skyldes en kombination af stigning i DDD og et fald i 
antallet af sengedage. 
Gruppen af penicilliner udgjorde 50 % af det samlede hospi-
talsforbrug, heraf penicilliner med udvidet spektrum 16 % og 
kombinationspenicilliner 15 %.  2.generations cefalosporiner 
og fluorkinoloner udgjorde hhv. 11 % og 9 %.  
Fra 2013 til 2014 steg forbruget af kombinationspenicilliner 
fra 13,64 DBD til 16,04 DBD (18 %). Denne kraftige stigning 
kan forklares med at Piperacillin/tazobactam er blevet en 
væsentlig del af den empiriske sepsisbehandling på de fleste 
hospitaler. Penicilliner med udvidet spektrum øgedes fra 15,06 
DBD til 16,40 DBD (9 %) og imidazol-derivater fra 4,08 DBD til 
4,48 DBD (9 %), mens der sås et fald i forbruget af 2. generati-
ons cefalosporiner (cefuroxim) fra 12,31 DBD til 11,68 DBD (5 
%). Forbruget af beta-laktamase følsomme penicilliner (totalt 
10,31 DBD), beta-laktamase resistente penicilliner (9,57 DBD), 
Antibiotikaforbruget til dyr faldt med 2 % i 2014. Det 
totale forbrug til svin, målt i kg aktivt stof såvel som 
beregnet i DAPD, faldt med 5 %. Brugen af kritisk 
vigtige antibiotika i den danske svineproduktion er 
fortsat lav. Brugen af især kritisk vigtige antibiotika 
til kæledyr er forholdsmæssigt højt sammenlignet 
med forbruget til produktionsdyr, dog er forbruget af 
disse stoffer til kæledyr faldet i både 2013 og 2014. 
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carbapenemer (totalt 4,09 DBD) og fluorkinoloner (totalt 9,88 
DBD) ændredes ikke væsentligt. 
De største ændringer over tid, der er observeret på hospita-
lerne er i forbruget af de forskellige typer penicilliner: Mens 
forbruget af beta-laktamase sensitive penicilliner er faldet 
markant siden 2005 fra 12,17 DBD til 10,31 DBD (15 %) er 
forbruget af kombinationspenicilliner mere end tidoblet, fra 
1,16 DBD til 16,04 DBD. Kombinationspenicilliner udgør nu den 
andenstørste gruppe af antibiotika i hospitalssektoren sva-
rende til 15 % af forbruget. 
De væsentligste ændringer i antibiotikaforbruget på hospita-
lerne skyldes formentlig indførelse af nye lokale retningslinjer 
vedrørende antibiotisk behandling af sepsis, der på de fleste 
hospitaler har medført et skift fra cefalosporiner som første-
valgs præparat til et beta-laktam (evt i kombination med 
gentamicin). Disse retningslinjer følger Sundhedsstyrelsens 
anbefalinger om et reduceret forbrug af cefalosporiner. Derud-
over er der lanceret nye retningslinjer for behandling af KOL, 
hvor amoxicillin med clavulansyre nu er førstevalg.
I 2014 udgjorde det totale antibiotikaforbrug til 
mennesker 18,58 DID, et fald på 3 % sammenlignet 
med 2013. Dette er primært betinget af ændringer 
i forbruget af tetracykliner i primærsektoren. Siden 
2005 er det totale antibiotikaforbrug steget med 
11 %, den største stigning blev observeret frem til 
2011 (hvor det totale forbrug var på 19,31 DID), 
siden er forbruget stagneret. De største ændringer 
i forbruget over tid er observeret i gruppen af peni-
cilliner, hvor forbruget af kombinationspenicilliner i 
begge sektorer er steget markant over det sidste årti, 
mens forbruget af beta-laktamase følsomme penicil-
liner er faldet. Dette fald ses især i primærsektoren. 
Kombinationspenicilliner udgør nu den andenstørste 
gruppe af antibiotika på hospitalerne (15 %) og er 
blandt de største grupper i primær sektoren (8 %). 
Resistens i zoonotiske bakterier
Zoonotiske bakterier som Salmonella og Campylobacter er 
sygdomsfremkaldende bakterier, som kan overføres fra dyr til 
mennesker. Udvikles der resistens i disse bakterier i husdyrpro-
duktionen, kan resistens overføres til mennesker via fødevarer, 
og kan i visse tilfælde medføre behandlingssvigt ved sygdom.
EU Harmonisering af resistensovervågningen
I 2014 blev antibiotikapanelerne, som anvendes til at 
undersøge for resistens, ændret i henhold til Europa Kom-
missionens afgørelse om gennemførelse af en koordineret 
kontrolplan for overvågning af antimikrobiel resistens hos 
zoonotiske agenser [Decision 2013/653/EU]. For Salmonella, 
Campylobacter, og indikator E. coli og Enterococcus betyder 
det, at flere af panelernes antibiotika blev skiftet ud. Dette 
skete for at prioritere resistensundersøgelser for de antibio-
tika, som anses for at have størst relevans for folkesund-
heden: Herunder screening for carbepenemase-enzymer i 
Salmonella og E. coli. Som konsekvens af ændringerne kan 
opgørelser af multiresistensresultater og fuldt følsomme iso-
later i 2014 ikke umiddelbart sammenlignes med resultater 
fra tidligere år.
Salmonella Typhimurium er en af de mest almindeligt fore-
kommende serotyper i danske svin, dansk svinekød såvel som 
i humane Salmonella infektioner. Blandt svin var 66 - 70 % af 
isolaterne resistente overfor ampicillin, sulfonamid og tetra-
cyklin, og forekomsten af resistens overfor disse antibiotika 
er steget over de sidste fem år. Dette kan primært tilskrives 
den stigende forekomst af monofasiske varianter, som ofte er 
multiresistente. I 2014, var 56 % af de undersøgte S. Typhimu-
rium isolater fra svin monofasiske. Generelt var forekomsten af 
multiresistens blandt S. Typhimurium isolater fra danske svin 
på 64 %. Dette er højere end i samlet set alle Salmonella typer 
(Salmonella spp.), hvor 32 % var multiresistente i 2014. Der 
blev fundet Salmonella i 22 % af raske svin, og det estimeres 
at 7 % af svinene havde multiresistent Salmonella. Også i prø-
ver fra dansk svinekød var forekomsten af resistens blandt S. 
Typhimurium isolater høj. Som i de foregående år blev der ikke 
påvist resistens overfor cefalosporiner (ceftiofur og cefotaxim) 
eller kinoloner (ciprofloxacin og nalidixansyre) blandt Salmo-
nella isolater fra svin eller dansk svinekød.
Ligesom for svin og svinekød, er der de seneste fem år sket en 
stigning i den relative forekomst af monofasiske S. Typhimuri-
um varianter blandt isolater fra patienter, som havde erhvervet 
infektionen i Danmark (både sporadiske og udbrudstilfælde).  I 
2014 blev der påvist multiresistens i 48 % af S.  Typhimurium 
isolater fra sporadiske tilfælde erhvervet i Danmark, og resi-
stens niveauet var generelt på niveau med 2013. I tidligere 
år har forekomsten af resistens været højere i isolater fra 
patienter med rejserelaterede infektioner sammenlignet med 
infektioner erhvervet i Danmark. I 2014 derimod, var det kun 
forekomsten af kinolonresistens (ciprofloxacin og nalidixan-
syre) som var højere i de rejserelaterede infektioner.
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I alt syv S. Typhimurium isolater (2 % af tilfældene) var resi-
stente overfor 3. generations cefalosporiner (cefotaxime og/
eller ceftazidime) og disse isolater var også resistente overfor 
ciprofloxacin. Co-resistens med ciprofloxacin og 3. generations 
cefalosporiner giver anledning til øget bevågenhed, da disse to 
antibiotika anses for kritisk vigtige for behandling af alvorlige 
Salmonella infektioner. 
Ingen af de resistensbestemte Salmonella isolater fra dyr, kød 
eller mennesker udviste carbapenemase aktivitet (meropenem 
resistens).
Forekomsten af monofasiske Salmonella Typhimurium, 
som ofte er multiresistente, er steget i svin, svinekød 
og blandt humane infektioner de seneste fem år. 
Resistensforekomsten har, blandt de humane infek-
tioner erhvervet herhjemme, ligget stabilt højt de se-
neste fire år (50 – 60 %). I 2014 var det udelukkende 
forekomst af kinolon-resistens som var højere blandt 
de humane infektioner erhvervet i udlandet.
I 2014 var resistensforekomsten i Campylobacter jejuni isolater 
fra kyllinger og kvæg på samme niveau som de seneste fem år. 
Der ses generelt lav til moderat forekomst af resistens og stør-
stedelen (74 - 81 %) af isolaterne var fuldt følsomme overfor alle 
seks antibiotika i testpanelet. Set i en europæisk sammenhæng 
er resistensforekomsten i C. jejuni fra danske slagtekyllinger og 
kyllingekød samt C. coli fra svin blandt Europas laveste.
I flere år har forekomsten af fluorkinolon resistens i C. jejuni 
været højere blandt isolater fra importeret kyllingekød (82 
%) end fra dansk kyllingekød (15 %), og forskellen på det 
importerede og det danske kød er blevet mere udtalt.
Som i de foregående år var forekomsten af fluorkinolon resistens 
i C. jejuni isolater fra patienter med rejse-relaterede infektioner 
(81 %) højere end i isolater fra patienter, hvor infektionen var 
erhvervet i Danmark (35 %).
Fluorkinolon resistens i C. jejuni er fortsat højere 
blandt isolater fra importeret kyllingekød sammen-
lignet med dansk kyllingekød, og blandt C. jejuni fra 
patienter med rejse-relaterede infektioner i forhold til 
patienter, hvor infektionen var erhvervet i Danmark. 
Resistens i indikatorbakterier
Indikatorbakterier er inkluderet i DANMAP overvågningen for 
at kunne give et indblik i den generelle forekomst af resistens i 
raske husdyr og i kød. 
Blandt Enterococcus faecalis isolater fra danske slagtekyllin-
ger og kyllingekød blev der fundet moderate til høje forekom-
ster af tetracyklin resistens (henholdsvis 49 % og 35 %) og 
erythromycin resistens (henholdsvis 27 % og 19 %). Derimod 
var der meget lidt resistens for de øvrige antibiotika i test-
panelerne. I E. faecium isolater fra importeret kyllingekød, var 
resistensen generelt højere end i det danske kyllingekød.
 
Der blev fundet højere forekomst af resistens blandt isolater 
fra svin end fra slagtekyllinger, hvilket sandsynligvis afspejler 
antibiotikaforbrugsmønstrene til disse dyrearter. Blandt E. 
faecalis isolater fra svin var der højest forekomst af resistens 
for tetracyklin (83 %) og erythromycin (49 %).
Tetracykliner er og har været det mest anvendte antimikrobielle 
stof til danske svin i en årrække og har primært været brugt 
til behandling af E. coli infektioner. Forekomst af resistens var 
højere i importeret end i dansk produceret svinekød.
Generelt blev der fundet mindre resistens i E. faecium end i 
E. faecalis og forekomsten af resistens overfor kritisk vigtige 
antibiotika var lav. 
Resistens blandt Indikator Escherichia coli fra slagtekyllinger 
faldt for en lang række antibiotika; tetracyclin, ampicillin, tri-
methroprim og sulfonamid, uagtet at der har været en stigning 
af forbruget til slagtekyllinger de seneste år. Der blev påvist 
fluorkinolon (ciprofloxacin) resistens i 12 % af isolaterne. 
Resistensforekomsten i E. coli fra slagtekyllinger og dansk kyl-
lingekød var sammenlignelige. Resistens overfor 3. generati-
ons cefalosporiner (ceftiofur) blev fundet i et isolat fra danske 
slagtekyllinger, men ikke i kyllingekød. Resistensforekomsten 
i isolater fra kvæg og dansk oksekød var som det foregåede år 
ganske lav. Resistens i E. coli fra svin var den højeste blandt 
produktionsdyrene for ampicillin, sulfonamid og tetracyklin (33 
– 37 %) og forblev på samme høje niveau som i 2012 og 2013.
Blandt isolaterne fra kød, var der generelt højere resistensfore-
komst blandt isolaterne fra importeret kyllingekød, også når det 
gjaldt de kritisk vigtige antibiotika.  Sammenlignet med dansk 
kyllingekød havde E. coli isolater fra importeret kyllingekød 
højere resistens overfor 6 af de 13 testede antibiotika. I E. coli 
isolater fra dansk svinekød var resistensforekomsten lavere 
overfor kinoloner (ciprofloxacin og nalidixin syre) end i isolater 
fra importeret svinekød.
ESBL-producerende bakterier er et af de hurtigst voksende re-
sistensproblemer verden over. Flere nyere undersøgelser finder 
de samme ESBL gener, plasmider og kloner i E. coli isolater fra 
både dyr og mennesker, hvilket tyder på et zoonotisk link. 
Forekomsten af enterobakterier, der er resistente overfor car-
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bapenemer, er også en voksende trussel, idet carbapenemer er 
blandt de få antibiotika, der kan behandle infektioner forårsaget 
af multiresistente Gram-negative bakterier i mennesker.
ESBL (ceftriaxon) resistens blev fundet i 9 % af E. coli isolater fra 
dansk kyllingekød og i 25 % af isolater fra importeret kyllingekød. 
Som i tidligere år er forekomsten generelt lav (< 1 %) i dansk og 
importeret okse- og svinekød.
Faldet i forekomsten af ESBL-producerende E. coli i dansk kyllin-
gekød fortsatte i 2014. For første gang blev der også set et sig-
nifikant fald i importeret kyllingekød. Dette skyldes sandsynligvis 
et frivilligt stop af brug af 3. generations cefalosporiner i toppen 
af avlspyramiden i udlandet, hvilket resulterer i at der overføres 
færre ESBL- producerende E. coli fra importerede forældredyr til 
de danske slagtekyllinger. I lighed med 2012 og 2013 var der i 
2014 stadig ingen fund af carbapenemase-producerende E. coli.
I 2014 var der et signifikant fald i forekomsten af 
ESBL-producerende E. coli i dansk kyllingekød, hvilket 
også ses i kyllingekød importeret fra udlandet  
(hovedsageligt fra EU lande) og sandsynligvis skyldes 
et frivilligt stop i brug af cefalosporiner i toppen af 
avlspyramiden i udlandet.
Resistens i bakterier fra diagnostiske indsendelser 
fra mennesker 
Rapporteringen af antibiotikaresistens i kliniske isolater fra 
mennesker er baseret på frivillig indrapportering af data fra 
de Klinisk Mikrobiologiske Afdelinger (KMA) i Danmark. Undta-
gelser omfatter methicillin-resistente Staphylococcus aureus 
(MRSA) og invasive Streptococcus pneumoniae, som er anmel-
depligtige. Data vedr. disse bakterier kommer fra referencela-
boratorierne på SSI.
Blandt Escherichia coli isolater fra blod var forekomsten 
af 3. generations cefalosporin resistens 7 % i 2014, hvilket 
har været stort set uændret siden 2010. I de andre nordiske 
lande var resistensen 5 - 6 % (EARS-Net 2013). Ciprofloxacin 
resistens var 12 %, det samme som i 2013. Den eneste signi-
fikante stigning, der blev observeret, var for piperacillin/tazo-
bactam, hvor resistensen steg fra 4 - 5 %. Mecillinam resistens 
var 8 %. I løbet af det seneste årti steg resistensen for genta-
micin (fra 2 - 7 %), men steg ikke signifikant fra 2012 til 2014, 
mens resistens for cefalosporiner og ciprofloxacin steg frem til 
hhv. 2009 og 2011, men siden har været faldende. Resistens 
for meropenem er fortsat < 1 %.
Blandt E. coli isolater fra urin fra patienter på hospital var 
forekomsten af ciprofloxacin resistens 11 % i 2014 mod 12 % 
i 2013. I 2005 var 5 % resistente. Resistensen for aminoglyko-
sid (gentamicin) og mecillinam forblev uændret (henholdsvis  
5 % og 7 %).
Blandt E. coli isolater fra urin fra patienter i almen praksis 
var forekomsten af ciprofloxacin resistens i 2014 9 %.
Hos 2.283 hospitalspatienter blev der i 2014 påvist en 3. ge-
nerations cefalosporin resistent E. coli i urinen. Dette svarer til 
6 %. Resistens mod 3.generations cefalosporiner i urin-isolater 
har siden den første registrering i 2008 svinget mellem 5 
og 6 %. Blandt E. coli urin-isolater fra patienter i praksis steg 
forekomsten af 3. generations cefalosporin resistens fra 3 % i 
de foregående fem år til 4 % i 2014. 
I 2014 blev der iværksat en frivillig overvågning af ESBL/
AmpC producerende E. coli fra blodinfektioner. I alt blev 261 
E. coli isolater hel-genom sekventeret. I 245 isolater blev der 
fundet gener der kodede for ESBL produktion og/eller carba-
penemase produktion. For 240 isolater var der oplysning om 
demografi; 53 % af patienterne var mænd og gennemsnits-
alderen var 70 år. Syvogtyve (11 %) af patienterne døde inden-
for 30 dage efter diagnosen.
Blandt de 245 isolater, blev der påvist 21 forskellige ESBL 
(inkluderende plasmid AmpC) gener og carbapenemaser. 
CTX-M-15 (49 %) var den hyppigste enzymtype, efterfulgt af 
CTX-M-14, CTX-M-27 og CTX-M-101. Forskellige varianter af 
CMY blev påvist i 7 % af isolaterne. Der blev påvist OXA-48 i et 
isolat og OXA-181 i to isolater.
De 245 isolater tilhørte 51 forskellige MLST typer, hvor ST131 
var den mest dominerende type (51 %), (Tekstboks 8.1).
Blandt Klebsiella pneumoniae isolater fra blod var forekom-
sten af 3. generations cefalosporin resistens 8 % i 2014 mod 
9 % i 2013 og aminoglykosid (gentamicin) 5 % i 2014 mod 4 
% i 2013. Ciprofloxacin resistens faldt fra 9 % i 2013 til 7 % i 
2014. Dette var på niveau med de andre nordiske lande (EARS-
Net 2013). 
Blandt K. pneumoniae isolater fra urin var forekomsten 
af 3. generations cefalosporin resistens 7 % i isolater fra 
hospitaler og 5 % i isolater fra praksis, hvilket er på samme 
niveau som i 2013. Ciprofloxacin resistens var uændret 8 % 
i urin-isolater fra hospitaler og 7 % i urin-isolater fra praksis. 
Mecillinam resistens var på 10 % i urin-isolater fra hospitaler 
og 9 % i urin-isolater fra praksis. Sulfonamid resistens var fal-
dende på andet år i træk til hhv. 19 % i hospitals-isolater og 
17 % i praksis-isolater. I 2009 var resistens mod sulfonamid 
på 27 % i urin-isolater fra hospitaler og 30 % i urin-isolater 
fra praksis.
Blandt Pseudomonas aeruginosa isolater fra blod var 
niveauet af resistens for alle testede antibiotika det samme 
som i 2013, med undtagelse af gentamicin som faldt fra 2013 
til 2014 (fra 5 % til 2 %). 
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I 2014 blev der ikke fundet stigende forekomst af 
resistens blandt indberettede data fra de klinisk 
mikrobiologiske afdelinger. I 4.500 E.coli fra blodiso-
later var resistensen for 3.generations cefalosporiner 
7 % og for ciprofloxacin 12 % . Begge var uændret 
fra 2013. For 943 K.pneumoniae var resistensen for 
3.generations cefalosporiner 8 % (mod 9 % i 2013) og 
for ciprofloxacin 7 % (9 % i 2013). Generelt har resist-
ensen været stigende i årene frem mod 2011, men 
har siden været let faldende eller stagneret. Sam-
menlignet med de andre nordiske lande har Danmark 
i flere år haft en lidt højere forekomst af cefalosporin-
resistens, men tallene for 2014 tyder på at Danmark 
nu nærmer sig sine nordiske naboer (EARS-Net fra 
2013 viste5-6 % cefalosporinresistens i E.coli).
CPO overvågning. I 2014 modtog Antibiotika Reference 
Laboratoriet 55 carbapenemase-producerende bakterier fra 48 
patienter som en del af den frivillige overvågning (Textbox 
8.2). Der indgik mere end et isolat per patient, hvis isolaterne 
tilhørte forskellige bakteriearter og/eller hvis isolaterne inde-
holdt forskellige carbapenemaser. Tretten af patienterne (28 
%) døde indenfor 30 dage efter diagnosen. I mange tilfælde 
var kilden til de carbapenemase-producerende bakterier 
ukendt, eller de var relateret til spredning imellem patienter i 
Danmark. Dette er anderledes i forhold til de tidligere år, hvor 
de fleste tilfælde var relateret til rejser.  
I 2014 blev der påvist 35 carbapenemase-producerende 
enterobakterier (CPE) fra 29 patienter sammenlignet med 19 i 
2013 og 20 i perioden 2008-2012. NDM-1 C. freundii udbrud-
det, der startede i Nordjylland i 2012 fortsatte i 2014. Der 
var udbrud af NDM-5 producerende K. pneumoniae i Region 
Hovedstaden.
Der blev i 2014 påvist 12 carbapenemase-producerende 
Acinetobacter sp, hvilket var på samme niveau som i 2013. 
Der blev påvist otte carbapenemase-producerende P. aer-
uginosa.  
I 2014 var forekomsten af resistens for penicillin og erythro-
mycin stadig lav blandt Streptococcus pneumoniae i isolater 
fra blod og spinalvæske (henholdsvis 5 % og 7 %). I gruppen 
af hæmolytiske streptokokker var resistensen for penicillin  
< 1 %, mens den varierede for erythromycin: 1 % i gruppe A, 4 
% i gruppe C, 10 % i gruppe G og 22 % i gruppe B.
Forekomsten af ampicillin resistens i Enterococcus faecium 
isolater fra blod var 94 % i 2014. Vancomycin resistens var  
4 % i E. faecium og < 1 % i Enterococcus faecalis blod-isola-
ter. I 2014, sås en stigning i antallet af vancomycin resistente 
enterokokker der blev indsendt frivilligt til Antibiotika Referen-
ce Laboratoriet. I 2014 var der 297 vanA E. faecium fra kliniske 
prøver sammenlignet med 231 i 2013 (Tekstboks 8.3).
I 2014 var der en stor stigning i antallet af patienter, 
som fik infektioner med multiresistente bakterier 
som vancomycin resistente enterokokker (VRE) og 
carbapenemase-producerende enterokokker (CPE) på 
de danske hospitaler. I 2014 blev der rapporteret 303 
tilfælde hvor VRE var påvist, hvilket er en stigning 
på 30 % i forhold til 2013 (235). Antallet af blodfor-
giftninger med VRE steg i 2014 til 33 sammenlignet 
med 23 i 2013. I 2014 blev der fundet 35 prøver med 
carbapenemase-producerende enterobakterier (CPE 
bakterier) hos 29 patienter.
Ciprofloxacin resistens i Neisseria gonorrhoeae faldt i 
2014 til 46 % (55,8 % i 2013). I perioden fra 2005 til 2009 
var resistensen øgedes støt fra 30 % til 75 %. Penicillinase 
produktion blandt Gonococci isolater fluktuerede mellem 24 % 
i 2005 og 11 % i 2014. Som i de foregående år blev der ikke 
rapporteret om ceftriaxon resistente isolater eller tilfælde med 
behandlingssvigt overfor ceftriaxon. Azithromycin og cefixime 
resistens lå på henholdsvis 36% og 6%. (Textbox 8.4).
Der blev i 2014 indberettet 1.964 tilfælde af Staphylococcus 
aureus bakteriæmi, svarende til en incidens på 34,9 tilfælde 
per 100.000 indbyggere. Antallet af methicillin-resistente S. 
aureus (MRSA) var 57 (2,9 %) sammenlignet med 30 i 2013. 
Trods den betydelige stigning er antallet af MRSA bakteriæmi-
er stadig meget lavt sammenlignet med de andre europæiske 
lande. De højeste niveauer af resistens ud over penicillin var 
fusidinsyre (15 %), erythromycin (8 %), clindamycin (8 %) og 
norfloxacin (6 %). Prævalensen af resistens over for de enkelte 
antibiotika var på samme niveau som i 2013.
Antallet af nye MRSA tilfælde steg i 2014 til 2.965 
(infektioner og bærertilstand), til sammenligning var 
antallet i 2013 på 2.092. Stigningen sås primært 
blandt husdyrs associeret MRSA LA-MRSA (først og 
fremmest CC398), hvor der i 2014 var 1.277 tilfælde, 
sammenlignet med 643 i 2013. Det svarede til en 
samlet andel på 43 % af alle tilfælde. Størstedelen 
(89 %) af personerne, der var inficeret med eller 
bærer af CC398, havde tæt kontakt til husdyr (70 
%), eller boede i samme husstand med personer, der 
havde kontakt til husdyr (17 %). Der var fortsat ingen 
tegn på væsentlig spredning til byområder, hvilket 
indikerer, at fødevarer ikke har en nævneværdig be-
tydning for spredningen.
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Andelen af tilfælde hvor der var infektion var lavere i 2014 
end i 2013 (henholdsvis 38 % og 45 %). Det skyldes den 
store stigning og andel af CC398, der overvejende findes ved 
 screening. Antallet af hospitalserhvervede tilfælde var fortsat 
lavt og udgjorde kun 3 % af samtlige antal MRSA tilfælde i 2014.
Den mest almindelige spa type relateret til CC398 var type 
t034 (n = 185), hvoraf 75 af t034- tilfældene havde en egent-
lig MRSA infektion. MRSA isolater med den nye mecA homolog 
mecC blev fundet i 24 tilfælde. 
Der blev i 2014 foretaget en undersøgelse blandt 70 avlsbe-
sætninger og 205 tilfældigt udvalgte produktionsbesætnin-
ger for at estimere prævalensen af LA-MRSA. Der blev konsta-
teret MRSA i 63 % af avlsbesætningerne og 68 % af produk-
tionsbesætningerne. Dette er en kraftig stigning i forhold til 
foregående undersøgelser, hvor 16 % af besætningerne blev 
fundet positive (DANMAP 2010 og DANMAP 2011, Tekstboks 
8.5 ).
2.2 Summary 
 
DANMAP (Danish Antimicrobial Resistance Monitoring and 
Research Program) has monitored antimicrobial resistance and 
consumption of antimicrobial agents in food animals and in 
humans in Denmark since 1995. This report describes trends 
and changes in 2014.
Antimicrobial consumption in animals
Data on all medicines prescribed by veterinarians have been 
registered at the farm and species level by the official VetStat 
programme since 2001.
The total consumption of antimicrobial agents in 2014 
amounted to 114 tonnes of active compound, a decrease 
of 2% compared with 2013. Pigs accounted for 76%, cattle 
for 11%, fur animals for 4%, aquaculture for 4%, and poultry 
for 1% of the total veterinary consumption of antimicrobials 
measured in kg active compound. The remaining 4% was used 
in pets, horses and others.
The overall changes in veterinary consumption were gener-
ally driven by changes in consumption in the pig production. 
Pigs account for approximately 86% of the meat production in 
Denmark, but only for about 43% of the total live biomass.
Pigs. The total consumption of veterinary antimicrobial agents 
in the Danish pig production was approximately 86 tonnes. 
Measured in DAPD, this represented a 5% decrease from 2013 
to 2014 (adjusted for export of live animals). DAPD is a mea-
sure that estimates the proportions of animals (treated daily) 
with a standard dose of an antimicrobial agent. The decrease 
was attributed mainly to a decrease in tetracyclines and to a 
lesser extent, pleuromutilins and macrolides. Pleuromutilins 
and tetracyclines are mainly used in feed or water medication 
for gastrointestinal disease. The use of 3rd and 4th genera-
tion cephalosporins in pigs was  4 kg in 2014 (3 kg in 2013), 
and thus remained at a low level as a result of a voluntary ban 
on cephalosporins introduced by the Danish pig industry in 
2010. Legal restrictions on the use of fluoroquinolones were 
enforced in 2003. Since the clinical trials, for which fluoroqui-
nolones have largely been used for over the past years, were 
discontinued in 2014 the consumption of flouroquinolones 
was reduced to 4 kg in 2014.
Cattle. Following an overall 14% decrease in consumption 
from 2010 to 2013, there was an 8% increase from 12 to 
13 tonnes in 2014. Measured in standard doses (DADD), the 
use of drying-off treatment increased by 12%, whereas the 
number of DADDs for treatment of clinical mastitis decreased 
by 2% compared with 2013. The beta-lactamase sensitive 
penicillins accounted for the majority of the consumption. For 
critically important antimicrobials, the use of fluoroquinolones 
has been close to zero since 2003. The use of 3rd and 4th 
generation cephalosporins for systemic treatment decreased 
by 27% compared with 2013.
17DANMAP 2014
2.SUMMARY
Poultry. In 2014, the overall consumption of antimicrobial 
agents in poultry was approximately 1,548 kg active com-
pound, which represents a 22% increase compared with 2013. 
The increase was mainly driven by an increase in the use of 
tetracyclines and to a lesser extent broad spectrum penicillins. 
There seem to be several reasons for this continued increase 
in consumption for poultry; increased occurrence of bacterial 
arthritis and diarrhoea in the broiler production along with 
widespread problems with respiratory disease in turkey flocks 
produced in early 2014. The reported use of fluoroquinolones 
in poultry has been low since 2006, and they were not used in 
the poultry production in 2014. Furthermore, use of cephalo-
sporins has not been reported in Danish poultry production for 
more than a decade.
Aquaculture. The antimicrobial consumption in aquaculture in-
creased by 43% to 5,116 kg in 2014. This is the highest level 
of antimicrobial consumption in aquaculture in a decade. As 
in 2013, the relatively large increase in consumption in 2014 
was caused by extraordinary high temperatures during the 
summer, leading to higher water temperatures and increased 
occurrence of bacteriological infections. The aquaculture 
industry continues to focus on developing improved vaccines 
and vaccination strategies to reduce the occurrence of dis-
eases that require antimicrobial treatment.
Fur animals. As in 2013, the antimicrobial consumption for fur 
animals continued to decrease in 2014. The overall use was 
4,202 kg active compound, which represented a 14% reduction 
compared with 2013. Use of fluoroquinolones and cephalospo-
rins has been close to zero for several years. In recent years, 
the industry, farmers and veterinarians have had increased 
focus on the consumption of antimicrobial agents, quality of 
feed and animal welfare in the mink production, and this may 
explain the reduced consumption.
Pets and horses. The information available on antimicrobial 
consumption in pet animals and horses is less detailed than 
for production animals. The overall antimicrobial consumption 
for pets remained almost at the same level in 2014 as in 2013 
(1,989 kg in 2013 to 2,017 kg in 2014). An increase was seen 
for several antimicrobial classes; beta-lactamase sensitive 
penicillins, sulphonamides, trimethoprim, as well as for tetracy-
clines and aminoglycosides. The consumption of antimicrobials 
critical for human treatment such as cephalosporins and flou-
roquinolones decreased in both 2013 and 2014. This slight 
shift in consumption of the different antimicrobial classes may 
be an effect of the treatment guidelines published by the Dan-
ish Veterinary Association in 2012. Nonetheless, consumption 
of broad-spectrum antimicrobials in pet animals and the use 
of antimicrobial agents critical for treatment of human infec-
tions remains high compared with production animals and is a 
continued matter of concern.
In 2014 the overall antimicrobial consumption in 
animals decreased by 2%. In the pig production – the 
main driver of veterinary consumption - the total con-
sumption decreased by 5%. Use of critically important 
antimicrobials in the pig production remained low. 
However, the use of critically important antimicrobi-
als in pets remained relatively high compared with 
other species, but decreased in both 2013 and 2014.
Antimicrobial consumption in humans 
In Denmark all antimicrobial agents are sold only by prescrip-
tion and the sale is recorded through the Register of Medicinal 
product Statistics at Statens Serum Institut. Detailed monitor-
ing has been performed since 1994.
The DANMAP report covers consumption of all antimicrobials 
under the ATC code J01. This report also covers the consumption 
of the per oral and rectal products of metronidazole (P01AB01) 
and vancomycin (A07AA09) for both hospital and primary 
sector. Data have been updated 10 years back. Metronidazol 
is an  important drug in the treatment of different anaerobic 
infections, and both metronidazol and vancomycin are first line 
treatment of infections with Clostridium difficile which has been 
an emerging problem in Danish hospitals since 2006.
Total consumption. In 2014 the total consumption of anti-
microbials was 18.58 DDD per inhabitant per day (DID), which 
is a decrease of 3% or 0.5 DID compared to 2013 (19.10 DID). 
The decrease in consumption was primarily driven by a marked 
decrease (15%) in the consumption of tetracyclines in the 
primary sector (see below). The consumption in primary health 
care accounts for 90% of the total antimicrobial consumption 
and thus significant changes in prescription here will markedly 
affect the total consumption. 
During the last decade, the total consumption increased by 
11%; since 1997 the increase has been almost 40 % until 
2011 (19.31 DID) where after it has stagnated. 
The total consumption in 2014 corresponds to 52,819 kg ac-
tive substance.
Primary health care. Primary health care accounted for 16.40 
DID of the total consumption (16.95 DID in 2013). Penicillins 
were the most used  group with a consumption of 10,57 DID 
accounting for 65% of the total consumption; of these beta-
lactamase sensitive penicillins accounted for 27%, penicillins 
with extended spectrum for 22% and the beta-lactamase 
resistant penicillins and combination penicillins for each 8%. 
Macrolides and tetracyclines accounted for 11% and 10%, 
respectively.
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The most marked changes were observed for tetracyclines, 
which decreased with 15% from 1.96 DID in 2013 to 1.66 DID 
in 2014. However, this is primarily due to marked changes in 
consumption of doxycycline, showing an unexplained increase 
from 2012 to 2013 but returning to the 2012 level in 2014.
For the penicillin group, beta-lactamase sensitive penicillins 
decreased from 4.65 DID to 4.38 DID (6%),  whereas combina-
tion penicillins increased from 1.22 DID to 1.30 DID (7%) and 
beta-lactamase resistant penicillins from 1.30 DID to 1.36 DID 
(5 %). The increased consumption of combination penicillins 
partly owed to changes in recommendations for the treatment 
of pneumonia in patients with chronic lung disease (COPD), 
but increased consumption was also observed for other age 
and patient populations. These changes will be investigated 
further in the future.
Fluoroquinolones (primarily ciprofloxacin) accounted for 3% of 
the consumption (0.50 DID). The consumption of ciprofloxacin 
increased from 2005 to 2011 (from 0.33 to 0.57 DID) and has 
since shown a decreasing trend.
No significant changes were shown for trimethoprim and 
sulfonamides or nitrofurantoin.
During the last decade the total consumption in the primary 
sector increased by almost 10%, from 14.96 DID in 2005 to 
16.40 DID in 2014. The increase reflects an increase in the 
number of DDD per treated patient as well as an increased 
number of DDD per package. These might reflect changed rec-
ommendations in the treatment of patients with higher doses 
and shorter treatment periods.
Hospitals. At somatic hospitals, the consumption of antimi-
crobial agents increased when calculated in DDD per 100 bed 
days (DBD): from 99.88 DBD in 2013 to 104.30 DBD in 2014.
During the last decade the consumption increased with 57% 
(from 66.32 DBD in 2005).
Penicillins accounted for 50% of the total consumption. The 
biggest group of these were the penicillins with extended 
spectrum (primarily ampicillin and mecillinam), constituting 
17% of the total consumption at hospitals, which has not 
changed significantly for the last decade. Notably decreasing 
changes since 2005 were observed for the beta-lactamase 
sensitive penicillins: While a decade ago these constituted the 
second biggest group (with 12.17 DBD in 2005, corresponding 
to 20% of the total consumption), the consumption in 2014 
had decreased to 10.31 DBD, corresponding to 11% of the 
total consumption at hospitals.    
From 2013 to 2014 the consumption of the combination peni-
cillins increased from 13.64 to 16.04 DBD (18%). The group 
of combination penicillins covers two drugs: amoxicillin with 
clavulanic acid and piperacillin with tazobactam. Consumption 
of both has increased following changed recommendations 
on treatment of septic and severely ill patients, as well as 
the mentioned changes in recommendations for treatment of 
COPD patients suffering from pneumonia. 
Penicillins with extended spectrum increased from 15.06 to 
16.40 DBD (8%) and imidazole-derivatives from 4.08 to 4.48 
DBD (9%), while decreases were shown for 2nd generation 
cephalosporins (cefuroxime) from 12.31 to 11.68 DBD (5%). 
No marked changes were observed for the beta-lactamase 
sensitive penicillins (10.31 DBD), beta-lactamase resistant 
penicillins (9.57 DBD), carbapenems (4.09 DBD) and fluoro-
quinolones (9.88 DBD). The latter two remained unchanged 
despite recommendations on reduction of consumption
When presented in DID (for comparison with the consumption 
in the primary sector) the hospital sector accounted for 2.18 
DID (2.15 in 2013). A continuing increase has been observed 
for this sector over the last decade, from 1.76 DID in 2005. 
The steady increases in consumption at hospitals are primarily 
caused by an increase in DDDs and a decrease in the number 
of hospital bed-days.  
 
From 2005 to 2014, the total consumption of antimicrobial 
agents by humans in Denmark increased by 11%, since 1997 
the increase has been 40%.  
In humans, the overall consumption of antimicrobial 
agents for systemic use in 2014 was 18.58 DID, 
which is a 3% decrease from 2013. Most of this 
decrease owes to notable changes in the consump-
tion of tetracyclines in the primary sector, where 
especially consumption of doxycycline had shown 
an unexplained peak in consumption from 2012 to 
2013 but in 2014 returned to a lower level. For the 
last decade most prominent changes in consumption 
in both primary sector and hospital sector have been 
observed for the different groups of penicillins. While 
the consumption of beta-lactamase sensitive penicil-
lins continues to fall the consumption of combination 
penicillins increases. Combination penicillins now 
constitute the second biggest antimicrobial group at 
hospitals accounting for 15% and one of the biggest 
groups consumed in the primary sector accounting 
for 8%. 
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Resistance in zoonotic bacteria 
Zoonotic bacteria such as Salmonella and Campylobacter can 
develop resistance in the animal reservoir. The resistant bac-
teria may be transferred to humans via food and may subse-
quently compromise treatment attempts when causing disease 
in humans.
Harmonised monitoring of antimicrobial resistance
In 2014, the panel of test antimicrobials was changed to ac-
commodate the European Commission’s decision on harmonis-
ing the monitoring of antimicrobial resistance in zoonotic and 
commensal bacteria [Decision 2013/652/EU]. For Salmonella, 
Campylobacter as well as indicator E. coli and Enterococcus, 
several compounds were replaced in order to prioritise testing 
for resistance to antimicrobial agents most relevant from a 
public health perspective. For Salmonella and indicator E. coli 
isolates, screening for carbapenemase enzymes was initiated. 
As a consequence, trends in proportions of fully sensitive 
and multi-resistant isolates, as well as occurrence of selected 
resistance profiles, cannot be directly compared with results 
from previous years.
Salmonella Typhimurium is one of the most common se-
rovars in Danish pigs and pork as well as in human infections. 
Among S. Typhimurium from healthy pigs, 66 - 71% of the 
isolates were resistant to ampicillin, sulfonamide, and tetracy-
cline; and the occurrences of resistance to these antimicrobial 
agents have increased over the last five years. This can mainly 
be attributed to an increasing prevalence of monophasic S. 
Typhimurium that has a strong tendency to be multi-resistant. 
In 2014, 56% of the S. Typhimurium isolates from pigs were of 
the monophasic S 4,[5],12:i; variants. High levels of resistance 
in S. Typhimurium were also found among isolates from Danish 
pork. In general, we found higher levels of multi-resistance 
among S. Typhimurium (including the monophasic variants) 
isolates from healthy Danish pigs (64%) than on average 
among all Salmonella serotypes isolated from pigs (32%) in 
2014. Salmonella was recovered from 22% of the healthy pigs 
tested, and it was estimated that overall 7% of Danish pigs 
were positive with multi-resistant Salmonella. As in previous 
years, resistance to cephalosporins (cefotaxime, ceftazidime or 
ceftiofur) or quinolones (ciprofloxacin or nalidixic acid) was not 
detected among Salmonella from Danish pigs or pork.
As in isolates from pigs and pork, the occurrence of mono-
phasic variants of S. Typhimurium in humans increased in 
prevalence among both domestic sporadic cases and outbreaks 
over the last five years. In 2014, multi-resistant isolates were 
recovered from 48% of all cases, and generally the levels of 
resistance were comparable to 2013. The tendency seen in 
previous years of higher levels of resistance among travel-
associated isolates compared to domestic infections is not 
distinct in 2014; only resistance to ciprofloxacin and nalidixic 
acid resistance were higher in isolates from travel-related 
cases compared with isolates from domestic cases.
Resistance to 3rd generation cephalosporins (cefotaxime and/or 
ceftazidime) was found in seven S. Typhimurium isolates (1.6% 
of cases); however these seven isolates were also resistant to 
ciprofloxacin. Co-resistance to ciprofloxacin and 3rd generation 
cephalosporins are of major concern as these two antimicrobial 
agents are considered the most important for treatment of 
severe salmonellosis.
None of the susceptibility tested Salmonella isolates from ani-
mals, meat or human cases displayed carbapenemase activity 
(meropenem resistance).  
The occurrence of monophasic Salmonella 
Typhimurium, which are often multi-resistant, has 
increased in pigs, pork and among isolates from 
human infections over the past five years. Among 
isolates from human infections acquired in Denmark, 
resistance to ampicillin, sufonamide and tetracycline 
have stabilised at a fairly high level in the past 
four years (50 – 60%). In 2014 only resistance to 
quinolone were higher among isolates from the travel 
related human cases.
In 2014, resistance in Campylobacter jejuni isolates from 
Danish cattle, broilers and Danish broiler meat were generally 
similar to the levels observed over the last five years. Low to 
moderate levels of resistance were observed, and the majority 
(74 - 81%) of isolates were fully sensitive to the six antibiotic 
agents included in the test panel. In a European context, Den-
mark reports relatively low levels of antimicrobial resistance 
among C. jejuni from cattle, broilers and broiler meat.
For several years, the level of fluoroquinolone resistance in C. 
jejuni has been higher among isolates from imported broiler 
meat (82%), compared with isolates from Danish broiler meat 
(15%); a difference that has been increasingly pronounced. 
As observed in previous years, the C. jejuni isolates from the 
travel-associated human cases continued to have a significant-
ly higher level of fluoroquinolone resistance (81%) compared 
with domestic cases (35%).  
The level of fluoroquinolone (ciprofloxacin) resistance 
in Campylobacter jejuni remains higher among isolates 
from imported broiler meat compared with isolates 
from Danish broiler meat, and among C. jejuni from 
travel-associated cases compared with domestic cases.
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Resistance in indicator bacteria
Indicator bacteria, enterococci and Escherichia coli, are includ-
ed in the DANMAP programme to provide information about 
the general levels of resistance in healthy production animals 
and in meat.
In Enterococcus faecalis from broilers and Danish broiler 
meat, resistance to tetracycline (49% and 35%, respectively) 
and erythromycin (27% and 19%, respectively) was moderate 
to high, but low or absent for the other compounds in the test 
panel. Resistance to tetracycline in E. faecalis from broilers has 
been increasing over the last five years. In E. faecium from 
imported broiler meat resistance was generally higher com-
pared with broiler meat produced in Denmark.
Higher levels of antimicrobial resistance were observed among 
E. faecalis isolated from pigs compared to poultry, which 
reflects the differences in usage pattern of antimicrobials in 
these animal species. Among E. faecalis from pigs, the high-
est occurrence of resistance was to tetracycline (83%) and 
erythromycin (49%). Tetracycline has been the most widely 
used antimicrobial agent in the Danish pig production for more 
than a decade and has primarily been used for treatment of E. 
coli infections in piglets. Tetracycline resistance in E. faecalis 
was higher in imported pork when compared with domestic-
produced pork.
Generally lower levels of resistance are observed in E. faecium 
compared with E. faecalis, and resistance to antimicrobial 
agents of critical importance for human treatment was low. 
Among Indicator Escherichia coli from broilers, resistance to 
tetracycline, ampicillin, trimethoprim and sulfonamide de-
creased compared with 2012 and 2013, despite an increased 
consumption of these compounds in the broiler production in 
2014. Resistance to fluoroquinolones was observed in 12% 
of the isolates from broilers. Resistance in E. coli from Dan-
ish broiler meat was similar to the findings in broilers, and 
resistance to ceftiofur (3rd generation cephalosporin) was 
observed in one E. coli isolate from Danish broiler meat; but not 
among isolates from broilers. The highest occurrence of resis-
tance, including resistance to critically important antimicrobial 
agents, was found in imported broiler meat. Compared with 
Danish broiler meat, resistance was higher for 6 of 13 tested 
antimicrobial agents from imported broiler meat.
As in previous years, the highest levels of resistance for ampi-
cillin, sulphonamides, trimethoprim and tetracyclines among E. 
coli from production animals were observed in pigs (33 – 37%), 
whereas resistance in isolates from cattle was generally low – 
at levels comparable to 2013. Also resistance levels in Danish 
and imported pork and beef were comparable in 2014.  
ESBL-producing bacteria is one of the fastest emerging 
resistance problems worldwide. Lately, several studies have 
found the same ESBL genes, plasmids and clones in E. coli 
isolates originating from animals and isolates involved in 
human infections, suggesting a zoonotic link. The occurrence 
of Enterobacteriaceae resistant to carbapenems is a growing 
threat in human medicine because carbapenems are the last 
resort for treatment of infections caused by multidrug resis-
tant Gram-negative bacteria in humans.
ESBL (ceftriaxone) resistant E. coli was found in 9% of Dan-
ish broiler meat and 25% of imported broiler meat samples. 
As in previous years, the occurrences were generally low (< 
1%) in the Danish and imported beef and pork. The decreas-
ing occurrence of ESBL-producing E. coli in Danish broiler meat 
continued in 2014. For the first time a significant reduction 
was also observed in imported broiler meat. This is most likely 
due to a voluntary stop in the usage of 3rd generation cepha-
losporins in the top of the breeding pyramid abroad resulting in 
a reduced transmission of ESBL-producing E. coli from imported 
parent animals to the Danish broilers. As in 2012 and 2013 no 
carbapenemase producing E. coli were found. 
We observed a significant decrease in the occurrence 
of ESBL-producing E. coli in Danish broiler meat as 
well as in broiler meat produced abroad (mainly in EU 
countries). This is most likely due to a voluntary stop 
in usage of cephalosporins at the top of the breeding 
pyramid abroad. 
 
 
Resistance in human clinical bacteria 
The Departments of Clinical Microbiology (DCM) in Denmark 
reported data on antimicrobial resistance in human clinical 
blood and urine isolates of Escherichia coli, Klebsiella pneu-
moniae, Pseudomonas aeruginosa, Enterococcus faecalis and 
Enterococcus faecium. For methicillin-resistant Staphylococcus 
aureus (MRSA) and invasive Streptococcus pneumoniae data 
were obtained from the reference laboratories at SSI where 
these bacteria are received for surveillance.
Data on the antimicrobial susceptibility of approximately 4,500 
Escherichia coli blood isolates were referred. The resistance to 
ampicillin was 45%, ciprofloxacin 12%, mecillinam 8%, genta-
micin 7% and 3rd generation cephalosporins 7%. There were 
no significant changes compared to 2013 except for piperacil-
lin/tazobactam, which increased from 4 - 5%. Compared with 
EARS-Net data from 2013 the resistance in Danish isolates was 
slightly higher than in the other Scandinavian countries, but 
lower than in most other European countries. 
In E. coli urine isolates from hospital patients, ampicillin 
resistance was 42%, sulfonamide resistance was 33% and 
aminoglycoside (gentamicin) resistance was 5%, which are at 
the same levels as in the previous three years. Resistance to 
3rd generation cephalosporins was 6% - the same level as in 
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2013. The occurrence of ciprofloxacin resistance (11%) was 
slightly lower than in 2013 (12%), but a steady increase has 
been seen in ciprofloxacin resistance from 3% in 2005. 
In E. coli urine isolates from primary health care the oc-
currence of ampicillin resistance was 39% and sulfonamide 
resistance was 32%. No significant changes in resistance since 
2013 were observed but both decreased since 2009 (from 
42% and 38% respectively). For 3rd generation cephalospo-
rins, resistance was 4%, unchanged since 2012. Ciprofloxacin 
resistance was 9%. Resistance has increased steadily from the 
beginning of the century (1% in 2000) and reached its highest 
peak in 2011 with 11%.
Data on 943 Klebsiella pneumoniae blood isolates were 
received. Resistance to ciprofloxacin was 7%, mecillinam 8%, 
piperacillin/tazobactam 8%, 3rd generation cephalosporins 
8% and gentamicin 5%. There were no significant changes 
compared with 2013.
In K. pneumoniae urine isolates from hospital patients 
resistance to mecillinam (10%), sulfonamide (19%), gentamicin 
(4%), 3rd generation cephalosporins (7%) and ciprofloxacin 
(8%) all remained at the same level as in 2013. For all of these 
drugs, marked decreases have been observed since 2009 (de-
creasing from 14%, 33%, 7%, 13% and 17%, respectively). 
In K. pneumoniae urine isolates from primary health care, 
resistance to mecillinam (9%), 3rd generation cephalosporins 
(5%) and ciprofloxacin (7%) remained at the same level as in 
2013. Sulfonamide resistance decreased from 22% in 2013 to 
17% in 2014.
In 2014, the first data from the Surveillance of ESBL/AmpC 
producing E. coli from bloodstream infections were re-
ported in the DANMAP report. In total, 261 E. coli isolates were 
whole-genome sequenced. In 245 isolates genes encoding 
ESBL/AmpC or carbapemase production were detected. For 
240 isolates demographic were available; 53% of the patients 
were men and the mean age was 70 years. Twenty-seven 
(11%) of the patients died within 30 days after the diagnosis.   
Among the 245 isolates, 21 genes encoding ESBL/AmpC or 
Carbapemase production were detected. CTX-M-15 was most 
common (49%), followed by CTX-M-14, CTX-M-27 and CTX-
M-101. Different variants of CMY were detected in 7% of the 
isolates.OXA-48 was detected in one isolate and OXA-181 in 
two other isolates. The 245 isolates belonged to 51 different 
MLST types, ST131 was most common (51%).
In Pseudomonas aeruginosa isolates from blood, resis-
tance to all tested antimicrobial agents was at the same level 
as in 2013, except for gentamicin, which decreased from 2013 
to 2014.
For 2014 no increases in resistance were observed 
for data on blood isolates received from the Depart-
ments of Clinical Microbiology. In 4,500 E.coli resist-
ance to 3rd generation cephalosporins was 7% and 
for ciprofloxacin 12%. Both were unchanged from 
2013. In 943 K. pneumoniae resistance to 3rd gener-
ation cephalosporins was 8% and to ciprofloxacin 7% 
(compared to 9% for both in 2013). In general resist-
ance in both bacteria has been increasing during the 
last decade but since 2011 stagnation or even de-
creases were observed. Compared to the other Nordic 
countries Denmark has for some years shown higher 
resistance towards cephalosporins but the results 
from 2014 point towards a positive change (EARS-
Net 2013 showed 5 – 6% resistance to cephalosporins 
in E.coli for the other Nordic countries).
In 2014, 35 carbapenemase producing enterobacteria 
(CPE) were detected from 29 patients, whereas 19 CPE were 
detected in 2013 and 20 in the period 2008-2012. The NDM-
1 producing C. freundii outbreak, which started in 2012 in the 
North Denmark Region, continued in 2013 and 2014. During 
2014, NDM-5 producing K. pneumoniae were detected from 
three patients at a hospital in the Capital Region of Denmark.
In 2014, 12 carbapenemase producing Acinetobacter spp 
were detected, which was at the same level as in 2013. In 
2014, 8 carbapenemase producing P. aeruginosa were 
detected.
In 2014, resistance to ampicillin was 93 % in Enterococcus 
faecium isolates from blood. Vancomycin resistance was 4% 
in E. faecium and 0.2% in Enterococcus faecalis isolates 
from blood. During 2013 and 2014, an increasing number 
of vancomycin resistant enterococci were referred to SSI. I 
2014, 297 vanA E. faecium from clinical samples were ob-
tained compared with 231 in 2013 (Textbox 8.3).  
In 2014, there was a large increase in the number 
of patients with infections caused by vancomycin 
resistant Enterococci (VRE) and carbapenemase- 
producing Enterococci (CPE) in Danish hospitals.
In 2014 303 clinical isolates with VRE (vancomycin 
resistant enterococci) were referred to the reference 
laboratory at Statens Serum Institut, 297 of these 
were VanA –positive E.faecium. This is an increase 
of 30% from 2013 (235 isolates). VRE was found in 
33 bacteremias (compared to 23 in 2013). In 2014, 
carbapenemase-producing Enterococci were found on 
35 samples from 29 patients.
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Resistance to penicillin and erythromycin in Streptococ-
cus pneumoniae and in group A, B, C and G streptococci 
remained low in 2014.
Ciprofloxacin resistance in Neisseria gonorrhoeae increased 
steadily from 30% in 2005 to 75% in 2009, followed by a de-
crease to 46% in 2014. Penicillinase production among gono-
coccus isolates fluctuated between 24% in 2005 and 11% in 
2014. As in previous years no ceftriaxone resistant isolates or 
cases of ceftriaxone treatment failure were reported. Azithro-
mycin and cefixime resistance was 36% and 6%, respectively 
(Textbox 8.4).
In 2014, 1,964 cases of Staphylococcus aureus bacte-
raemia were reported, corresponding to 34.9 cases per 
100,000 inhabitants. The number of methicillin-resistant 
S. aureus (MRSA) from bacteraemia was 57 (2.9%). This is a 
steep increase compared with the levels in previous years 
but still among the lowest incidences recorded in Europe. 
The highest frequency of resistance in addition to penicil-
lin was observed for fusidic acid (15%), erythromycin (8%), 
clindamycin (8%) and norfloxacin (6%). Susceptibility to 
the tested antimicrobial agents was at the same level as in 
2013.
Among all MRSA cases, the proportion of cases presenting 
infection was lower in 2014 compared with 2013 (38% and. 
45%, respectively). The number of hospital-acquired (HA) 
cases continued to be low and constituted only 3% of the total 
number of MRSA cases in 2014.
A national survey was carried out in 2014 to estimate the 
prevalence of LA-MRSA in 70 breeding herds and 205 ran-
domly selected slaughter pig herds. The prevalence of MRSA 
was 63% in breeding herds and 68% in slaughter pig herds, 
which is a marked increase compared to previous surveys, 
where only 16% of the herds were found positive for MRSA, 
(Textbox 8.5)
The number of new cases of MRSA (both infected and colonized persons) increased in 2014 to 2,965 compared 
with 2,092 in 2013.The increase was primarily seen in livestock associated MRSA, belonging to clonal complex 
398 (CC398), with 1,277 cases in 2014 compared with 643 cases in 2013. In 2014, CC398 constituted 43% 
of all new MRSA cases in Denmark. The majority (89%) of persons infected or colonized with CC398 had close 
contact to pigs or were household members to persons, who had pig contact. There were, however, no signs of 
significant spread of CC398 to urban areas, which indicates that food does not constitute an important trans-
mission route.
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3. Background information
The following sections present general information about the 
human population in Denmark in 2014, as well as the produc-
tion of food animals and the amount of meat available for 
human consumption in Denmark over the past decade. It also 
provides an overview of the antimicrobial agents for systemic 
and intramammary therapeutic use in humans and animals in 
2014.
3.1  Populations
 
The distribution of the Danish human population, which could 
potentially have received antimicrobial treatment in 2014, 
is displayed in Figure 3.1, together with the five healthcare 
regions and the 11 Departments of Clinical Microbiology (DCM) 
in Denmark.
The production of food animals and the production of meat 
and milk are presented in Table 3.1. 
While the number of pigs produced was approximately 3% 
higher than in 2013, the number of fattening pigs (15–50 kg) 
exported increased by 13%, and the export has increased by 
more than six-fold since 2005. As in the previous years, the 
amount of milk produced increased (2%). 
The number of broilers produced decreased by approximately 
2% from 2013 to 2014, and approximately 11% of the broilers 
produced in 2014 were exported for slaughter. The annual 
production of turkeys has fluctuated considerably over the last 
decade, and decreased with 14% from 2013 to 2014. Since 
2006, more than 99% of the turkeys produced have been 
exported for slaughter, thus almost all turkey meat available in 
Denmark is listed as imported.
Figure 3.1 The five health care regions and 11 Departments of Clinical Microbiology (DCM) in Denmark DANMAP 2014
North Denmark Region
No. of inhabitants 582,413
No. of inhabitants/km2 73
No. of inhabitants/GP 1713
Central Denmark Region
No. of inhabitants 1,282,250
No. of inhabitants/km2 98
No. of inhabitants/GP 1528
Capital Region of Denmark
No. of inhabitants 1,766,677
No. of inhabitants/km2 690
No. of inhabitants/GP 1605
Region Zealand:
No. of inhabitants 819,385
No. of inhabitants/km2 113
No. of inhabitants/GP 1629
Region of Southern Denmark
No. of inhabitants 1,205,025
No. of inhabitants/km2 99
No. of inhabitants/GP 1493
Source: Statistics Denmark (www.dst.dk) and 
the Danish Medical Association (www.laeger.dk) 
GP=general practitioner.
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3.2  Marketed antimicrobial agents
 
Table 3.2 shows the antimicrobial agents that are registered 
to treat bacterial infections in humans and animals. Some of 
these are considered to be critically important for treating 
bacterial infections in humans. An antimicrobial agent is con-
sidered critically important if it is the only compound, or one of 
a limited number compounds, available to treat serious human 
disease. Fluoroquinolones, 3rd and 4th generation cephalospo-
rins, macrolides and glycopeptides are among these critically 
important antimicrobial agents [AGISAR, 3.revision, WHO 
2011]. Critically important antimicrobial agents are also used 
to treat diseases in food animals and pets, and bacteria that 
are resistant to critically important agents may be transmit-
ted to humans. Also, bacteria that cause human disease may 
acquire resistance genes from bacteria of animal origin. 
Growth promoters, which are no longer used for animals in 
Denmark, are shown in parentheses in Table 3.2. Most of these 
had effects on Gram-positive bacteria. Since 1995, the indica-
tor enterococci from animals and meat (and in some years from 
healthy humans) have been used as a measure of resistance to 
growth promoters.
Source: Statistics Denmark (www.dst.dk) and The Danish AgriFish Agency. Live animals exported prior to slaughter are included in number of 
animals and amount of meat produced. Export data for 15-50 kg live pigs from the Danish Agriculture and Food Council.  
a) The numbers for 2014 are not final. The production of farmed fish includes fish transferred from one production facility to another.  
b) Assume a final slaughtered weight of 1.51 kg per broiler produced (Danish Agriculture and Food, 2013).  
c) Export of 15-50 kg live pigs. These are included in total number of heads, but antimicrobial use after export until slaughter is not registered as 
it takes place outside of Denmark. 
d) Increase from 2013 to 2014.            
      
Table 3.1. Production of food animals and the production of meat and milk, Denmark DANMAP 2014
Year Broilers Turkeys 
Cattle
(slaughtered)
Dairy cows Pigs
 Farmed fish(a) 
Fresh 
water
Marine
1,000 
heads
mill. kg(b)
1,000 
heads
mill. kg
1,000 
heads
mill. kg
1,000 
heads
mill. kg
milk
1,000 
heads
Export
1,000
heads(c)
mill. kg mill. kg mill. kg
1990 94560 116 571 2.5 789 219 753 4542 16425 - 1260 - -
1992 107188 137 761 5.4 862 236 712 4405 18442 - 1442 35 7
1994 116036 152 1091 8.6 813 210 700 4442 20651 - 1604 35 7
1996 107895 149 961 9.3 789 198 701 4494 20424 - 1592 32 8
1998 126063 168 1124 11.6 732 179 669 4468 22738 - 1770 32 7
2000 133987 181 1042 10.3 691 171 636 4520 22414 - 1748 32 7
2001 136603 192 1086 13.2 653 169 623 4418 23199 - 1836 31 8
2002 136350 190 1073 12.8 668 169 611 4455 24203 - 1892 32 8
2003 129861 197 777 11.2 625 161 596 4540 24434 - 1898 34 8
2004 130674 198 1086 19.6 632 165 569 4434 25141 1712 1967 34 9
2005 122179 183 1237 17.4 549 145 559 4449 25758 2720 1988 31 8
2006 106182 161 785 11.3 509 140 556 4492 25763 3204 1957 29 8
2007 107952 163 1009 14.4 512 141 545 4515 26311 3522 2046 31 10
2008 107595 163 1068 12.3 509 138 559 4585 27078 4943 1985 30 10
2009 108851 165 1175 11,1 507 137 569 4734 27603 6642 1898 29 11
2010 117653 178 1184 14 519 142 574 4830 28505 7074 1974 28 10
2011 115454 175 960 9,4 551 145 575 4801 29399 7632 2008 28 11
2012 111080 168 1103 12,4 539 138 580 4928 29047 8794 1902 28 13
2013 117315 177 692 8.3 551 140 574 5025 28996 9318 1896 30 13
2014 115497 174 595 8.8 556 143 563 5113 29926 10517 1924 28 12
Increase(d) -2% -2% -14% 1% 1% 2% -2% 2% 3% 13% 1% -5% -9%
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Table 3.2.  Antimicrobial agents marketed for systemic and veterinary intramammary therapeutic  
use in animals and humans, Denmark 2014   DANMAP 2014
ATC / ATCvet codes (a) Therapeutic group Antimicrobial agents within the therapeutic groups
Animals Humans
J01AA / QJ01AA,QJ51AA Tetracyclines Chlortetracycline, doxycycline, 
oxytetracycline
Doxycycline, lymecycline, 
oxytetracycline, tetracycline, 
tigecycline
J01BA / QJ01BA Amphenicols Florfenicol Chloramphenicol
J01CA / QJ01CA Penicillins with extended spectrum Ampicillin, amoxicillin Ampicillin, pivampicillin, amoxicillin, 
pivmecillinam, mecillinam
J01CE / QJ01CE Beta-lactamase sensitive penicillins Benzylpenicillin, 
phenoxymethylpenicillin, procaine 
penicillin, penethamate hydroiodide
Benzylpenicillin, 
phenoxymethylpenicillin
J01CF / QJ51CF Beta-lactamase resistant penicillins Cloxacillin, nafcillin Dicloxacillin, flucloxacillin
J01CR / QJ01CR Comb. of penicillins, incl. beta-
lactamase inhibitors
Amoxicillin/clavulanate Amoxicillin/clavulanic acid, 
piperacillin/tazobactam
J01DB / QJ01DB,QJ51DB First-generation cephalosporins Cefalexin, cefadroxil, cefapirin Cefalexin
J01DC Second-generation cephalosporins Cefuroxime
J01DD / QJ01DD,QJ51DD Third-generation cephalosporins Cefoperazone, ceftiofur, cefovecin Cefotaxime, ceftazidime, 
ceftriaxone
J01DE / QJ51DE Fourth-generation cephalosporins Cefquinome
J01DF Monobactams Aztreonam
J01DH Carbapenems Meropenem, ertapenem, doripenem
J01DI Fifth-generation cephalosporins Ceftaroline
J01EA Trimethoprim and derivatives Trimethoprim
J01EB / QJ01EQ Short-acting sulfonamides Sulfadimidine Sulfamethizole
J01EE / QJ01EW Comb.of sulfonamides and 
trimethoprim, incl. derivatives
Sulfadiazine/trimethoprim, 
sulfadoxine/trimethoprim,
sulfamethoxasol/trimethoprim
J01FA / QJ01FA Macrolides Spiramycin, tylosin, tilmicosin, 
tylvalosintartrat, tulathromycin, 
gamithromycin, tildiprocin
Erythromycine, roxithromycine, 
clarithromycine, azithromycine
J01FF / QJ01FF Lincosamides Clindamycin, lincomycin Clindamycin
J01FG / QJ01XX (b) Streptogramins (Virginiamycin)
J01G / QJ01RA,QA07AA Aminoglycosides Streptomycin, dihydrostreptomycin, 
gentamicin, neomycin, apramycin
Tobramycin, gentamicin, amikacin, 
netilmicin
J01MA / QJ01MA Fluoroquinolones Enrofloxacin, marbofloxacin, 
difloxacin, ibafloxacin, pradofloxacin
Ofloxacin, ciprofloxacin, 
levofloxacin, moxifloxacin
QJ01MB Other quinolones Oxolinic acid
QJ01MQ (b) Quinoxalines (Carbadox, olaquindox)
J01XA,A07AA / Not in ATCvet (b,c) Glycopeptides (Avoparcin) Vancomycin, teicoplanin
J01XB / QA07AA (b) Polypeptides (incl. polymyxins) Colistin, bacitracin Colistin
J01XC Steroid antibacterials Fusidic acid 
J01XD,P01AB (c) Imidazole derivatives Metronidazole
J01XE Nitrofurane derivatives Nitrofurantoin 
J01XX / QJ01FF Other antibacterials Spectinomycin Methenamine, linezolid, 
daptomycin, tedizolide
QJ01XQ Pleuromutilins Tiamulin, valnemulin
QP51AG04 Antiprotozoals, sulfonamides Sulfaclozine
Not in ATCvet (b) Oligosaccharides (Avilamycin)
Not in ATCvet (b) Flavofosfolipols (Flavomycin)
a) ATCvet codes starts with a Q   
b) Animal growth promoters used before 1999 are listed in parentheses   
c) intestinal antiinfectives (A07AA) and imidazole derivatives for protozoal diseases (P01AB) are for the first time included in the DANMAP 
rapport 2014, since their widespread use in the treatment of Clostridium difficile infections makes them belong to the most used antibiotics in 
human infections in Denmark.  
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4. Antimicrobial consumption in animals
4.1 Introduction
 
The use of antimicrobial agents in humans and animals has 
been monitored by the DANMAP programme since 1995. Since 
the early 1990s, there has been both political and public focus 
on the use of antimicrobial agents in the Danish animal produc-
tion. This resulted in discontinued use of several antimicrobial 
agents used for growth promotion from 1994-1999, and more 
recently, in a voluntary ban of use of cephalosporins in the pig 
and dairy cattle production, as well as in regulatory legislation 
regarding therapeutic use [DANMAP 2010].
Overall, the antimicrobial consumption for both humans and 
animals has increased since the late 1990s. While the con-
sumption for humans has gradually increased throughout the 
period, the consumption in animals has fluctuated notably. 
Increases in veterinary consumption can partly be explained 
by the increase in pork production, which constitutes ap-
proximately 86% of the meat production in Denmark (Table 
3.1). Figure 4.1 shows the total antimicrobial consumption in 
animals and humans since 1994 and 1997, respectively.
The prescription pattern has been clearly influenced by imple-
mented legislation. For example, the decrease in antimicrobial 
consumption after 1994 was likely the result of the folllowing 
important actions: 1) limitation of veterinarians profit from 
sales of medicine 2) implementation of preventive veterinary 
strategies with Veterinary Advisory Service contracts (Textbox 
4.1) and regular monthly visit from the veterinarian in order 
to promote preventive veterinary strategies and optimize 
antimicrobial use, and 3) enforcement of the so called “cascade 
rule” [Order (DK) 142/1993], which limits the use of (cheaper) 
extemporaneously produced medicines - this particularly af-
fected the use of tetracyclines from 1994. Another important 
intervention was the restriction on the use of fluoroquinolones 
in production animals through legislation implemented in 2002 
and 2003. Furthermore, in July 2010, the pig industry imposed 
a voluntary ban on the use of cephalosporins, concerns regard-
ing the emergence of extended beta-lactamase resistance 
(ESBL) in Gram-negative bacteria, followed by a similar initia-
tive by dairy cattle farmers in July 2014.
From 2010 to 2011, consumption decreased following the 
introduction of threshold values for antimicrobial consumption 
adopted within the “yellow card initiative”. This enforces legal 
actions on pig farmers with high antimicrobial agent use per 
pig [DANMAP 2010]. Effects from other parts of the legislation 
may be less obvious, but are important to keep in mind, when 
interpreting the veterinary prescription patterns.
Official guidelines for veterinarians, regarding the selection of 
antimicrobial agents for pigs and cattle, have been available 
since 1996. The guidelines provide specific recommendations 
for selection of the appropriate antimicrobial treatment of all 
common indications in the major production animal species. 
Initially, guidelines were developed by the National Veterinary 
Laboratory (presently, National Veterinary Institute, DTU). 
Since 2005, the guidelines have been updated by the Danish 
Veterinary and Food Administration (DVFA) in collaboration 
with National Veterinary Institute DTU, National Food Institute 
DTU, the Practicing Veterinarians Organization, university 
experts, the Danish Association of the Veterinary Pharmaceu-
tical Industry and the Danish Agriculture and Food Council. 
The latest update was in 2010, when new dynamic evidence-
based treatment guidelines for pigs were launched [DANMAP 
2010, www.fvst.dk]. In 2012, the Danish Veterinary Associa-
tion published treatment guidelines to promote prudent use of 
antimicrobials in dogs and cats, prepared by clinical specialists 
and expert scientists from the Faculty of Health and Medical 
Sciences at the University of Copenhagen and National Food 
Institute DTU.
4.1.1 Data sources 
Data on antimicrobial use at the product level have been col-
lected in Denmark since 1996, including historical data back to 
1990. In Denmark, all therapeutic medicine is by prescription 
only, and since 2001, data on all medicine prescribed for use in 
animals, including vaccines, have been collected (at end users) 
in a national database (VetStat). Data on consumption of coc-
cidiostatic agents (non-prescription) and antimicrobial growth 
promoters (no longer used), are also collected by VetStat.
Consumption data for 2014 - for use in DANMAP - were 
extracted from VetStat by the Danish Veterinary and Food Ad-
ministration (DVFA) in May 2015. National Food Institute DTU 
has carried out no further validation of the received data.
4.1.2 Methods 
Metrics of antimicrobial consumption are numerous, each with 
its own advantages and limitations. Therefore, the chosen 
measures must depend on the purpose and the available 
information.
The overall amount of antimicrobial agents is measured in kg 
active compound and is used in Section 4.2 for the purpose of 
an overall crude comparison of antimicrobial use in the veteri-
nary and human sectors and to enable international compari-
sons (Figure 4.1).
In DANMAP 2012, we introduced two new metrics to follow 
trends in antimicrobial consumption to ensure the robust-
ness of the analyses over time and to facilitate comparisons 
between animal species, as well as comparisons between the 
veterinary and human sectors. The new metrics are defined 
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below, and for more information on methodology, please refer 
to Chapter 9 and the web annex [www.Danmap.org].
DADD (Defined animal daily dose)
DADD is the average maintenance dose per day for a drug used 
for its main indication in the appropriate animal species.
The DADD is not defined at product level but for each antimi-
crobial agent, administration route and animal species; and 
when appropriate, also age group. DADD has been specifically 
defined for use in DANMAP and does not always completely 
match the prescribed daily dose or the recommended dosage 
in the Summaries of Product Characteristics (SPC) or in the 
VetStat database.
Since 2012, the DADD has replaced the ADD (as defined in 
VetStat), which had been used since DANMAP 2003. For more 
details, see Chapter 9, Materials and Methods. The DADDs used 
in DANMAP 2014 are presented in the web annex.
DAPD (DADD per 1,000 animals per day) - estimated 
treatment proportion
Trends in veterinary consumption, both within and across spe-
cies, are presented in DAPD, allowing for comparison between 
sectors and adjusting for changes in live biomass. The esti-
mated live biomass is expressed as the number of standard 
animals with an estimated average weight on a given day. 
This may also be referred to as the ‘standard-animals-at-risk’, 
and takes into account species differences in body-mass and 
life-span.
DAPD or estimated treatment proportion is a statistical 
measure, providing a rough estimate of the proportion of 
animals treated daily with a particular antimicrobial agent. 
For example, 10 DAPDs indicate that an estimated 1% of the 
pig population, on average, receives a certain treatment on a 
given day (Section 4.3 and Chapter 9, Materials and Methods). 
Furthermore, presenting the veterinary consumption in DAPD 
allows comparisons with the antimicrobial consumption in the 
human sector as expressed in defined daily dose per 1,000 
inhabitants per day (DID), see Chapter 10, Terminology, for a 
description of DID.
At the European level, the ESVAC (European Surveillance 
of Veterinary Antimicrobial Consumption) project monitors 
veterinary usage in a number of countries. ESVAC monitoring 
is based on the quantity by weight of antimicrobials, using a 
“population correction unit” (PCU) as denominator to adjust for 
changes in size of the production animal population within the 
respective countries over time. A description of the methodol-
ogy used by ESVAC is contained in the first report “Trends in 
the sales of veterinary antimicrobial agents in nine European 
countries 2005-2009” [www.ema.europa.eu].
In the context of DANMAP, we base our comparison on dos-
ages in order to keep in focus the newer, potent antimicrobials 
Figure 4.1. Prescribed antimicrobial agents for humans, and for animals compared with the number of pigs produced, Denmark
Sources: Human therapeutics: The Danish Medicines Agency. Veterinary consumption: Until 2001, data are based on reports from the 
pharmaceutical industry of total annual sales from the Federation of Danish pig producers and slaughterhouses (1994-1995) and Danish 
Medicines Agency and Danish Plant Directorate (1996–2000). Data from 2001–2014 originate from VetStat. 
DANMAP  2014
Sources:  Human  therapeutics:  The  Danish  Medicines  Agency.  Veterinary  consumption:  Until  2001,  data  are  based  on  reports  from  the  
pharmaceutical  industry  of  total  annual  sales  from  the  Federation  of  Danish  pig  producers  and  slaughterhouses  (1994-­1995)  and  Danish  
Medicines  Agency  and  Danish  Plant  Directorate  (1996–2000).  Data  from  2001–2014  originate  from  VetStat
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such as fluoroquinolones and cephalosporins that are critically 
important in the treatment of human infections. Furthermore, 
the biomass of the live population is used as denominator to 
allow for comparisons of selection pressure between animal 
populations.
4.2 Total antimicrobial consumption
 
In 2014, the total veterinary consumption of antimicrobial 
agents, including agents used for companion animals, amount-
ed to 114 tonnes active compound (Table 4.1), representing a 
2% decrease compared with 2013. 
The decrease was mainly attributed to a 5% decrease in the 
amount used in pigs. The two major species, cattle and pigs, 
comprise equal proportions of live biomass. However, the vast 
proportion of cattle biomass consists of dairy cows, which have 
a very low consumption of antimicrobial agents compared with 
growing animals. In 2014, the antimicrobial consumption in 
pigs, cattle and poultry comprised 76%, ~11%, and ~1% of the 
total veterinary consumption, respectively (Figure 4.2).
Historically, the overall consumption – measured as kg active 
compound - was 44% lower in 2014 compared with 1994 - 
while the total meat production increased by 15% during this 
period (Table 3.1 and Figure 4.1). A major part of the decrease 
in consumption can be explained by the discontinued use of 
growth promoters (1994-1999). 
Note: Only the ATCvet group contributing mostly to the antimicrobial group is mentioned. Combination drugs are divided into active compounds. 
a) Penicillins with extended spectrum, cloxacillin and amoxicillin/clavulanic acid.        
b) Antimicrobials used for companion animals: DVFA has allocated kg active compound to the appropriate target species (horses/pets) based on 
knowlegde of which products are used for the particular species.
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Pigs, total 244 4,494 4 4 0 2,067 11,049 8,120 16,675 7,784 8,074 26,850 655 86,020
Sows and piglets 206 1,826 2 4 0 480 652 602 8,883 3,529 5,631 2,239 86 24,140
Weaners 32 2,446 2 0 0 729 6,899 3,123 1,735 3,250 2,149 15,207 559 36,131
Finishers 7 222 0 0 0 858 3,499 4,395 6,056 1,005 294 9,403 10 25,749
Cattle, total 539 492 101 0 0 6 193 0 7,979 948 1,048 1,720 22 13,048
Intramammaries - 25 72 - - 2 - - 226 164 6 - 2 497
Cows and bulls 11 259 27 0 0 2 129 0 7,306 581 888 1,174 1 10,377
Calves < 12 mdr 525 191 2 0 0 2 62 0 363 195 143 506 19 2,008
Heifers and steers 3 18 0 0 0 0 3 0 84 8 10 40 0 166
Poultry, total 9 21 0 0 0 10 359 0 120 326 83 617 2 1,548
Poultry incl. broilers, layers 
and other poultry
2 3 0 0 0 1 137 0 81 187 83 184 2 679
Turkeys 7 18 0 0 0 9 222 0 39 139 0 434 1 869
Other production animal 
species
297 247 0 0 1,678 123 514 0 1 1,574 4,264 613 6 9,318
Fur animals 0 247 - 0 - 123 514 - 1 1,565 1,132 613 6 4,202
Aquaculture 297 - - - 1,678 - - - - 9 3,132 - - 5,116
Companion animals 0 164 216 15 1 74 37 0 853 838 1,670 186 34 4,088
Horses 0 7 4 6 0 0 0 0 810 150 1,065 28 0 2,071
Pets(b) 0 156 211 9 1 74 37 0 43 687 605 158 34 2,017
Total 1,089 5,418 321 19 1,679 2,281 12,153 8,121 25,628 11,469 15,138 29,987 720 114,023
DANMAP 2014Table 4.1. Antimicrobial agents sold (kg active compound) by animal species and age group, Denmark 
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However, from 2001 to 2009, the antimicrobial consumption 
in production animals increased by 36% (Figure 4.1). This 
increase was driven mainly by an increase in consumption in 
pigs and should be seen in the context that the number of pigs 
produced increased by 19% (Table 3.1). At the same time the 
proportion of live pigs (approx. 30 kg) being exported has in-
creased and thus resulted in a decrease in the overall biomass 
of the pig population.
4.3 Antimicrobial consumption by animal species 
4.3.1 Antimicrobial consumption in pigs
In 2014, the total antimicrobial consumption in pigs was 86.0 
tonnes active compound (Table 4.1), a decrease of 4.6 tonnes 
(5%) compared with 2013. The treatment proportions (DAPD) 
in the pig population overall and by age group are presented in 
Figure 4.3 and in the web annex (Table A4.2).
The treatment proportion (DAPD) is much higher in the wean-
ing pigs, compared with finishers and sows (Figure 4.3). How-
ever, the biomass of the weaning pigs is very small (7.5-30 kg, 
4 weeks), compared with the finishers (31-107 kg, 12 weeks) 
and the sows. 
The DAPD of the total population should reflect the trends in 
selection pressure in the population. Due to the differences in 
treatment proportion between age groups, the DAPD of the 
total population is affected by changes in population structure. 
For example, an increased export of live pigs at 30 kg would, in 
itself, cause an increase in DAPD for the remaining population, 
because the DAPD for finishers is relatively low. Any changes 
in export and productivity must therefore be taken into ac-
count to get a true impression of the antimicrobial consump-
tion pattern and selection pressure in the pig production.  
Historically, the treatment proportion (DAPD) increased from 
2004 to 2009, followed by a decreased in 2010 and 2011, 
which most likely was a result of DFVA’s implementation of the 
“yellow card initiative” – a special provision for reduction of an-
Figure 4.2. Live biomass (mill. kg) and antimicrobial consumption (kg) in main animal species, Denmark DANMAP 2014
Note: The live biomass is estimated from census data (pigs, cattle and pet animals) and production data (poultry, fur animals, aquaculture). For 
poultry: the figures comprise only the biomass for the main production types (turkey and broiler production). The live biomass estimates for 
cattle, broiler, turkey, fur animals, aquaculture and pet animals based on 2012 data. The estimation procedures are described in Chapter 9.
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Note:  The  live  biomass  is  estimated  from  census  data  (pigs,  cattle  and  pet  animals)  and  production  data  (poultry,  fur  animals,  aquaculture).  For  
poultry:  the  figures  comprise  only  the  biomass  for  the  main  production  types  (turkey  and  broiler  production).  The  live  biomass  estimates  for  cattle,  
broiler,  turkey,  fur  animals,  aquaculture  and  pet  animals  based  on  2012  data.  The  estimation  procedures  are  described  in  Chapter  9.
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Figure  4.3.  Antimicrobial  consumption  (a)  in  the  pig  
production,  and  the  distribution  on  age  groups,  
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Figure 4.3. Antimicrobial consumption (a) in the pig production, 
and the distribution on age groups, Denmark 
Note: The” adjusted total” is adjusted for the increasing export of pigs 
at 30 kg (see text). “Sows” includes treatment in boars and piglets 
pre-weaning. 
a) The DAPD is calculated as the number of standard doses for one kg 
animal divided by the estimated live biomass in the age group at the 
total population (in tonnes).
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Figure 4.4. Antimicrobial consumption(a) in the total pig production(b), and in finishers, weaners, sows and piglets, Denmark
Note: Amphenicols, colistin, fluoroquinolones, intramammaries, gynecologicals and topical drugs are not included in the figure. Data from veteri-
nary practice are not included (<1% of the consumption in pigs). 
a) The DAPD is calculated as the number of standard doses for one kg animal divided by the estimated live biomass in the age group or the total 
population (in tonnes). 
b) Total pigs produced includes pigs exported at 30 kg, which has increased in numbers from 2.7 mill. in 2005 to 10.5 mill. in 2014. Consumption 
in these pigs is included only from birth to 30 kg body weight. See discussion in the DANMAP 2011. 
c) Beta-lactamase sensitive penicillins.         
DANMAP  2014 Bemærk	  data	  til	  denne	  graf	  er	  i	  excel ilen	  med	  figur	  4.3
:   henicols,  colistin,  fluor quinolones,  intramammaries,  gynecologicals  and  topical  drugs  are  not  included  in  the  figure.  Data  from  veterinary  practice  are  not  included  (<1%  of  the  consumption  in  pigs).
a)  The  DAPD  is  calculated  as  the  number  of  standard  doses  for  one  kg  animal  divided  by  the  estimated  live  biomass  in  the  age  group  or  the  total  population  (in  tonnes).
b)  Total  pigs  produced  includes  pigs  exported  at  30  kg,  which  has  increased  in  numbers  from  2.7  mill.  in  2005  to  10.5  mill.  in  2014.  Consumption  in  these  pigs  is  included  only  from  birth  to  30  kg  body  weight.  See  discussion  in  the  DANMAP  2011.
c   Bet -­lactamase  sensitive  penicillins.
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timicrobial consumption in pig production (See DANMAP 2010). 
The reductions in antimicrobial use were associated with in-
creasing use of vaccines (Textbox 4.2) and a slight temporary 
decrease in productivity in some herds, but disease outbreaks 
did not increase [Danish Veterinary Bulletin no. 6, 2012]. The 
antimicrobial consumption in pigs in 2014 was 14% lower than 
in 2009 (Figure 4.3).
In 2014, the antimicrobial consumption in pigs decreased by 
5% to approximately 28 DAPD (Figure 4.3) when adjusted 
for changes in export. Overall the number of pigs produced 
in 2014 increased by 3%, and the number of pigs exported 
increased by 13% (Table 3.1). 
Within the different age groups, the DAPD decreased in all 
age groups; 5% in sow herds, and 2% in weaners and 7% in 
finishers. The decrease was associated primarily with the use 
of tetracyclines, and to a lesser extent, to the use of pleuromu-
tilins and macrolides (Figure 4.4). Tetracyclines and pleuromu-
tilins have been the most commonly used antimicrobial agents 
in the Danish pig production for a decade (Figure 4.4). They 
are almost entirely administered orally, and particularly used 
for treatment of gastrointestinal disease in weaning pigs and 
finishers. The overall treatment proportion (DAPD) of pleu-
romutilins decreased by 11%, while the use of tetracyclines 
decreased by 9%.
For the critically important antimicrobial agents, the use of 
flouroquinolones decreased markedly from 11 kg to 4 kg, 
because a clinical trial for which the flouroquinolones have 
largely been used for over the past years did not continue in 
2014. The use of cephalosporins continued to increase (from 
3 to 4 kg), but still constitutes less than 1 per mille of the total 
consumption in pigs (Figure 4.4).
In 2014 the Danish pig producers committed themselves to 
reduce the consumption of tetracyclines by 50% by the end of 
2015. 
DANMAP 2014 includes an overview of the use of vaccines 
and consumption of zinq in the Danish pig production, see 
Textbox 4.2. and 4.3.
Note: For intramammary therapeutic treatment, 1 DADD is defined as the dose to treat two teats for 24 hours. For drying off treatment, 1 DADD is 
defined as the dose to treat 4 teats. One product used for both indications is included as half drying off and half therapeutic treatments.
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total doses per indication (a) DADDs (1000's)
Drying off treatment  (4 teats) 73 75 71 76 82 99 97 117 125 140
Therapeutic treatment (2 teats) 420 408 388 377 378 350 307 279 253 259
Table  4.3. Number of treatments with antimicrobial agents for intramammary application in cattle, Denmark DANMAP 2014
DANMAP 2014Table  4.2. Use of antimicrobial agents for intramammary application in cattle, Denmark
Note: For intramammary treatment, 1 DADD is defined as the dose to treat two teats for 24 hours. 
a) Includes benzylpenicillin, cloxacillin, and cloxacillin-ampicillin combinations (QJ51CE, QJ51CF, QJ51RC). 
b) Mainly dihydrostreptomycin-benzyl benicillin combinations; includes also combinations of penicillin/aminoglycoside with bacitracin or nafcillin 
(QJ51RC). 
c) Lincosamides, neomycin-lincomycin combinations and trimethoprim-sulfonamide combinations.  
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Doses per antimicrobial class DADDs (1000's)
Penicillins(a) 201 211 211 236 282 314 318 324 311 317
Aminoglycoside-benzylpenicillin 
combinations(b)
130 104 101 101 110 93 48 47 58 90
Cephalosporins,
1st generation
103 98 89 85 89 89 99 105 111 113
Cephalosporins,
3rd and 4th generation
110 124 127 112 76 51 34 30 24 21
Others(c) 21 20 16 15 14 12 9 8 0 0
Total 566 558 544 549 570 559 508 514 504 541
Total DADD per cow per year 1.0 1.0 1.0 1.0 1.0 1.0 0.9 0.9 0.9 1.0
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4.3.2 Antimicrobial consumption in poultry 
In Denmark, poultry production comprises mainly the broiler 
production (Gallus gallus), followed by egg layers (Gallus gal-
lus) and turkey production. In addition, there is a very small 
production of ducks, geese, and game birds. 
In Denmark, the antimicrobial consumption in the broiler 
production is generally low compared with other species and, 
a few disease outbreaks in some farms can seriously affect 
the national consumption, causing considerable fluctuations in 
annual consumption data. 
In 2014, the total antimicrobial consumption in poultry (all 
poultry) was 1,548 kg active compound, an increase of 22% 
compared with 2013, and was the highest amount recorded 
for more than a decade. The increase was marked in both 
turkeys (12%) and in other poultry (incl. Gallus gallus) (38%). 
The increase was mainly driven by a remarkable increase in 
the use of tetracyclines, and to a lesser extent broad spectrum 
penicillins and macrolides (not in turkeys) (Table 4.1). There 
appear to be several reasons for these increases. In the broiler 
production there has been widespread problems particularly 
with bacterial arthritis and gastrointestinal infections, in 2013 
and 2014. The turkey production has been challenged with 
prevalent respiratory disease during the same period.
For broilers, amoxicillin has been the most commonly used 
antimicrobial agent for at least a decade. Fluoroquinolones 
were the second most commonly used antimicrobial agent until 
2007 (when new medicines were approved for poultry), but 
has not been used in broilers in 2010-2014.
4.3.3 Antimicrobial consumption in cattle
In 2014, the consumption continued to increase to approxi-
mately 13 tonnes, which represents an 8% increase compared 
with 2013. The production of veal and beef remained more 
or less at the same level from year to year, while the milk 
production increased (Table 3.1)..The increase in antimicrobial 
consumption was mainly driven by a 13% increase in the use 
of beta-lactamase sensitive penicillins for adult cattle, from 
6,636 kg in 2013 to 7,532 kg in 2014.
The majority of the parenteral use in cattle is for cows (Table 
4.1), and is mainly prescribed for mastitis. The use of fluoroqui-
nolones in cattle has been low for the last decade and no use 
of fluoroquinolones was reported for cattle in 2014. Approxi-
mately 29 kg of cephalosporins were used systemically, which 
represents a 27% decrease compared with 2013 and a 38% 
decrease compared with 2012 (Figure 4.5). 
From 2005 to 2013 there was a slight reduction in the overall 
level of intramammary treatment; however in 2014 the use 
of intramammary treatment increased (Table 4.2). The main 
increase was seen for drying-off treatment, which increased by 
12%. Therapeutic treatment, however, increased by only 2% 
(Table 4.3). A “milk quality campaign” conducted by the Danish 
Cattle Association (Agriculture and Food Council) since 2010, 
most likely has contributed to this trend. The goals of the 
campaign are to reduce treatment of clinical mastitis by 50%, 
mainly through a reduction of treatment of subclinical mastitis, 
but also by increased monitoring of cell counts to determine 
the need for treatment. 
Order (DK) 785/2010 provides legal regulations of use of 
antimicrobial agents for mastitis in cattle (recommending using 
simple penicillins). Furthermore the industry has emphasized 
that farmers should use narrow spectrum penicillins to treat 
mastitis caused by Gram-positive bacteria, unless sensitivity 
testing reveals resistance towards these antimicrobials.
4.3.4 Antimicrobial consumption in aquaculture, fur 
animals and companion animals
The overall antimicrobial consumption in aquaculture increased 
by 43% to 5,116 kg in 2014 compared with 2013 (Table 4.1). 
Measured in kg active compound sulfonamide/trimethoprim 
comprised 61%, quinolones 33% and amphenicols 6%. The 
antimicrobial consumption in both 2012 and 2011 was very 
low compared to previous years, probably due to cold summers 
in 2011–2012. The increases observed in both 2013 and 2014 
are explained by the extraordinary warm summers, leading to 
high water temperatures and increased occurrence of bacterial 
infections [personal communication: N. H. Henriksen, Danish 
Aquaculture]. However, the aquaculture industry continues 
to focus on developing new and better vaccines, as well as 
improving vaccination strategies to reduce the risk of diseases 
that may require antibiotic treatment.
In 2014, the production of mink increased slightly to 17.9 
million mink from 17.2 million in 2013 (Source: Kopenhagen 
Figure 4.5. Consumption of 3rd and 4th generation 
cephalosporins in pigs and cattle, Denmark
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Fur). Antimicrobial consumption in fur animals decreased by 
approximately 14% to 4,202 kg active compound compared 
with 2013 (Table 4.1). This is the second year in a row with a 
decrease in consumption for fur animals, which is in contrast 
to the increase in consumption observed from 2008-2012. In 
recent years, the industry, farmers and veterinarians have had 
increased focus on the consumption of antimicrobial agents, 
quality of feed and animal welfare in the mink production, and 
this may explain the reduced consumption. Use of fluoroqui-
nolones and cephalosporins in fur animal production has been 
close to zero for several years.
The information available on antimicrobial consumption in com-
panion animals is not as detailed as for production animals. In 
2014 the overall antimicrobial consumption in pets amounted 
to 2,017 kg active compound, which was almost at the same 
level as in 2013 (1,989 kg in 2013). 
A large proportion of antimicrobials used for pet animals are 
prescribed for treatment of chronic or recurrent disease, mainly 
dermatitis. Particularly the consumption of critically important 
antimicrobial agents in pet animals could pose an important 
risk to owners of diseased dogs that are frequently treated. 
In 2014, the use of fluoroquinolones for use in pets was 9 kg. 
Thus, the amount of flouroquinolones used in pets constituted 
nearly 47% the total veterinary use (kg) of fluoroquinolones. 
Similarly, the pets accounted for a significant proportion (211 
kg or 66%) of the use of cephalosporins used in animals. 
However, over the past two years the consumption of fluo-
roquinolones and cephalosporins has been reduced by 8% 
and 22%, respectively, while the consumption of other anti-
microbial classes such as penicillins and sulphonamides and 
trimethoprim increased. The small shift in use of the differ-
ent antimicrobial classes may be a an effect of the treatment 
guidelines put out by Danish Veterinary Association in Novem-
ber 2012 that call for critically important antimicrobials to be 
avoided as much as possible,   
Birgitte Borck Høg, Leonardo de Knegt
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Textbox 4.1 
National actions for prudent antimicrobial use in animals
Implementation of differentiated taxes on antimicrobial agents for veterinary use
In September 2013 the Danish Veterinary and Food Administration, in cooperation with the Danish Health and Medicines Au-
thority, implemented differentiated taxes on the sales of antimicrobials and other medicines for veterinary use (Table 1). The 
initiative was part of the Second Veterinary Action Plan running from 2013 to 2016 [FVST 2012, Forlig om veterinærområdet, 
in Danish]. The action plan is supported politically by the entire Danish Parliament.
The initiative strengthens the incentive to choose alternatives to antimicrobial treatment (e.g. vaccines) or when antimicrobial 
treatment has to be used, to choose the most responsible antimicrobial treatment in a One Health perspective. 
The tax is fixed by law [BEK 534 of 27/05/2014, in Danish] and gives a yearly income of approximately 8.3 mill. DKK (1.1 
mill. Euro), which contributes to the financing of the Danish effort of responsible and prudent use of veterinary antimicrobial 
agents. In practice, the tax is collected when pharmacies and other distributers sell veterinary medicines. 
Mette Kirkeskov Sie 
For further information: Mette Kirkeskov Sie (meksi@fvst.dk)
New legislation on antibiotic treatment of groups of pig
In June 2014, as part of the Second Veterinary Action Plan, the Danish Veterinary and Food Administration introduced legisla-
tion on treatment of flocks of pigs. The purpose of the legislation is to make veterinarians choose the most effective treat-
ment and thereby reduce the use of antibiotics in pigs in order to maintain the low level of antimicrobial resistance in Denmark.
The new legislative requirements apply for veterinarians and pig farmers with a Veterinary Advisory Service Contract (VASC). 
When veterinarians prescribe antibiotic treatment for respiratory or gastrointestinal infections for administration through feed 
and water the veterinarian must – in order to verify her/his clinical diagnosis - take samples for laboratory testing. The samples 
must be submitted to a laboratory approved by the Danish Veterinary and Food Administration or a foreign laboratory that has 
been approved [BEK 534 of 27/05/2014, § 46.1].
Medicine group Tax level (b)
Vaccines No tax
Penicillins, simple and narrow spectrum 0.8%
Other veterinary antimicrobials 5.5%
Critically important antimicrobials (a) 10.8%
Other veterinary medicines (not antimicrobials) 0.8%
a) 3rd and 4th generation cephalosporins and flouroquinolones.
b) Previously, sales of antimicrobials and other medicines for 
veterinary use was taxed by 0.84%. The differentiated taxes was 
implemented in September 2013.   
Table 1. Differentiated taxes on sales of antimicrobials and 
other medicines for veterinary use.  
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Veterinary Advisory Service Contracts
The first statutory order on Veterinary Advisory Service Contracts (VASC) in herds of cattle and pigs came into force in 1995. 
Since then, the concept has been improved and extended several times. Until 2010, the signing of a VASC was optional. Today 
the VASC is mandatory for large herds of cattle, pigs and mink farms and voluntary for smaller herds. On one hand, the VASC 
results in frequent veterinary advisory visits to the farm and consequently a close contact between the veterinarian and the 
farmer. On the other hand it provides the farmer with extended treatment possibilities. 
The aims of the VASC are to:
• Focus on advice and prevention of illness rather than treatment 
• Improve standard of animal health
• Minimise risk of infectious diseases
• Optimise use of antimicrobials in order to prevent antimicrobial resistance
• Improve animal welfare
• Incorporate an incentive scheme where documented prudent use of antibiotics may lead to a reduced frequency of 
 veterinary advisory visits.   
The farmer is free to choose between a basic or an advanced VASC. With an advanced VASC, the farmer is given extended 
rights in return for which he must have more advisory visits. Only an advanced VASC allows the farmer to initiate treatment 
and gives him access to veterinary medicine products for a prolonged period of time compared with the five days, which apply 
for farmers with a basic or no VASC.
The number of required advisory visits differs between species, age groups and category. 
VASCs are categorised as in ‘non-compliance’, if convicted for violating legislation regarding animal health, animal welfare or 
use of veterinary medicine or extended use of antimicrobials within the past two years. The Herds in the non-compliance cat-
egory have more advisory visits and shorter periods for prescription of veterinary medicine products. The VASCs in the compli-
ance category have the lowest number of advisory visits, and the veterinarian can prescribe veterinary medicine products for 
longer than a five day period.  
All VASCs have to be electronically registered in a database at www.vetreg.dk.  The database calculates and displays type of 
VASC, number of advisory visits, prescription periods and current category for the farmer, the veterinarians and the veterinary 
control officer.
Helle Kjær Nielsen 
For further information: Helle Kjær Nielsen (hkni@fvst.dk)
If the laboratory test shows that the initiated treatment is not optimal, the veterinarian must evaluate and correct treatment 
if necessary. If the laboratory test result is non-conclusive, the veterinarian must take samples for additional testing according 
to laboratory guidelines.
Following the initial laboratory test, the veterinarian must submit samples to the laboratory for verification. The intervals for 
re-sampling depend on the compliance category of the VASC. 
The prescription period for antibiotics for treatment of groups of pigs is shortened compared to the general prescription rules 
relating to VASC. Since veterinarians may only prescribe veterinary medicinal products (VMP) in connection with a visit to the 
farm, the veterinarian must consequently visit the farm repeatedly if there is need for continued use of medication for group 
treatment.
Anne Rath Petersen 
For further information: Anne Rath Petersen (arp@fvst.dk)
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Textbox 4.2
Use of vaccines in the Danish pig production 2004-2014
Background: During the last 10 years there has been a remarkable increase in the use of vaccines in the Danish pig produc-
tion. The development over this period is described below by dividing the vaccines in four groups, i.e. vaccines for: 1) gastroin-
testinal infections (GI), 2) respiratory infections, 3) systemic bacterial infections or bacterial and viral infections in combination, 
and 4) viral infections (monovalent vaccines). 
Vaccines for gastrointestinal infections: This group includes vaccines used for prevention of enteric diseases caused by 
Escherichia coli, Clostridium perfringens and Lawsonia intracellularis and reached 5.3 mill. doses in 2014. Vaccines against 
different types of E. coli and C. perfringens are used for prevention of neonatal diarrhea while the vaccine against L. intracel-
lularis is used for prevention of enteritis in weaners and finishers. From 2004 to 2014 the usages increased by 56% (Figure 
1); caused by introduction of a vaccine against L. intracellularis in 2005 reaching 1.9 mill. doses in 2014. In contrast, the use of 
vaccines for E. coli and C. perfringens remained almost constant throughout this period. 
Vaccines for respiratory infections: This group includes vaccines used for prevention of diseases caused by swine influen-
za, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae and toxin producing Pasteurella multocida. There has been 
an increase of 55% from 2004 till 2014 (13.7 to 21.3 mill. doses) which was mainly due to a 40% increase in vaccines for M. 
hyopneumoniae reaching 15 mill. doses in 2014 (Figure 1). Vaccines for A. pleuropneumoniae increased 115% reaching 4.8 
mill. doses in 2014, and influenza vaccines increased 14 times from 0.1 mill doses in 2004 to 1.4 mill. doses in 2014. 
Figure 1. Use of different groups of vaccines for pigs, Denmark 2004-2014 DANMAP 2014
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Vaccines for systemic bacterial infections: There has been a 27% increase reaching 6.3 mill. doses in 2014 of this group of 
vaccines which include vaccines against erysipelas, leptospirosis, Haemophilus parasuis and a few combi-vaccines also includ-
ing porcine parvovirus. The increase is related to increased vaccination against reproductive problems caused by swine specific 
leptospira.
Vaccines for systemic virus infections: This group comprises vaccines against PRRS (porcine respiratory and reproductive 
syndrome), PCV2 (porcine circovirus type 2) and PPV (porcine parvovirus). There has been a dramatic increase in the use of 
virus vaccines from 1.4 mill. doses in 2004 to 16.2 mill. doses in 2014. 
The major part of the increase is due to the introduction of vaccines against PCV2 in 2006, reaching 14.6 mill. doses in 2014. 
PCV2 is causing PMWS (post weaning multisystemic wasting syndrome) and PCVAD (porcine circo virus associated diseases). 
From 1999 onwards a spread of PMWS was recognized globally that resulted in reduced production and increased use of 
antibiotics in many pig herds. The introduction of PCV2 vaccines was quite effective in reducing the prevalence of PMWS and 
PCVAD. Hence, these vaccines have become very popular worldwide.  
The use of vaccines against PRRS increased from 0.3 mill. doses to 1,4 mill. doses. However, the use of PRRS vaccines is rela-
tively limited in Denmark, partly due to a relatively high health status of Danish pig herds. Many herds are free from PRRS as 
well as other important swine specific diseases. 
Remarks concerning relations between use of vaccination and antibiotics: The effect of vaccination on the antimicrobial 
use cannot be estimated by simply comparing the total consumption of antimicrobial agents and application of different groups 
of vaccines. Correlations between the two strategies for prevention and treatment of infectious diseases must be analysed 
applying herd level data. However, some general comments may be given. 
The use of vaccination against L. intracellularis usually replaces a significant amount of antimicrobial treatments for diarrhea 
in the pig herd. Lawsonia infections are usually treated with tetracyclines, macrolides and pleuromutilines. These antimicro-
bial agents are also used for treatment of respiratory diseases, but most of the consumption in pigs is related to diarrhea in 
weaners and finishers. Most vaccines for pigs are used for prevention of systemic viral and respiratory diseases; infections that 
often cannot be treated by antibiotics. However, it is without doubt that the vaccination strategies against bacterial as well as 
viral infections tend to diminish antimicrobial consumption in Denmark.
Svend Erik Lind Jorsal 
For further information: Sven Erik Lind Jorsal (selj@vet.dtu.dk)
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Textbox 4.3
Use of zinc oxide in the Danish pig production 2005-2014
Zinc is a critical trace element for animals (and humans). In humans, zinc deficiency may result in growth retardation, skin 
diseases, impaired wound healing and last but not least diarrhoea. Furthermore, undernourished children suffering from 
diarrhoea recover when given extra zinc. Generally, extra zinc is added to pig diets as the inherent amount of zinc in feeding-
stuffs and mixed diets is not sufficient to fulfil the dietary requirement of the piglets. The most commonly used source of zinc 
is zinc oxide (ZnO) which contains 80% zinc. 
The use of zinc oxide prescribed by veterinarians has increased markedly over the last 10 years  (Figure 1). From 2005 to 2011 
a three-fold increase in use of zinc and zinc oxide was reported to VetStat, whereas the number of pigs produced in Denmark 
increased by 14%. Since 2011, the consumption has been relative stable at approximately 500 tonnes of zinc oxide (ZnO) 
equivalent to 400 tonnes of zink (Zn).     
Since the late 1980s, the practice of adding high amounts of zinc oxide to the feed has become widespread in commercial pig 
production to prevent or alleviate post-weaning diarrhoea in early weaned piglets. Many hypotheses about the mode of action 
behind the beneficial effects of high inclusion levels of zinc oxide have been developed and tested. However, there is growing 
evidence that the hypothesis stated in 1989 that piglets suffer from transient zinc deficiency after weaning is credible. The 
original results showed that 2,500 ppm zinc oxide/kg feed resulted in a 60% reduction of in the diarrhoea incidence in piglets, 
compared with lower dietary zinc levels (addition of 0, 100, 200, or 1,000 ppm zinc as zinc oxide)[Poulsen, 1989]. The author 
found that the alleviating effect of high dietary levels of zinc oxide was accompanied by an increase in plasma zinc concentra-
tion (0.2 mg/100 mL) in piglets fed 2,500 ppm zinc (as zinc oxide), whereas the plasma zinc concentration remained constant 
at 0.1 mg/100 mL in pigs fed 0, 100, 200, or 1,000 ppm zinc as zinc oxide. The 1989-study also demonstrated that two 
weeks of high dietary zinc levels were needed to obtain the alleviating effect of 2,500 ppm zinc.   
Piglets must be fed a sufficient amount of zinc every day, since the immediately available plasma and body zinc pool is very 
limited. Since the feed intake is very low right after weaning, the concentration of zinc in the diet must be increased to coun-
terbalance this. Two weeks after weaning, the feed intake has increased to a normal level and lower dietary zinc content of 
about 100 ppm is sufficient.  
There is an apparent need to develop a strategy, balancing the nutritional requirements and the animal welfare of weaned 
piglets, against the ability of zinc to select for antimicrobial resistant bacteria, as well as considering the environmental impact 
of zinc.
Professor Hanne Damgaard Poulsen 
Dep. of Animal Science - Animal nutrition and environmental impact, Aarhus University 
For further information: Hanne Damgaard Poulsen, (hdp@anis.au.dk)
Figure 1. Consumption (tonnes) of zinc oxide (ZnO) and zinc (Zn) in the pig production, Denmark 2005-2014 DANMAP 2014
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5. Antimicrobial consumption in humans
5.1 Introduction
 
In Denmark, the Register of Medicinal Product Statistics at 
Statens Serum Institut records all use of antimicrobial agents 
for humans. Monitoring has been performed since 1994 and all 
data on consumption in both primary health care and hospi-
tal care are registered. Primary Health care is in this setting 
defined as all non-hospital activity and corresponds to anti-
microbials sold upon prescriptions from general practitioners, 
medical specialists as well as clinicians at hospitals when 
discharging a patient.  
In this part, the term ‘antimicrobial  agents’ covers only anti-
bacterial agents for systemic use in humans; topical agents as 
well as agents used for treatment of  viral and fungal infec-
tions are not included. The report covers antibacterials listed 
in the Anatomical Therapeutic Chemical (ATC) Classification 
System under the code J01. Currently available antimicrobial 
agents for systemic treatment in humans (and in animals) are 
listed in Table 3.2. 
Data on oral (and rectal) metronidazole (regis-
tered under the code for the antiparasitic products 
P01AB01) and oral vancomycin (registered under 
intestinal antiinfectives A07AA09) are included 
for the first time in this report. The oral and rectal 
preparations of these drugs are first line choice in the 
treatment of Clostridium difficile, which has been an 
emerging problem since 2006.  Figures and tables are 
updated 10 years back. 
Previously in DANMAP, antimicrobial agents have been 
grouped into narrow- and broad-spectrum activity and their 
consumption reported as such. In 2014, this classification has 
been abandoned due to a lack of a national or international 
consensus on the definition. The focus in this report is placed 
on evaluation of the total consumption as well as consumption 
of the most important single agents. 
5.2 Total consumption (primary health care and hospital care)
 
In 2014, the total consumption of antimicrobial agents for sys-
temic use (primary health care and hospital care) was 18.58 
DID, which is 3% lower than the previous year corresponding 
to a decrease of 0.5 DID (19.10 DID in 2013). Notably the 
majority of this reduction was due to decreased use of tetra-
cyclines in primary health care (see text 5.3.1). Consumption 
in the primary sector accounted for 16.40 DID and at hospitals 
for 2.18 DID (Figure 5.1). This corresponds to 52,819 kg active 
substance (Table A5.1 in web annex).
Since the first DANMAP report in 1997 the total consumption 
increased with 4.99 DID (approximately 40%) and from 2005 
with 1.96 DID (11%), reaching a peak in 2011 with a total DID 
of 19.31. Since 2011, the consumption, when measured in DID, 
has stagnated. 
Primary health care accounts for approximately 90% of the 
total antimicrobial consumption and thus significant changes 
in prescription here will markedly affect the total consumption. 
The distribution between the sectors for the individual antimi-
crobials is shown in Figure 5.2. 
Figure 5.1. Total consumption of antimicrobial agents in humans in primary health care vs hospital care, Denmark. DANMAP 2014
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Figure  5.2.  Distribution  of  DIDs  between  primary  health  care  and  hospital  care,  Denmark
DANMAP  2014
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Figure 5.2. Distribution of DIDs between primary health care and hospital care, Denmark
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ATC group(a) Therapeutic group
Year
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
J01AA                        Tetracyclines               1.28 1.38 1.48 1.54 1.61 1.69 1.64 1.76 1.96 1.66
J01CA                        Penicillins with extended spectrum 2.79 2.95 3.25 3.26 3.29 3.47 3.41 3.40 3.48 3.53
J01CE                        Beta-lactamase sensitive penicillins     5.28 5.40 5.67 5.30 5.12 5.25 5.31 4.68 4.65 4.38
J01CF                        Beta-lactamase resistant penicillins     0.97 1.05 1.09 1.12 1.13 1.17 1.14 1.21 1.30 1.36
J01CR                        
Combinations of penicillins, including  
beta-lactamase inhibitors   
0.08 0.12 0.19 0.27 0.45 0.68 0.89 1.05 1.22 1.30
J01D                        Cephalosporins and other β-lactam antibiotics 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
J01EA                        Trimethoprim and derivatives   0.44 0.47 0.49 0.49 0.48 0.51 0.50 0.52 0.53 0.55
J01EB                        Short-acting sulfonamides       0.35 0.35 0.31 0.28 0.27 0.26 0.24 0.22 0.22 0.21
J01EE                        
Combinations of sulfonamides and 
trimethoprim, including derivatives
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 0.00
J01FA                        Macrolides                  2.41 2.31 2.42 2.28 2.21 2.44 2.47 2.19 1.93 1.79
J01FF                        Lincosamides                0.01 0.02 0.02 0.03 0.03 0.04 0.04 0.04 0.05 0.05
J01GB Aminoglycosides 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01
J01MA                        Fluoroquinolones            0.33 0.37 0.44 0.51 0.52 0.57 0.57 0.55 0.52 0.50
J01XA Glycopeptides 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01XB                        Polymyxins                 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.02 0.02 0.02
J01XC                        Steroid antibacterials (kombination fusidic acid) 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01
J01XE Nitrofuran derivatives (nitrofurantoin) 0.45 0.46 0.47 0.47 0.49 0.51 0.50 0.49 0.49 0.48
J01XX                       Other antibacterials (methenamine >99%)                0.28 0.27 0.26 0.27 0.26 0.27 0.26 0.25 0.24 0.24
J01XD and P01AB Nitroimidazole derivatives (metronidazole) 0.21 0.22 0.23 0.24 0.27 0.28 0.28 0.28 0.28 0.28
J01 Antibacterial agents for systemic use (total) 14.96 15.45 16.45 16.15 16.22 17.21 17.34 16.75 16.95 16.40
Table 5.1. Consumption of antimicrobial agents for systemic use in primary health care (DDD/1000 inhabitant-days), Denmark
a) From the 2014 edition of the Anatomical Therapeutic Chemical (ATC) classification system.
DANMAP 2014
DANMAP 2014
Figure 5.4. Consumption of leading antimicrobial groups for systemic use in primary health care, Denmark
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5.3 Primary health care
 
5.3.1 Total consumption in primary health care
In primary health care, the consumption of antimicrobial agents 
was 16.40 DID in 2014, which is approximately 3% lower than 
observed in 2013 (Table 5.1). However, this is largely due to 
a decrease in consumption of tetracyclines, especially doxy-
cycline, which had an unusual peak in 2013. The reason for 
these fluctuations is presently unknown.
During the last decade the consumption increased from 14.96 
DID in 2005 to 17.34 DID in 2011 (16%), but has since stag-
nated. 
Beta-lactamase sensitive penicillins represented the largest 
therapeutic group of antimicrobial agents consumed (27%) – 
and penicillins in general (including combinations with beta-
lactamase inhibitors) accounted for 65% of the total consump-
tion in 2014. Macrolides accounted for 11%, tetracyclines for 
10%, sulfonamides and trimethoprim for 5%, nitrofurantoin 
and fluoroquinolones for each 3% (Figure 5.3). 
Metronidazole (J01XD and P01AB01) accounted in 2014 for 
0.28 DID (approximately 2%). The consumption increased from 
0.21 DID in 2005. The oral and rectal preparations of metro-
nidazole are registered as an antiparasitic drug but consump-
tion also covers treatment of anaerobic and mixed anaerobic 
infections, such as gynaecological or odontological infections. 
Since abdominal infections with Clostridium difficile became 
an emerging problem in hospitals in 2006, treatment of these 
have also become quite common in outpatient care. Patients 
might be infected at hospital, but treatment most often contin-
ues for weeks to months after discharge.
Changes over time for the consumption of the leading antimi-
crobials are presented in Figure 5.4. Fluoroquinolones (primar-
ily ciprofloxacin) increased from 2005 to 2011 (0.33 DID to 
0.57 DID), but have since 2012 shown a decreasing trend. In 
2014 the consumption of ciprofloxacin was 0.50 DID.
5.3.2 Measures at treated patient level
In 2014, each treated patient received 21.5 DDDs per year 
(Table 5.2). The number of patients treated was slightly lower 
compared to 2013 while the DDD per package remained at 
the same level (Table A5.2 and A5.3 in web annex). Dur-
ing the past decade, the total number of DDDs per package 
has increased by 22%, reaching the highest level in 2013. 
Similarly, the number of DDDs per patient has also increased 
notably since 2005 while the number of packages per patient 
has remained relatively constant. The biggest changes in DDD/
patient since 2005 have been observed for tetracyclines (from 
39.0 to 49.9 DDD/patient), for combination penicillins (from 
16.8 to 23.2 DDD/patient) and for beta-lactamase resistant 
penicillins (from 12.7 to 17.1 DDD/patient) (Table 5.2 and 
Table A5.3 in web annex). 
For tetracyclines, both the number of DDDs per patient and 
DDDs per package are significantly higher than for any other 
antimicrobial group, primarily due to the fact that tetracy-
clines are commonly used for acne treatment with higher 
Figure 5.3. Distribution of the total consumption of antimicrobial agents in primary health care, Denmark
DANMAP 2014
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dosages given in treatments of typically three, but up to six 
months. 
When examining the three different indicators at patient level 
in 2014, a slight decrease was observed for DIDs (Figure 5.5), 
thus receding to the same level as in 2009, while the num-
ber of packages and treated patients has remained relatively 
constant for the past decade. In other words, while the dosage 
prescribed for each patient and in each package has increased 
significantly since 2005 the data for 2014 might point 
towards a possible change in prescription and thus a drop in 
consumption. 
5.3.3 Penicillins
Penicillins account for 2/3 of all antimicrobial consumption in 
primary health care, but while this has remained unchanged 
since 2005 individual changes in the consumption of the dif-
ferent groups of penicillin have been observed.
The overall consumption of penicillins remained largely the 
same in 2014 (10.58 DID) compared to 2013 (10.65 DID), the 
first time in a decade where no apparent increase has been 
observed. From 2005 to 2014 the consumption of penicillins 
increased by 16% (9.12 DID in 2005). 
Figure 5.5. Indicators of antimicrobial consumption (J01) in primary health care, Denmark 
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Figure 5.6. Consumption of leading penicillins in primary health care, Denmark
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The consumption of beta-lactamase sensitive penicillins con-
tinued to decrease from 2013 to 2014 (6%), whereas increas-
es in consumption were observed for ‘combination penicillins’ 
(7%), beta-lactamase resistant penicillins (5%) and penicillins 
with extended spectrum (1.5%). 
The consumption of these three groups has also increased 
considerably over the past decade with particular increases 
for beta-lactamase resistant penicillins from 0.97 DID to 1.36 
DID (40%), penicillins with extended spectrum from 2.79 DID 
to 3.53 DID (27%) and the combination penicillins with beta-
lactamase inhibitors from 0.08 DID to 1.30 DID (1600%) (Table 
5.1). 
At the substance-level, phenoxymethylpenicillin continues 
to be the most commonly consumed penicillin despite a con-
tinuous decrease in consumption from 2005 to 2014 (from 
5.28 DID to 4.38 DID, a decrease of 17%). Similarly pivampi-
cillin and amoxicillin show a decrease over the last decade 
from 0.58 DID to 0.24 DID and from 1.21 DID to 0.99 DID, 
respectively.  Meanwhile the consumption of three other 
substances continued to increase; amoxicillin and enzyme 
inhibitor from 0.08 DID to 1.3 DID, pivmecillinam from 0.97 
DID to 2.28 DID and flucloxacillin from 0.01 DID to 0.45 DID 
(Figure 5.6).
A likely explanation for the increase in ‘combination penicillins’ 
might be changes in national recommendations for treatment 
of patients with exacerbation of chronic obstructive pulmo-
nary disease (COPD) where amoxicillin with clavulanic acid 
has become a first line drug. Still increases in consumption 
have also been observed for other patient and age groups e.g. 
small children, which points towards an altogether change in 
prescription habits.  
The increased consumption for flucloxacillin was accompanied 
by a minor decrease in dicloxacillin but as for the other broader 
penicillin groups the total increase in consumption remains yet 
to be explained. 
It is assumed that patients’ demands on receiving antibiotic 
treatment upon illness might play an important role in the 
increasing total consumption, as well as for changes in the 
consumption of individual antimicrobial agents. National 
campaigns targeting the problem have been launched. Focus 
in campaigns and in local guidelines, is placed on reducing the 
amount of antibiotics consumed altogether, as well as choos-
ing the agent with the most narrow spectrum when treatment 
seems necessary.   
Further investigations on prescription habits and trends and 
the increase in consumption of different penicillin groups will 
be undertaken over the next years.
5.3.4 Macrolides
The consumption of macrolides in Denmark often fluctuates 
from year to year depending primarily on the presence or 
absence of Mycoplasma pneumoniae outbreaks among the 
population.  
The consumption in 2014 (1.79 DID) was the lowest observed 
this decade. This follows the two ‘epidemic’ years of 2010 and 
2011 (DANMAP 2010- 2012), after which no significant M. 
pneumoniae outbreaks have been observed and the consump-
tion of macrolides has been accordingly low (Table 5.2). 
At the substance level, the consumption of clarithromycin 
and azithromycin increased, while the consumption of eryth-
romycin decreased substantially for the whole period. These 
Figure  5.7.  Consumption  of  macrolides  in  primary  health  care,  Denmark
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changes in consumption were observed for all age groups (not 
shown). For roxithromycin, the consumption decreased since 
2011. (Figure 5.7).
5.3.5. Tetracyclines
For the first time since 2005, the consumption of tetracyclines 
has decreased by 15% from 2013 to 2014 (1.96 DID to 1.66 
DID). The decrease was observed for all tetracyclines, however 
the reduction is primarily due to a marked decrease in the use 
of doxycycline, showing an unexplained increase from 2012 to 
2013 but returning to the 2012 level in 2014 (Figure 5.8). 
For tetracycline and lymecycline trends in consumption paral-
leled, increasing steadily from 2005 (0.61 and 0.18 DID re-
spectively) until 2013 (0.77 and 0.39 DID) and showing similar 
decrease from 2013 to 2014 (0.69 and 0.36 DID).
5.4 Hospital care
 
5.4.1  Introduction
The antimicrobial consumption for hospital care reported was 
related only to bed-days and admissions in public somatic 
hospitals. Specialized hospitals (psychiatric hospitals, hospices 
and rehabilitation centers) were omitted as they contribute a 
large proportion of bed-days and admissions but only a small 
proportion of antimicrobial consumption (approximately 3%), 
The consumption  of  antimicrobial  agents  in  hospital care  is  
presented  as  DDD  per  100  occupied  bed-days (DBD) and as 
DDD per 100 admissions (DAD) to account for hospital activ-
ity. Data are also presented as DID to enable comparison with 
primary health care.
During the past decade, the hospitalization pattern in Denmark 
has changed notably: more people are admitted to somatic 
hospitals while the average length of stay is considerably 
shorter (Figure 5.9, Table A5.4 and A5.5 in web annex). Selec-
tion pressure for the emergence of antimicrobial resistance 
increases with increasing hospital activity and thus the selec-
tion pressure has increased considerably from 2005 to 2014. 
5.4.2 Somatic hospitals – DDD per 100 occupied  
bed-days (DBD) 
In 2014, the consumption of antimicrobial agents in somatic 
hospitals increased from 99.88 DBD in 2013 to 104.30 DBD 
in 2014 (4%) (Table 5.3). In the past decade, the consumption 
increased from 66.32 DBD in 2005, an increase of 57%. This 
reflects a combination of the described increased hospital 
activity and decreased number of hospital bed-days with an 
increase in DDDs. 
In 2014 extended spectrum penicillins represented the largest 
group of antimicrobials consumed (16%), closely followed by 
combination penicillins (15%). Penicillins in general accounted 
for 50% of the total consumption. Cephalosporins (11%) and 
fluoroquinolones (9%) were also still among the most common-
ly consumed antimicrobial agents in hospitals (Figure 5.10).   
The total consumption of antimicrobials showed only minor 
changes compared to previous years. Nevertheless, from 2013 
to 2014 marked changes were observed for the imidazole 
derivatives from 4.08 DBD to 4.48 DBD (9%) and within the 
group of beta-lactams. Increases were thus observed in the 
consumption of combination penicillins from 13.64 DBD to 
16.04 DBD (18%) and in penicillins with extended spectrum 
from 15.06 to 16.40 DBD (9%), while a decrease was observed 
for 2nd generation cephalosporins from 12.32 DBD to 11.68 
DBD (5%) (Table 5.3).
These shifting trends in prescription of betalactams in somatic 
hospitals described for the period 2013 to 2014 were a con-
tinuation of changes observed for the last decade (Figure 5.11 
and table 5.3). Combination penicillins increased from 1.16 
DBD in 2005 to the mentioned 16.04 DBD in 2014 (380%), 
Figure 5.8. Consumption of tetracyclines in primary health care, Denmark
DANMAP 2014
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cephalosporins increased from 9.37 DBD in 2005 to 17.66 
DBD in 2011, but returned in 2014 with 12.76 DBD to a level 
slightly lower than in 2007 (13.47 DBD). Beta-lactamase sen-
sitive penicillins decreased from 12.17 DBD in 2005 to 9.32 
DBD in 2011, but increased again to 10.31 DBD in 2014. 
The observed increase in consumption of ‘combination peni-
cillins’ was most likely attributable to a change in empiric 
treatment from cefuroxime to piperacillin with tazobactam for 
severe infections. These changes were implemented dur-
ing 2011 to 2014 as recommended by the National Board of 
Health to lower the selection pressure for ESBL producing 
Enterobacteriaceae (DANMAP 2012). In the same period piper-
acillin with tazobactam became in many hospitals the first line 
drug in recommendations for the treatment of complicated 
pneumonia. These changes were paralleled by an increase in 
the recommended dosages of amoxicillin-clavulanic acid for 
treatment of acute exacerbation of chronic obstructive pulmo-
nary diseases (COPD). 
Although the recent changes in treatment of critically ill pa-
tients have had a significant effect on reduction in the con-
sumption of cephalosporins, cefuroxime still accounts for 11% 
of the total consumption, mainly because it  is still used as a 
first line drug in antibiotic prophylaxis for different surgical 
interventions. From 2005 to 2014 2nd generation cephalospo-
rins increased with 39% (from 8.39 to 11.68 DBD), peaking in 
2010 with 16.21 DBD.
Fluoroquinolones (primarily ciprofloxacin) showed an increase 
in consumption from 6.14 DBD in 2005 to 10.70 DBD in 2011 
(74%) but since then the consumption has stagnated and 
shown a decreasing trend for the last three years. In 2014, the 
consumption of fluoroquinolones was 9.88 DBD.
The consumption of carbapenems was 4.09 DBD in 2014, 
which is slightly higher than 2013 (4.02 DBD). From 2005 to 
2011, an increase of 370% was observed (1.16 to 4.16 DBD). 
Since then the consumption stagnated. Thus in spite of recom-
mendations from the National Board of Health on the reduced 
use of carbapenems and delivery problems for meropenem 
during the summer of 2014 no apparent decrease in merope-
nem consumption was observed. 
5.4.3 Other measures of somatic hospital consumption
DDD per 100 admissions (DAD) 
Because of the observed changes in the number of hospital 
bed-days over time, the consumption of antimicrobials in Dan-
ish hospitals may also be measured in relation to admissions 
(i.e. DDD per 100 admissions, DAD).
When expressed as DAD, the total consumption of antimicrobial 
agents in somatic hospitals showed only a slight decrease from 
2013 to 2014 (from 325.2 DAD to 324.1 DAD) (Table 5.4). Dur-
ing the past decade, DAD increased by 12%; an increase primar-
ily driven by a higher number of DDDs but counterbalanced by 
an increase in the number of hospital admissions. 
With respect to individual antimicrobial groups, increases were 
observed for ’combination penicillins’, beta-lactamase resistant 
penicillins and combinations of sulfonamide and trimethoprim. 
As observed since 2012, the consumption of 2nd generation 
cephalosporins and fluoroquinolones also decreased in 2014 
by 8.9% and 4.3%, respectively. The same trends were seen 
when consumption was expressed as DBD (Table 5.3)
DDD per 1,000 inhabitants per day (DID) 
The consumption of antimicrobial agents in somatic hospitals 
increased from 2.15 DID in 2013 to 2.18 DID in 2014. In the 
past decade, the DIDs consumed in hospitals have increased by 
22% (1.76 DID in 2005), (Table A5.4 in web annex). 
Katrin Gaardbo Kuhn, Maja Laursen 
and Ute Wolff Sönksen 
DANMAP  2014
Figure  5.9.  Number  of  bed-­days  and  admissions  in  somatic  hospitals,  Denmark
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Figure 5.10. Distribution of the total consumption of antimicrobial agents in somatic hospitals, Denmark
Figure  5.10.  Distribution  of  the  total  consumption  of  antimicrobial  agents  in  somatic  hospitals,  Denmark
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Cephalosporins  
(J01DB,DC,DD);;  11%
Penicillins  with  extended  
spectrum  (J01CA);;  16%
Fluoroquinolones   (J01MA);;  9%
Beta-­lactamase   sensitive  
penicillins  (J01CE);;  10%
Beta-­lactamase   resistant  
penicillins  (J01CF);;  9%
Comb.  of  penicillins,   incl.  beta-­
lactamase   inhib.  (J01CR);;  15%
Carbapenems   (J01DH);;  4%
Macrolides,   lincosamides   and  
streptogramins   (J01F);;  4%
Sulfonamides   and  trimethoprim  
(J01E);;  5%
Aminoglycosides   (J01G);;  2%
Other  antibacterials   (J01A,DF,X,  
P01AB01);;   13%
Table 5.2. Number of DDDs and packages per treated patient among leading groups of antimicrobial agents in primary health care, 
Denmark
ATC 
group(a)
Therapeutic group Indicator
Year
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
J01AA Tetracyclines               
DDDs / patient 39.0 40.9 43.0 44.4 45.2 45.9 44.0 47.6 51.6 49.9
Packages / patient 2.0 1.9 2.0 2.0 2.0 2.0 1.9 2.1 2.1 2.1
DDDs / package 19.6 21.0 22.0 22.7 22.7 22.7 22.6 23.1 25.5 23.8
J01CA
Penicillins with extended 
spectrum
DDDs / patient 13.9 14.2 14.4 14.7 14.8 14.9 14.8 16.1 16.7 17.2
Packages / patient 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.7 1.7 1.7
DDDs / package 8.5 8.9 9.0 9.2 9.2 9.0 9.2 9.7 10.0 10.0
J01CE
Beta-lactamase sensitive 
penicillins     
DDDs / patient 11.3 11.5 11.7 11.8 11.8 11.8 11.8 11.8 12.0 11.9
Packages / patient 1.5 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4
DDDs / package 7.7 8.0 8.2 8.2 8.4 8.4 8.4 8.4 8.5 8.5
J01CF
Beta-lactamase resistant 
penicillins     
DDDs / patient 12.7 13.0 13.4 13.7 13.9 14.2 13.8 15.5 16.4 17.1
Packages / patient 1.6 1.5 1.5 1.5 1.5 1.5 1.4 1.6 1.7 1.8
DDDs / package 8.0 8.6 8.7 9.0 9.1 9.3 9.6 9.7 9.4 9.7
J01CR
Combinations of penicillins, 
incl. beta-lactamase 
inhibitors   
DDDs / patient 16.8 19.3 19.1 19.9 20.4 21.1 21.9 22.3 22.6 23.2
Packages / patient 2.0 1.8 1.6 1.6 1.5 1.5 1.6 1.6 1.6 1.6
DDDs / package 9.3 10.7 11.7 12.4 13.3 13.7 14.1 14.3 14.3 14.3
J01FA Macrolides                  
DDDs / patient 12.4 12.6 12.4 12.5 12.5 12.2 11.5 12.4 12.6 12.8
Packages / patient 1.6 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.6 1.6
DDDs / package 8.0 8.3 8.1 8.1 8.1 8.1 7.9 8.0 8.0 7.9
J01MA Fluoroquinolones            
DDDs / patient 9.6 10.3 10.6 11.0 11.2 11.2 11.5 11.7 11.8 11.9
Packages / patient 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
DDDs / package 6.5 6.9 7.0 7.5 7.6 7.6 7.7 7.8 7.8 7.9
J01
Antibacterial agents for 
systemic use (total)
DDDs / patient 17.5 17.9 17.3 18.9 19.2 19.6 19.4 20.6 21.3 21.5
Packages / patient 2.1 2.0 1.9 2.1 2.1 2.1 2.1 2.1 2.1 2.2
DDDs / package 8.3 8.7 8.9 9.1 9.3 9.3 9.3 9.7 9.9 9.9
DANMAP 2014a) From the 2014 edition of the Anatomical Therapeutic Chemical (ATC) classification system.
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Figure 5.11. Total somatic hospital consumption (DBD) by leading groups of antimicrobial agents (J01), Denmark
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Combinations   of  penicillins.   incl.  
beta-­lactamase   inhibitors  
(J01CR)      
Cephalosporins   (J01DB,  DC,  
DD)
Carbapenems   (J01DH)
Fluoroquinolones   (J01MA)                          
Aminoglycosides   (J01GB)
Macrolides  (J01FA)                                       
Beta-­lactamase   sensitive  
penicillins  (J01CE)
Penicillins  with  extended  
spectrum  (J01CA)
ATC group(a) Therapeutic group
Year
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
J01AA                        Tetracyclines               0.33 0.39 0.63 0.78 1.04 1.09 1.18 1.58 1.52 1.73
J01CA                        Penicillins with extended spectrum 12.90 13.00 13.42 13.96 15.37 14.61 14.41 14.90 15.06 16.40
J01CE                        Beta-lactamase sensitive penicillins     12.17 10.67 10.79 9.98 9.90 9.49 9.32 10.13 10.13 10.31
J01CF                        Beta-lactamase resistant penicillins     6.71 6.51 6.70 6.81 7.40 7.71 7.30 8.37 9.07 9.57
J01CR                        
Combinations of penicillins. incl. beta-
lactamase inhibitors   
1.16 1.83 2.95 4.00 5.65 7.13 8.51 12.00 13.64 16.04
J01DB                  First-generation cephalosporins 0.15 0.14 0.13 0.18 0.13 0.13 0.13 0.12 0.11 0.06
J01DC Second-generation cephalosporins 8.39 9.38 12.31 13.32 15.76 16.21 16.14 14.15 12.32 11.68
J01DD Third-generation cephalosporins 0.83 0.83 1.03 1.25 1.42 1.26 1.39 1.07 1.08 1.02
J01DF Monobactams 0.00 0.00 0.04 0.07 0.06 0.09 0.19 0.15 0.14 0.06
J01DH Carbapenems 1.16 1.38 2.13 2.70 3.15 4.02 4.16 3.86 4.02 4.09
J01EA                        Trimethoprim and derivatives   0.41 0.42 0.44 0.44 0.44 0.36 0.36 0.38 0.41 0.52
J01EB                        Short-acting sulfonamides       0.99 0.75 0.34 0.35 0.35 0.33 0.25 0.20 0.20 0.18
J01EE                        
Combinations of sulfonamides and 
trimethoprim. incl. derivatives 
2.11 2.12 1.52 1.95 2.28 3.04 4.11 3.33 4.21 4.70
J01FA                        Macrolides                  2.89 2.83 3.08 3.06 3.42 3.52 3.69 3.56 3.39 3.88
J01FF                        Lincosamides                0.24 0.31 0.35 0.41 0.50 0.47 0.53 0.62 0.64 0.65
J01GB Aminoglycosides 1.95 1.81 1.79 1.64 1.56 1.71 1.91 2.14 2.13 1.61
J01MA                        Fluoroquinolones            6.14 6.74 8.16 9.53 10.71 10.44 10.70 10.02 9.77 9.88
J01XA Glycopeptides 0.52 0.56 0.63 0.68 0.99 1.07 1.24 1.29 1.29 1.15
J01XB                        Polymyxins                 0.12 0.12 0.05 0.05 0.07 0.10 0.09 0.09 0.16 0.27
J01XC                        Steroid antibacterials (fusidic acid)     0.25 0.28 0.28 0.26 0.31 0.34 0.27 0.23 0.22 0.23
J01XD                 Imidazole derivatives 2.62 2.78 2.62 3.27 3.84 3.93 4.19 4.16 4.08 4.48
J01XE Nitrofuran derivatives (nitrofurantoin) 0.29 0.29 0.28 0.29 0.36 0.31 0.33 0.34 0.38 0.36
J01XX05 Methenamine 0.08 0.11 0.09 0.10 0.09 0.08 0.10 0.09 0.09 0.07
J01XX08 Linezolid 0.15 0.20 0.16 0.21 0.22 0.22 0.32 0.32 0.35 0.34
J01XX09 Daptomycin 0.00 0.00 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.03
P01AB01 Nitroimidazole derivatives (metronidazole) 1.87 2.13 2.20 2.43 2.91 2.99 3.12 2.89 2.70 2.48
A07AA09 Intestinal antiinfectives (vancomycin) 1.87 2.11 2.19 2.43 2.93 2.96 3.12 2.98 2.75 2.55
J01 Antibacterial agents for systemic use (total) 66.32 67.71 74.33 80.14 90.87 93.67 97.08 98.94 99.88 104.30
Table 5.3. Consumption of antimicrobial agents for systemic use in somatic hospitals (DDD/100 occupied bed-days), Denmark
a) From the 2014 edition of the Anatomical Therapeutic Chemical (ATC) classification system.  DANMAP 2014
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Table 5.4. Consumption of antimicrobial agents for systemic use in somatic hospitals (DDD/100 admitted patients), Denmark
ATC group(a) Therapeutic group
Year
2005 2006 2007 2008(b) 2009 2010 2011 2012 2013 2014
J01AA                        Tetracyclines               1.45 1.67 2.59 3.19 3.63 3.55 3.66 5.15 4.97 5.37
J01CA                        Penicillins with extended spectrum 56.43 55.13 55.39 57.18 53.76 47.46 44.77 48.60 47.90 50.95
J01CE                        Beta-lactamase sensitive penicillins     53.20 45.26 44.55 40.90 34.61 30.83 28.98 33.04 33.13 32.03
J01CF                        Beta-lactamase resistant penicillins     29.33 27.60 27.64 27.89 25.86 25.04 22.71 27.30 29.64 29.73
J01CR                        
Comb. of penicillins. incl. beta-lactamase 
inhibitors   
5.09 7.77 12.17 16.37 19.74 23.15 26.47 39.14 44.60 49.81
J01DB                  First-generation cephalosporins 0.67 0.60 0.55 0.72 0.46 0.43 0.41 0.40 0.37 0.20
J01DC Second-generation cephalosporins 36.70 39.76 50.81 54.55 55.12 52.65 50.19 46.17 40.27 36.29
J01DD Third-generation cephalosporins 3.62 3.53 4.24 5.10 4.98 4.10 4.33 3.50 3.53 3.18
J01DF Monobactams 0.02 0.00 0.18 0.27 0.21 0.29 0.60 0.48 0.45 0.19
J01DH Carbapenems 5.05 5.86 8.78 11.08 11.01 13.07 12.55 12.60 13.14 12.70
J01EA                        Trimethoprim and derivatives   1.78 1.78 1.81 1.80 1.56 1.17 1.11 1.23 1.33 1.62
J01EB                        Short-acting sulfonamides       4.32 3.18 1.41 1.43 1.21 1.09 0.78 0.63 0.62 0.55
J01EE                        
Comb. of sulfonamides and trimethoprim. 
incl. derivatives 
9.21 8.98 6.28 7.98 7.96 9.88 12.79 10.87 13.76 14.53
J01FA                        Macrolides                  12.64 12.01 12.70 12.53 11.97 11.45 11.47 11.61 11.08 12.04
J01FF                        Lincosamides                1.05 1.31 1.46 1.69 1.74 1.52 1.63 2.01 2.09 2.03
J01GB Aminoglycosides 8.55 7.68 7.39 6.71 5.45 5.56 5.95 6.99 6.97 5.01
J01MA                        Fluoroquinolones            26.87 28.58 33.66 39.04 37.45 33.92 33.30 32.67 31.96 30.69
J01XA Glycopeptides 2.28 2.38 2.61 2.77 3.48 3.47 3.87 4.20 4.22 3.58
J01XB                        Polymyxins                 0.54 0.53 0.22 0.21 0.24 0.32 0.28 0.30 0.54 0.85
J01XC                        Steroid antibacterials (fusidic acid)     1.11 1.19 1.17 1.05 1.09 1.12 0.85 0.76 0.71 0.71
J01XD                 Imidazole derivatives 11.47 11.81 10.83 13.39 13.43 12.76 13.03 13.55 13.33 13.93
J01XE Nitrofuran derivatives (nitrofurantoin) 1.28 1.24 1.17 1.19 1.27 1.01 1.02 1.12 1.25 1.13
J01XX05 Methenamine 0.36 0.46 0.38 0.43 0.31 0.27 0.32 0.28 0.30 0.22
J01XX08 Linezolid 0.64 0.86 0.68 0.84 0.76 0.72 0.99 1.04 1.14 1.05
J01XX09 Daptomycin 0.00 0.00 0.03 0.06 0.06 0.07 0.05 0.06 0.07 0.10
P01AB01 Nitroimidazole derivatives (metronidazole) 8.18 9.02 9.10 9.99 10.20 9.72 9.70 9.44 8.83 7.72
A07AA09 Intestinal antiinfectives (vancomycin) 8.16 8.95 9.10 9.96 10.20 9.73 9.71 9.54 9.00 7.92
J01 Antibacterial agents for systemic use (total) 290.0 287.1 306.9 328.3 317.8 304.3 301.9 322.7 325.2 324.1
a) From the 2014 edition of the Anatomical Therapeutic Chemical (ATC) classification system.     
b) The number of admissions was affectedly low in 2008 due to a major hospital strike. 
DANMAP 2014
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Textbox 5.1
Antibiotic coverage as guidance for empirical  
antibiotic treatment of bacteraemia
Optimization of an antibiotic stewardship program 
 
Objectives: When using a guideline for the empirical treatment of bacteraemia, there is a need to assess its quality to ensure 
its applicability and the safety of the patients.  During 2011 Herlev Hospital introduced a new antibiotic guideline for empirical 
treatment. The primary recommendation for bacteraemia in the old guideline was cefuroxime, optionally in combination with 
gentamicin. We changed this recommendation to a combination therapy of ampicillin and gentamicin. There were two reasons 
for introducing the new guideline, firstly to increase the antibiotic coverage of the empirical treatment and secondly to reduce 
the consumption of cephalosporins and fluoroquinolones due to increasing rates of multiresistant bacteria and Clostridium 
difficile infections. This study aimed to develop an easily feasible method to compute the antibiotic coverage and to assess 
the use of coverage as a quality indicator for guidelines for empirical antibiotic treatment.
Methods: We conducted our study at Herlev Hospital, Denmark, which is a 736-bed university hospital covering a population 
of 425,000 inhabitants and we included all episodes of bacteraemia from January 2008 to December 2014. Episodes from 
the Department of Haematology and the Intensive Care Unit were also included, although the empirical guideline did not 
cover these departments. 5,381 episodes of bacteremia were identified and out of these138 fungemias were excluded. We 
combined results of antibiotic resistance testing with EUCAST Expert Rules by using an algorithm we developed in SAS 9.4. 
We defined antibiotic coverage for a given antibiotic as the number of episodes with susceptible bacteria compared with the 
total number of episodes tested for the antibiotic, and we computed the coverage quarterly.
Results: During the study period, 5,243 episodes of bacteraemia, with an average of 749 episodes per year were identified.  
The average antibiotic coverage of cefuroxime before 2011 was 69.9% and in combination with gentamicin 85.6%. This was 
below our target of 90% coverage for empirical treatment. To increase the coverage we changed our recommendation to the 
combination of ampicillin and gentamicin, which had an average coverage of 90.7% before 2011.  After the implementation of 
the new guideline in 2011, the coverage of ampicillin + gentamicin remained above the target with a small increase to 91.8% 
while the coverage of cefuroxime increased to 78.1% and in combination with gentamicin to 89.1%. In the same periode the 
consumption of cefuroxime decreased with 77.3% to 35.2 DDD/occupied bed-days. 
Conclusion: This study demonstrates that it is possible to use an algorithm to compute antibiotic coverage of bacteraemia 
and to use this coverage to evaluate the quality of guidelines for empirical antibiotic treatment. By decreasing the consump-
tion of cefuroxime, we have diminished its impact on the development of resistance to cephalosporins and thus increased its 
usefulness, giving us a larger armamentarium for serious infections. 
Jonas Boel and Magnus Arpi 
For further information: jonas.boel@regionh.dk
ATC group(a) Therapeutic group
Year
2005 2006 2007 2008(b) 2009 2010 2011 2012 2013 2014
J01AA                        Tetracyclines               1.45 1.67 2.59 3.19 3.63 3.55 3.66 5.15 4.97 5.37
J01CA                        Penicillins with extended spectrum 56.43 55.13 55.39 57.18 53.76 47.46 44.77 48.60 47.90 50.95
J01CE                        Beta-lactamase sensitive penicillins     53.20 45.26 44.55 40.90 34.61 30.83 28.98 33.04 33.13 32.03
J01CF                        Beta-lactamase resistant penicillins     29.33 27.60 27.64 27.89 25.86 25.04 22.71 27.30 29.64 29.73
J01CR                        
Comb. of penicillins. incl. beta-lactamase 
inhibitors   
5.09 7.77 12.17 16.37 19.74 23.15 26.47 39.14 44.60 49.81
J01DB                  First-generation cephalosporins 0.67 0.60 0.55 0.72 0.46 0.43 0.41 0.40 0.37 0.20
J01DC Second-generation cephalosporins 36.70 39.76 50.81 54.55 55.12 52.65 50.19 46.17 40.27 36.29
J01DD Third-generation cephalosporins 3.62 3.53 4.24 5.10 4.98 4.10 4.33 3.50 3.53 3.18
J01DF Monobactams 0.02 0.00 0.18 0.27 0.21 0.29 0.60 0.48 0.45 0.19
J01DH Carbapenems 5.05 5.86 8.78 11.08 11.01 13.07 12.55 12.60 13.14 12.70
J01EA                        Trimethoprim and derivatives   1.78 1.78 1.81 1.80 1.56 1.17 1.11 1.23 1.33 1.62
J01EB                        Short-acting sulfonamides       4.32 3.18 1.41 1.43 1.21 1.09 0.78 0.63 0.62 0.55
J01EE                        
Comb. of sulfonamides and trimethoprim. 
incl. derivatives 
9.21 8.98 6.28 7.98 7.96 9.88 12.79 10.87 13.76 14.53
J01FA                        Macrolides                  12.64 12.01 12.70 12.53 11.97 11.45 11.47 11.61 11.08 12.04
J01FF                        Lincosamides                1.05 1.31 1.46 1.69 1.74 1.52 1.63 2.01 2.09 2.03
J01GB Aminoglycosides 8.55 7.68 7.39 6.71 5.45 5.56 5.95 6.99 6.97 5.01
J01MA                        Fluoroquinolones            26.87 28.58 33.66 39.04 37.45 33.92 33.30 32.67 31.96 30.69
J01XA Glycopeptides 2.28 2.38 2.61 2.77 3.48 3.47 3.87 4.20 4.22 3.58
J01XB                        Polymyxins                 0.54 0.53 0.22 0.21 0.24 0.32 0.28 0.30 0.54 0.85
J01XC                        Steroid antibacterials (fusidic acid)     1.11 1.19 1.17 1.05 1.09 1.12 0.85 0.76 0.71 0.71
J01XD                 Imidazole derivatives 11.47 11.81 10.83 13.39 13.43 12.76 13.03 13.55 13.33 13.93
J01XE Nitrofuran derivatives (nitrofurantoin) 1.28 1.24 1.17 1.19 1.27 1.01 1.02 1.12 1.25 1.13
J01XX05 Methenamine 0.36 0.46 0.38 0.43 0.31 0.27 0.32 0.28 0.30 0.22
J01XX08 Linezolid 0.64 0.86 0.68 0.84 0.76 0.72 0.99 1.04 1.14 1.05
J01XX09 Daptomycin 0.00 0.00 0.03 0.06 0.06 0.07 0.05 0.06 0.07 0.10
P01AB01 Nitroimidazole derivatives (metronidazole) 8.18 9.02 9.10 9.99 10.20 9.72 9.70 9.44 8.83 7.72
A07AA09 Intestinal antiinfectives (vancomycin) 8.16 8.95 9.10 9.96 10.20 9.73 9.71 9.54 9.00 7.92
J01 Antibacterial agents for systemic use (total) 290.0 287.1 306.9 328.3 317.8 304.3 301.9 322.7 325.2 324.1
Figure textbox 5.1, Antibiotic coverage as guidance for empirical antibiotic treatment of bacteraemiaFigur  textbox 5.1, ntibiotic coverage as guidance for empi ical antibiotic treatment of b cteraemia
0.6
0.7
0.8
0.9
1.0
An
tib
iot
ic 
co
ve
ra
ge
Cefuroxime
Cefuroxime + Ciprofloxacin
Cefuroxime + Gentamicin
Ampicillin + Gentamicin
DANMAP 2014
DANMAP 2014 54
ANTIMICROBIAL CONSUMPTION IN HUMANS5.
Textbox 5.2
Consumption of antimicrobial agents and incidence of  
multi-resistant bacteria in Greenland
Background: Greenland has a population of 56,282 inhabitants (January 2014) and Nuuk is the capital with around 16,000 
inhabitants. Greenland has its own Ministry of Health and the country is divided into five health regions: Qeqqa (the former 
health districts Sisimiut and Maniitsoq), Disko (the former health districts Aasiaat, Kangaatsiaq, Qeqertarsuaq and Qasigi-
annguit), Avannaa (the former health districts Ilulissat, Uummannaq, Upernavik and Qaanaaq), Sermersooq (the former health 
districts Nuuk, Paamiut/Ivittuut, Tasiilaq and Illoqqortoormiut), and Kujataa (the former health districts Qaqortoq, Nanortalik 
and Narsaq). 
The largest hospital, Dronning Ingrids Hospital, is situated in Nuuk (185 beds). There are several smaller hospitals and health 
care centres in the five health regions. Around 15-16,000 persons are admitted to hospital once or several times a year. The 
primary health care is organized different from that in Denmark: In Nuuk, a large health care center has combined function 
as medical clinic, emergency room and primary health care with doctors and nurses. The settlements have nursing stations 
(supervised by doctors via phone or telemedicine and doctors visiting three to four times a year). Medication on prescription is 
free of charge. Patients with specific/serious diseases are transferred to Denmark or Iceland for further treatment (e.g. hemo-
dialysis, cancer treatment, brain surgery etc.).  
Resistant bacteria: Surveillance of resistant bacteria was begun in 2000. From then until 2014, 16 patients have been 
diagnosed with MRSA, 49 patients with ESBL-producing Enterobacteriaceae, and 45 out of 104 patients with Clostridium 
 difficile infection with serotype 027. Most of these resistant bacteria were imported from Denmark or abroad, but in some 
cases, especially in patients with an ESBL-producing Enterobacteriaceae, treatment with broad-spectrum antimicrobial agents 
in Greenland has probably selected for these bacteria. Since 2011 there has been an  increasing problem with C. difficile infec-
Figure 1. Consumption of selected antimicrobial agents in humans in Greenland (DDD/1,000 inhabitants/day) 2007–2014: (a) 
consumption of narrow- and broad-spectrum penicillins, macrolides and tetracyclines; and (b) consumption of cephalosporins, 
meropenem, fluoroquinolones, piperacillin/tazobactam and gentamicin. (Note: Narrow-spectrum penicillins include benzylpenicillin, 
phenoxymethylpenicillin and dicloxacillin, and broad-spectrum penicillins include ampicillin, pivampicillin, amoxicillin and amoxicillin 
with enzyme inhibitor).
Figure  1:  Total  consumption  Greenland,  DDD,  selected  antibiotics
Measures DDD  
ATC  code  and  product   2007 2008 2009 2010 2011 2012 2013 2014
J01CE01  Benzylpenicillin 1.777                         2.166                         2.009                         1.918                         1.748                         1.400                         1.652                     1.042              
J01CE02  Phenoxymethylpenicillin 109.093                 106.223                 103.296                 116.683                 121.366                 121.263                 112.477             81.809          
J01CF01  Dicloxacillin 17.022                     20.754                     24.570                     28.051                     23.120                     28.245                     35.625                 31.801          
J01CA01  Ampicillin 1.654                         1.195                         1.398                         1.155                         1.135                         1.026                         647                           958                    
J01CA02  Pivampicillin 37.972                     28.086                     32.672                     28.443                     21.186                     22.258                     15.986                 17.886          
J01CA04  Amoxicillin 16.418                     18.624                     15.324                     21.990                     25.093                     23.442                     26.543                 22.217          
J01CR02  Amoxicillin  og  enzym-­inhibitor 1.478                         2.190                         4.010                         7.065                         10.480                     16.750                     20.655                 20.450          
J01FA01  Erythromycin 7.270                         9.383                         5.241                         7.783                         7.635                         3.948                         4.181                     5.102              
J01FA06  Roxithromycin 7.780                         5.260                         5.510                         4.340                         6.900                         6.150                         10.130                 8.420              
J01FA09  Clarithromycin 6.584                         6.327                         7.922                         8.257                         7.581                         8.865                         8.188                     9.522              
J01FA10  Azithromycin 34.113                     49.175                     35.729                     36.102                     34.606                     33.555                     25.983                 27.218          
J01AA02  Doxycyclin 11.150                     16.160                     20.970                     17.460                     14.730                     18.850                     13.250                 14.300          
J01AA04  Lymecyclin 100                               50                                   100                               50                                   100                               100                               100                           100                    
J01AA06  Oxytetracyclin -­                                 100                               -­                                 -­                                 -­                                 -­                                 -­                             -­                      
J01AA07  Tetracyclin 6.730                         6.920                         4.875                         5.025                         5.425                         5.775                         4.925                     4.735              
J01DC02  Cefuroxim 3                                       62                                   3                                       14                                   2                                       4                                       8                                   29                        
J01DD04  Ceftriaxon 4.743                         5.850                         4.000                         6.350                         6.215                         6.408                         6.388                     7.388              
J01DH02  Meropenem 358                               458                               680                               980                               965                               570                               630                           510                    
J01MA02  Ciprofloxacin 5.861                         11.917                     10.004                     9.278                         11.163                     8.929                         9.623                     9.897              
J01MA14  Moxifloxacin -­                                 316                               245                               1.946                         1.049                         1.806                         434                           2.107              
J01CR05  Piperacillin  og  enzym-­hæmmer 21                                   -­                                 -­                                 -­                                 26                                   389                               526                           554                    
J01GB03  Gentamicin 705                               517                               272                               251                               368                               552                               596                           36                        
Forbrug  landet  -­  DDD
2007 2008 2009 2010 2011 2012 2013 2014
Penicilliner  -­  smalspektret 127.892                 129.142                 129.875                 146.653                 146.234                 150.908                 149.753             114.652      
Penicilliner  -­  bredsprektret 57.521                     50.095                     53.403                     58.653                     57.894                     63.475                     63.830                 61.511          
Makrolider 55.747                     70.145                     54.402                     56.482                     56.722                     52.518                     48.482                 50.262          
Tetracykliner 17.980                     23.230                     25.945                     22.535                     20.255                     24.725                     18.275                 19.135          
Cefalosporiner 4.746                         5.912                         4.993                         6.364                         6.217                         6.412                         6.395                     7.417              
Meronem 358                               458                               680                               980                               965                               570                               630                           510                    
Fluoroquinoloner 5.861                         12.233                     10.249                     11.224                     12.212                     10.735                     10.057                 12.004          
Piperacillin  og  enzym-­hæmmer 21                                   -­                                 -­                                 -­                                 26                                   389                               526                           554                    
Gentamicin 750                               517                               272                               251                               368                               552                               596                           36                        
56.648                     56.462                     56.194                     56.452                     56.615                     56.749                     56.370                 56.282
2007 2008 2009 2010 2011 2012 2013 2014
Penicillins  (narrow-­spectrum) 6,185                         6,266                         6,332                         7,117                         7,077                         7,286                         7,278                     5,581              
Penicillins  (broad-­spectrum) 2,782                         2,431                         2,604                         2,847                         2,802                         3,064                         3,102                     2,994              
Macrolides 2,696                         3,404                         2,652                         2,741                         2,745                         2,535                         2,356                     2,447              
Tetracyclines 0,870                         1,127                         1,265                         1,094                         0,980                         1,194                         0,888                     0,931              
Cephalosporins 0,230                         0,287                         0,243                         0,309                         0,301                         0,310                         0,311                     0,361              
Meropenem 0,017                         0,022                         0,033                         0,048                         0,047                         0,028                         0,031                     0,025              
Fluoroquinolones 0,283                         0,594                         0,500                         0,545                         0,591                         0,518                         0,489                     0,584              
Piperacillin/tazobactam 0,001                         -­                                 -­                                 -­                                 0,001                         0,019                         0,026                     0,027              
Gentamicin 0,036                         0,025                         0,013                         0,012                         0,018                         0,027                         0,029                     0,002              
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5.ANTIMICROBIAL CONSUMPTION IN HUMANS
tions (mainly type 027) in the hospitals and transmission within the country has occurred. A project focusing on identification 
of risk factors for acquisition of C. difficile infections, mapping of C. difficile types and prevention strategies will be performed 
the next two years.
Consumption of antimicrobial agents:  All antimicrobial agents in Greenland are purchased and disseminated from the Na-
tional Pharmacy, who reports to Statens Serum Institut. Because of the small population, purchase and delivery to the clinics 
varies over time; thus fluctuations in consumption are seen. Consumption has been monitored since 2007. 
The figures show the total purchase of selected antimicrobial agents in DDD per 1,000 inhabitants per day (DID) from 2007 
to 2014. Penicillins are grouped in narrow spectrum (including benzylpenicillin, phenoxymethylpenicillin and dicloxacillin) and 
broad spectrum (including ampicillin, pivampicillin, amoxicillin and amoxicillin/clavulanic acid). From 2007–2013, an increase of 
narrow-spectrum (18%) and broad-spectrum penicillins (12%) has been seen, but from 2013 to 2014 decreases have occurred 
(23% and 4% respectively). Not shown are variations within the group: Phenoxymethylpenicillin is the most consumed penicil-
lin, accounting for 46% of penicillin consumption and 31% of the total antimicrobial consumption in 2014 , but changes in the 
consumption over the last decade have been observed. Thus the consumption of benzylpenicillin/phenoxymethylpenicillin, 
amoxillin and pivampicillin has been steadily declining, while the consumption of dicloxacillin and the combination penicillin 
amoxicillin/clavulanic acid has been rising simultaneously. From 2013 to 2014 an increase in broad-spectrum antimicrobial 
agents such as macrolides (4%), tetracyclines (5%), fluoroquinolones (19%), and cephalosporins (16%) was observed. Merope-
nem decreased with 19% from 2013 to 2014. From 2012 to 2014 piperacillin-tazobactam increased with 42%.
Conclusion: The consumption data of antimicrobial agents are based on purchases, and fluctuations are therefore seen from 
year to year. However, as a result of the increased focus on prescription of antibiotics (especially at Dronning Ingrids Hospital  
where antibiotic audits are conducted and teaching carried out every year) a decrease in purchase of meropenem and an 
increase in purchase of piperacillin-tazobactam have been seen. Continued focus on the use of broad-spectrum antimicrobial 
agents - both in hospitals and in primary health care - and the incidence of multi-resistant bacteria in Greenland is very impor-
tant in the future.
Anne Kjerulf, Jette Holt, Anne Birgitte Jensen, Charlotte Mørup Olsen, Turid B. Skifte, Peter Poulsen, Inge Mortensen 
For further information: Anne Kjerulf (alf@ssi.dk)
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Figure  1:  Total  consumption  Greenland,  DDD,  selected  antibiotics
Measures DDD  
ATC  code  and  product   2007 2008 2009 2010 2011 2012 2013 2014
J01CE01  Benzylpenicillin 1.777                         2.166                         2.009                         1.918                         1.748                         1.400                         1.652                     1.042              
J01CE02  Phenoxymethylpenicillin 109.093                 106.223                 103.296                 116.683                 121.366                 121.263                 112.477             81.809          
J01CF01  Dicloxacillin 17.022                     20.754                     24.570                     28.051                     23.120                     28.245                     35.625                 31.801          
J01CA01  Ampicillin 1.654                         1.195                         1.398                         1.155                         1.135                         1.026                         647                           958                    
J01CA02  Pivampicillin 37.972                     28.086                     32.672                     28.443                     21.186                     22.258                     15.986                 17.886          
J01CA04  Amoxicillin 16.418                     18.624                     15.324                     21.990                     25.093                     23.442                     26.543                 22.217          
J01CR02  Amoxicillin  og  enzym-­inhibitor 1.478                         2.190                         4.010                         7.065                         10.480                     16.750                     20.655                 20.450          
J01FA01  Erythromycin 7.270                         9.383                         5.241                         7.783                         7.635                         3.948                         4.181                     5.102              
J01FA06  Roxithromycin 7.780                         5.260                         5.510                         4.340                         6.900                         6.150                         10.130                 8.420              
J01FA09  Clarithromycin 6.584                         6.327                         7.922                         8.257                         7.581                         8.865                         8.188                     9.522              
J01FA10  Azithromycin 34.113                     49.175                     35.729                     36.102                     34.606                     33.555                     25.983                 27.218          
J01AA02  Doxycyclin 11.150                     16.160                     20.970                     17.460                     14.730                     18.850                     13.250                 14.300          
J01AA04  Lymecyclin 100                               50                                   100                               50                                   100                               100                               100                           100                    
J01AA06  Oxytetracyclin -­                                 100                               -­                                 -­                                 -­                                 -­                                 -­                             -­                      
J01AA07  Tetracyclin 6.730                         6.920                         4.875                         5.025                         5.425                         5.775                         4.925                     4.735              
J01DC02  Cefuroxim 3                                       62                                   3                                       14                                   2                                       4                                       8                                   29                        
J01DD04  Ceftriaxon 4.743                         5.850                         4.000                         6.350                         6.215                         6.408                         6.388                     7.388              
J01DH02  Meropenem 358                               458                               680                               980                               965                               570                               630                           510                    
J01MA02  Ciprofloxacin 5.861                         11.917                     10.004                     9.278                         11.163                     8.929                         9.623                     9.897              
J01MA14  Moxifloxacin -­                                 316                               245                               1.946                         1.049                         1.806                         434                           2.107              
J01CR05  Piperacillin  og  enzym-­hæmmer 21                                   -­                                 -­                                 -­                                 26                                   389                               526                           554                    
J01GB03  Gentamicin 705                               517                               272                               251                               368                               552                               596                           36                        
Forbrug  landet  -­  DDD
2007 2008 2009 2010 2011 2012 2013 2014
Penicilliner  -­  smalspektret 127.892                 129.142                 129.875                 146.653                 146.234                 150.908                 149.753             114.652      
Penicilliner  -­  bredsprektret 57.521                     50.095                     53.403                     58.653                     57.894                     63.475                     63.830                 61.511          
Makrolider 55.747                     70.145                     54.402                     56.482                     56.722                     52.518                     48.482                 50.262          
Tetracykliner 17.980                     23.230                     25.945                     22.535                     20.255                     24.725                     18.275                 19.135          
Cefalosporiner 4.746                         5.912                         4.993                         6.364                         6.217                         6.412                         6.395                     7.417              
Meronem 358                               458                               680                               980                               965                               570                               630                           510                    
Fluoroquinoloner 5.861                         12.233                     10.249                     11.224                     12.212                     10.735                     10.057                 12.004          
Piperacillin  og  enzym-­hæmmer 21                                   -­                                 -­                                 -­                                 26                                   389                               526                           554                    
Gentamicin 750                               517                               272                               251                               368                               552                               596                           36                        
56.648                     56.462                     56.194                     56.452                     56.615                     56.749                     56.370                 56.282
2007 2008 2009 2010 2011 2012 2013 2014
Penicillins  (narrow-­spectrum) 6,185                         6,266                         6,332                         7,117                         7,077                         7,286                         7,278                     5,581              
Penicillins  (broad-­spectrum) 2,782                         2,431                         2,604                         2,847                         2,802                         3,064                         3,102                     2,994              
Macrolides 2,696                         3,404                         2,652                         2,741                         2,745                         2,535                         2,356                     2,447              
Tetracyclines 0,870                         1,127                         1,265                         1,094                         0,980                         1,194                         0,888                     0,931              
Cephalosporins 0,230                         0,287                         0,243                         0,309                         0,301                         0,310                         0,311                     0,361              
Meropenem 0,017                         0,022                         0,033                         0,048                         0,047                         0,028                         0,031                     0,025              
Fluoroquinolones 0,283                         0,594                         0,500                         0,545                         0,591                         0,518                         0,489                     0,584              
Piperacillin/tazobactam 0,001                         -­                                 -­                                 -­                                 0,001                         0,019                         0,026                     0,027              
Gentamicin 0,036                         0,025                         0,013                         0,012                         0,018                         0,027                         0,029                     0,002              
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Textbox 5.3
Hospital-Acquired Infections Database (HAIBA): monitoring 
hospital-acquired infections using existing data sources
Hospital-acquired infections (HAI) constitute a large burden for both patients and the healthcare system. An estimated 60.000 
Danish patients acquire such infections each year. With increased antimicrobial resistance, treatment options become limited 
and prevention becomes more important. Surveillance of these infections can play a crucial role in the prevention of disease. 
The Hospital-Acquired Infections Database (HAIBA) was launched on the 4th of March 2015 with the aim to provide timely 
and continuous data for the most frequent HAI using existing data sources. HAIBA initially showed numbers and incidences 
of hospital-acquired bacteremia and Clostridium difficile infections (CDI). Data are publicly available through eSundhed, the 
internet portal hosted by Statens Serum Institut which presents healthcare data at regional, hospital and municipal level. Later 
in 2015, surveillance data for specific surgical site infections and for urinary tract infections will be added. 
Since HAIBA is based on existing data sources, there is no additional workload on healthcare personnel. Linking data from the 
National Patient Registry (NPR), the Danish Microbiology Database (MiBa) and regional medication modules allows computer 
algorithms to be created which help  to identify the different types of infections. 
The case definition for bacteremia is divided into two parts: (1) bacteremia based on at least one positive blood culture with 
a pathogenic bacterium and (2) a probable bacteremia, where three negative blood cultures were taken within 48 hours and 
relevant antibiotic treatment was given and/or a diagnosis code (ICD-10) for bacteremia was recorded. A bacteremia was con-
sidered hospital-acquired if the sample was taken more than 48 hours after admission and up to 48 hours after discharge.
In accordance with the European surveillance for CDI, the case definition for CDI was divided into Hospital Onset Hospital 
Acquired (HOHA) and Community Onset Hospital Acquired (COHA). This case definition was based on detection of Clostridium 
difficile through culture or PCR. Samples for which it was indicated that they contained a non-toxigenic strain were excluded. 
A CDI was considered a HOHA if the sample was taken more than 48 hours after admission and up to 48 hours after discharge. 
A CDI was registered as a COHA if the sample was taken between 48 hours after discharge and up to 4 weeks after discharge, 
or in the same period after an outpatient visit.
These data are publicly available in aggregate form, and can be accessed at different levels: national, regional, hospital and 
hospital department. The database contains data from both public and private hospitals, and includes cases which are associ-
ated with transfer from one hospital to another.
In the future, it will be possible for Departments of Clinical Microbiology (DCMs) to access data on individual patients in order 
to carry out infection control measures on a more detailed level. This will, for example, allow DCMs to look up resistance data 
in their own systems and closely investigate the patterns and trends in their hospitals on-site. 
HAIBA is envisioned to be a practical infection control tool for microbiologists, infection control nurses and clinicians, and to 
provide transparency for regional and national politicians as well as citizens. Unlike prevalence studies, HAIBA allows following 
trends over time and therefore is valuable for more timely infection control measures. In the coming period, it will be interest-
ing to learn from the first experiences in using HAIBA and to evaluate how it contributes to the quality of infection control. 
Sophie Gubbels, Jens Nielsen, Brian Kristensen, Marianne Voldstedlund, Kåre Mølbak
More information 
HAIBA surveillance data: http://www.esundhed.dk/sundhedskvalitet/HAIBA/Sider/HAIBA.aspx
HAIBA background: http://www.ssi.dk/English/News/EPI-NEWS/2015/No%209%20-%202015.aspx 
CDI in HAIBA: http://www.ssi.dk/English/News/EPI-NEWS/2015/No%2010%20-%202015.aspx
Bacteremia in HAIBA: http://www.ssi.dk/English/News/EPI-NEWS/2015/No%2011%20-%202015.aspx
Contact: haiba@ssi.dk 
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RESISTANCE IN ZOONOTIC BACTERIA6.
6. Resistance in zoonotic bacteria
Zoonoses are infectious diseases that can be transmitted be-
tween animals and humans, either through direct contact with 
animals or indirectly by contaminated food. Zoonotic bacteria, 
such as Salmonella and Campylobacter, can develop resistance 
towards antimicrobial agents as a result of treatment of both 
animals and humans, which subsequently may lead to limited 
treatment possibilities or even treatment failure of human 
infectious diseases. Especially successful multi-resistant Sal-
monella clones have spread extensively during the last years, 
resulting in a very complex relationship between antimicrobial 
use and levels of resistance.
A more detailed description of the trends and sources of 
zoonoses in Denmark and of national surveillance and control 
programmes can be found in the Annual Report on Zoonoses in 
Denmark 2014 [www.food.dtu.dk].
6.1 Salmonella
 
Salmonella is the second most important zoonotic bacterial 
pathogen in Denmark and can have a severe impact on both 
animal production and human health. 
In Denmark and the rest of the European Union, S. Enteritidis 
and S. Typhimurium are the serotypes most frequently found 
to be associated with human illness. Human cases caused by 
S. Enteritidis are most commonly associated with the consump-
tion of contaminated eggs or poultry meat, whereas S. Ty-
phimurium cases are mostly associated with the consumption 
of contaminated pork, beef or poultry meat.
For Salmonella, DANMAP 2014 includes isolates from healthy 
pigs (caecum samples) and pork (carcass swabs) collected at 
the slaughterhouses as part of national surveillance and con-
trol programmes and from human cases. Salmonella isolates 
from broiler, layer and cattle farms as well as isolates from 
other types of meat (Danish and imported) are not presented 
as relatively few isolates were obtained. Only one isolate per 
farm, meat sample or human case was included in the analysis.
The report primarily presents resistance among S. Typhimuri-
um. During the last ten years, the numbers of poultry flocks 
and meat samples infected or contaminated with S. Enteritidis 
has decreased, and therefore resistance in S. Enteritidis will 
not be presented in this report. Resistance in all Salmonella 
serotypes from pigs and Danish pork is presented for 2011 
and onwards; the year when Denmark started to susceptibility 
test all serotypes according to EU legislation. For details on 
methodology see Chapter 9, Materials and Methods.
Isolates from all reported human S. Typhimurium cases are 
included. In contrast, S. Enteritidis isolates from human 
infections are not susceptibility tested, so resistance levels 
including all Salmonella serotype cannot be calculated cor-
rectly. Thus, please note that the overall resistance levels of 
Salmonella spp. from human cases in Denmark presented in 
the European Summary Report on Antimicrobial Resistance [EU 
Summary Report on AMR 2013. ECDC/EFSA] does not include 
S. Enteritidis; a serotype which commonly has a relatively low 
level of resistance.  
In DANMAP, S. Typhimurium includes the monophasic variants 
with antigenic formulas S. 4, [5],12:i:, as recommended by the 
European Food Safety Authority [EFSA journal 2010. 8(10): 
1826]. In the text, generic S. Typhimurium indicates results 
only covering isolates of the non-monophasic variants. 
MIC distributions for S. Typhimurium from pigs, pork and 
humans, as well as for all Salmonella serotypes from pigs and 
Danish pork in 2014 are presented in the web annex (Tables 
A6.1 - A6.5). 
In 2014 the panel for susceptibility testing was changed. For 
Salmonella; apramycin, ceftiofur, florfenicol, neomycin, strep-
tomycin and spectinomycin were excluded, whereas the new 
panel requested by EFSA includes ceftazidime, meropenem 
and tigecycline. A Salmonella isolate is considered fully sensi-
tive if susceptible to all 13 antimicrobial agents included in the 
test new panel, and multi-resistant if resistant to 3 or more of 
the 11 antimicrobial classes (Table 9.2). Thus, 2014 calcula-
tions of fully sensitive and multi-resistance isolates cannot 
be directly compared with results from previous years. Please 
note that ooccurrences of fully sensitive and multi-resistant 
isolates were not estimated for Salmonella from Danish pork, 
as these isolates were tested using the old DANMAP panel.   
6.1.1 Salmonella in pigs and domestic-produced pork – all 
serotypes
As in the previous years, S. Typhimurium (including the mono-
phasic variants) and S. Derby were the most common sero-
types isolated from Danish pigs (40% and 56%, respectively) 
and pork (43% and 47%, respectively) in 2014. In general, the 
serotype distribution in the Danish pork is similar to the distri-
bution among isolates from pigs (Table 6.1).
Among the Salmonella isolates from healthy Danish pigs (n 
= 173), we observed high levels (range: 34% - 49%) of resis-
tance to ampicillin, sulfonamide, and tetracycline (Table 6.2). 
Resistance to sulfonamide increased from 2013 to 2014, 
whereas resistance to ampicillin and tetracycline was not sig-
nificantly higher than in 2013. The other tested antimicrobial 
agents had similar resistance levels as in 2013 (Figure 6.1). 
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Multi-resistance was observed in 32% of the isolates from 
healthy pigs; the isolates were primarily co-resistant to am-
picillin, sulfonamide and tetracycline (ASuT co-resistance). As 
22% of the healthy pigs tested Salmonella positive in 2014 
[Annual Report on Zoonoses in Denmark 2014], it is estimated 
that multi-resistant Salmonella was present in approximately 
7% of the Danish pigs at slaughter i 2014.
The occurrence of resistant Salmonella (all serotypes) from 
Danish pork resembles the occurrences in the isolates from 
pigs (Figure 6.1), however only 1% of the tested pig carcasses 
was estimated to be Salmonella positive [Annual Report on 
Zoonoses in Denmark 2014]. 
The majority of the S. Derby isolates from pigs were fully 
sensitive (50%) or resistant to tetracycline only (23%, data not 
presented), and the overall occurrences of resistance among 
all Salmonella serotypes in pigs and Danish pork were lower 
than observed among the S. Typhimurium isolates only. Even 
though S. Derby is very common among pigs, only few human 
S. Derby cases (N = 21) were reported in Denmark in 2014 
[www.ssi.dk].
None of the Salmonella isolates from pigs or pork were 
resistant to cephalosporins (cefotaxime, ceftiofur and ceftazi-
dime), quinolones (ciprofloxacin, nalidixic acid) or carbapenems 
(meropenem).
6.1.2 S. Typhimurium in pigs, domestic-produced and 
imported pork
Levels of resistance were comparable among S. Typhimurium 
isolates from Danish pigs and pork (Table 6.3), and resistance 
to the tested antimicrobial agents were similar to levels re-
ported in 2013. 
S. Typhimurium isolated from pigs (n = 70) had very high levels 
of resistance to ampicillin (66%), sulfonamide (74%), and tet-
racycline (66%, Table 6.3). The majority of isolates (64%) were 
multi-resistant; primarily with the ASuT co-resistance. The 
monophasic S. Typhimurium variants constituted 56% of the 
total number of S. Typhimurium isolates from pigs, represent-
ing 71% of the multi-resistant isolates. 
The occurrence of ASuT co-resistance has been increasing 
among S. Typhimurium from pigs since 2010, partly due to an 
Note: Isolates from Danish pork has been analysed using a different 
test panel than isolates from pigs.  An isolate is considered fully 
sensitive if susceptible to all antimicrobial agents included in the 
test panel and multi-resistant if resistant to 3 or more of the 11 
antimicrobial classes (see Table 9.2).   
Pigs Pork
Antimicrobial agent %
Danish 
%
Derby 56 47
4,[5],12:i:- 23 28
Typhimurium 18 15
Infantis 1 8
Goettingen 1 -
Rissen 1 -
Livingstone 1 -
Not typeable - 2
Number of isolates 173 60
Pigs Pork
Antimicrobial agent %
Danish 
%
Tetracycline 49 42
Tigecycline 2 -
Chloramphenicol 5 7
Florfenicol - 3
Ampicillin 34 30
Cefotaxime 0 0
Ceftazidime 0 0
Meropenem 0 -
Trimethoprim 13 10
Sulfonamide 41 38
Streptomycin - 37
Gentamicin 1 2
Neomycin - 7
Apramycin - 2
Ciprofloxacin 0 0
Nalidixic acid 0 0
Colistin 2 2
Spectinomycin - 8
Fully sensitive 39 -
Multi-resistant 32 -
Number of isolates 173 60
Table 6.1. Serovar distribution (%) among 
Salmonella from pigs and pork, Denmark
Table 6.2. Resistance (%) among all Salmonella 
serotypes from pigs and pork, DenmarkDANMAP 2014 DANMAP 2014
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increase in the occurrence of the monophasic variants of S. Ty-
phimurium often carrying the ASuT co-resistance (Figure 6.2). 
In Danish pork (n = 26), 64% of the isolates were of the mono-
phasic variants and high levels (58%) of ASuT co-resistance 
were observed. As in S. Typhimurium isolates from pigs, the 
occurrence of monophasic variants has generally increased 
since 2010.
The increased occurrence of monophasic S. 4,[5],12:i:- is not 
an isolated Danish phenomenon, but related to new pandemic 
strains of Salmonella in Europe [Hopkins et al. 2010. Eurosur-
veillance 3:1]. As the changes in occurrences of antimicrobial 
resistance among Salmonella are highly influenced by the 
spread of such successful multi-resistant clones, the rela-
tionship between antimicrobial use and levels of resistance 
becomes very complex.
None of the S. Typhimurium isolates from Danish pigs and pork 
were resistant to 3rd generation cephalosporins or quinolones 
in 2014. Among the eight EU Member States reporting resis-
tance in S. Typhimurium (incl. monophasic variants) from pigs 
in 2013, most Member States reported no resistance to 3rd 
generation cephalosporins (cefotaxime), whereas quinolone re-
sistance was more common ranging up to 21% of the isolates 
[EU Summary Report on AMR 2013. ECDC/EFSA].
6.1.3 Salmonella in humans
In 2014, Salmonella continued to be the second most frequent 
cause of bacterial intestinal infections in Denmark. A total of 
1,122 human laboratory-confirmed cases of salmonellosis was 
reported (19.9 cases per 100,000 inhabitants) [Annual report 
on Zoonoses in Denmark 2014]. The most common serotypes 
were S. Typhimurium (including the monophasic variants) and 
S. Enteritidis with 7.6 and 4.8 cases per 100,000 inhabitants, 
respectively. 
As in previous years, SSI collected information on travel history 
through phone interviews. Patients were asked about the 
date of disease onset and whether they had travelled abroad 
Table 6.3. Resistance (%) among Salmonella Typhimurium(a) from pigs, Danish pork and human cases(b), Denmark
”Note: Isolates from Danish pork have been analysed using a different test panel than isolates from pigs and humans.  
An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 3 or 
more of the 11 antimicrobial classes (see Table 9.2).      
a) Include isolates verified as monophasic variants of S. Typhimurium with antigenic formulas S. 4,[5],12:i:-  
b) An isolate was categorised as ‘domestic sporadic’ if the patient did not travel outside Denmark one week prior to the onset of the disease and 
was not reported as being part of an outbreak.
DANMAP 2014
Pigs Pork Human cases
Antimicrobial agent %
Danish         
%
Domestic
sporadic 
%
Domestic 
outbreak 
%
Travel  
abroad
%
Total 
%
Tetracycline 66 69 56 63 53 57
Tigecycline 3 - 6 0 8 4
Chloramphenicol 7 8 7 0 11 6
Florfenicol - 8 - - - -
Ampicillin 66 65 51 61 55 54
Cefotaxime 0 0 2 0 3 1
Ceftazidime 0 - 1 0 5 1
Ceftiofur - 0 - - - -
Meropenem 0 - 0 0 0 0
Trimethoprim 11 8 8 1 11 7
Sulfonamide 74 73 54 61 53 55
Streptomycin - 73 - - - -
Gentamicin 1 4 2 0 5 2
Neomycin - 4 - - - -
Apramycin - 4 - - - -
Ciprofloxacin 0 0 6 0 17 6
Nalidixic acid 0 0 4 0 11 4
Colistin 0 0 4 0 6 3
Spectinomycin - 12 - - - -
Fully sensitive 21 - 29 35 31 32
Multi-resistant 64 - 45 58 47 48
Number of isolates 70 26 163 89 64 423
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within a seven-day period prior to the onset of the disease. 
Furthermore, patients who had been abroad were asked about 
their destinations. Cases were categorised as “domestically 
acquired” if the patients had not travelled within the last week 
prior to the onset of the disease. Patients were categorised as 
of ‘unknown origin’ if no telephone interview was conducted 
and travel information had not been reported to the general 
practitioners. In 2014, travel information was obtained for 
71% of all reported Salmonella cases [Annual report on Zoono-
ses in Denmark 2014]. 
Human cases associated with a detected outbreak reported in 
the Annual Report on Zoonoses in Denmark in 2014 were con-
sidered ‘outbreak-related’ and all other domestic cases were 
considered ‘sporadic domestic’ in this report.
6.1.4 S. Typhimurium in humans
S. Typhimurium, including the monophasic variants (antigenic 
formula: 1,4,[5],12:i:-), was the most common serotype among 
the human cases (427 cases). For the first time, the mono-
phasic variants represented more than half of these cases 
(230 monophasic versus 197 generic Typhimurium). Available 
isolates were susceptibility tested (n = 423).
Among the reported human S. Typhimurium isolates included 
in DANMAP, 15% of the cases were categorised as travel- as-
sociated, whereas 39% and 21% most likely had acquired 
their infection in Denmark as sporadic incidences or as part of 
detected outbreaks, respectively (Table 6.3). 
Five domestic foodborne outbreaks caused by S. Typhimurium 
were reported in 2014, representing 89 cases. Two of these 
outbreaks were caused by fully sensitive strains and three 
outbreaks were caused by monophasic strains with the typical 
Figure 6.1. Resistance (%) in all Salmonella serotypes from pigs 
and Danish pork, Denmark 
Note: The number of isolates varies between years (pigs: n = 173-404, 
Danish pork: n = 60-148).  Before 2011, not all serotypes were suscep-
tibility tested.    
Note: The number of isolates varies between years (pigs: n = 144-434, Danish pork: n = 26-70, domestic sporadic human cases: n = 106-227 and 
travel related human cases: n = 51-95). 
a) Include isolates verified as monophasic variants of S. Typhimurium with antigenic formulas S. 4,[5],12:i:- 
b) An isolate is categorised as ’domestic sporadic’ if the patient did not travel outside Denmark one week prior to the onset of disease and was 
not reported as being part of an outbreak.
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Figure  6.1.  Resistance  (%)  in  all  Salmonella   serotypes  
from  pigs  and  Danish  pork,  Denmark
Note:  The  number  of  isolates  varies  between  years  (pigs:  n  =  173-­404,  
Danish  pork:  n  =  60-­148).    Before  2011,  not  all  serotypes  were  
su epctibility  tested
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ASuT resistance profile. The proportion of outbreak-related 
cases in 2014 (21%) was similar to 2013 (22%). 
High levels of resistance to ampicillin, sulfonamide, and tetra-
cycline were observed. Resistance to these three antimicrobial 
agents occurred at similar levels (51 - 63%) among isolates 
from domestic and travel-associated cases (Table 6.3). Overall, 
45% of all S . Typhimurium isolates carried the ASuT resistance 
profile (n = 190). Comparison with previous years showed 
that the proportion of isolates resistant to these antimicrobial 
agents have stabilised at this fairly high level in the past four 
years. In general, levels of resistance were similar to previous 
years (Figure 6.2).
The tendency seen in previous years of higher levels of resis-
tance among travel-associated isolates compared with domes-
tic infections is not distinct in 2014; only fluoroquinolone (cip-
rofloxacin) resistance was higher in isolates from travel-related 
cases (17%) compared with isolates from domestic cases (6%). 
This may reflect a higher prescription of fluoroquinolones in 
production animals in the countries of destination. In general, 
the levels of resistance in S. Typhimurium from domestic cases 
were similar to those of Danish pork and pigs, except for the 
occurrence of resistance to ciprofloxacin and nalidixic acid. In 
Denmark, fluoroquinolones are rarely used in animal husbandry 
(except for pet animals) since the implementation of legal 
restrictions in 2002-2003 [DANMAP 2010]. Ciprofloxacin or 
other fluoroquinolones are often used for empirical treatment 
of adults with severe bacterial gastroenteritis.
Regarding resistance to antimicrobial agents critical for 
treatment of human infections, resistance to 3rd generation 
cephalosporins (cefotaxime and/or ceftazidime) was found in 
seven S. Typhimurium isolates (2% of cases); from three travel-
related cases, three sporadic domestic cases and one case of 
unknown origin. These seven isolates were also resistant to 
ciprofloxacin. Co-resistance to ciprofloxacin and 3rd generation 
cephalosporins are of major concern as these two antimicrobial 
agents are considered the most important for treatment of 
severe salmonellosis [Joint Opinion on antimicrobial resistance 
(AMR) focused on zoonotic infections 2009. ECDC]. 
Helle Korsgaard and Eva Møller Nielsen
6.2 Campylobacter
 
Thermotolerant Campylobacter are the most commonly 
reported causes of gastrointestinal bacterial infections in 
humans in Denmark as well as in the European Union [EU Sum-
mary Report 2013. ECDC/EFSA]. The species most commonly 
associated with human infections is C. jejuni, but other species 
may also cause infections. In Denmark, 85 - 95% of the human 
campylobacteriosis cases are caused by C. jejuni.
Campylobacter are widespread in nature and the most impor-
tant reservoirs are the alimentary tract of wild and domesticat-
ed birds and mammals. Among sporadic human cases, broilers 
have been identified as the primary source of infection, though 
other sources also exist, e.g. water from untreated water 
sources and other infected animals.
For Campylobacter, DANMAP 2014 includes randomly collected 
isolates from broilers and cattle at slaughter and from fresh 
broiler meat ready for retail. Isolates from human cases origi-
nates from three out of five geographical regions in Denmark. 
One isolate per farm, batch of meat or human case is included, 
and data are only presented if a sufficient number of isolates 
were obtained (>15) from a given source. For details see Chap-
ter 9, Materials and Methods.
MIC distributions for C. jejuni from broilers and cattle, broiler 
meat and humans are presented in the web annex (Tables 
A6.6 - A6.8). 
In 2014, the panel of tested antimicrobials was changed. For 
Campylobacter; chloramphenicol was excluded in the new panel 
requested by EFSA. A Campylobacter isolate was considered 
fully sensitive if susceptible to all six antimicrobial agents 
included in the new test panel, and multi-resistant if resistant to 
three or more of the five antimicrobial classes (Table 9.2). Thus, 
2014 calculations of fully sensitive and multi-resistance isolates 
cannot be directly compared with results from previous years. 
6.2.1 C. jejuni in broilers and domestic-produced broiler 
meat
In 2014, we observed moderate levels of resistance to cipro-
floxacin (18%) and tetracycline (12%) among C. jejuni isolates 
from broilers (n = 165, Table 6.4) compared with 2013 (26% 
and 20%, respectively). The majority (74%) of isolates were 
fully sensitive to the six antimicrobial agents included in 
the test panel. From broilers, all C. jejuni isolates resistant to 
ciprofloxacin were also resistant to nalidixic acid (n = 29) and 
often also to tetracycline (n = 13). Only one isolate was multi-
resistant (resistant to tetracycline, erythromycin, streptomycin, 
ciprofloxacin and nalidixic acid).  
In C. jejuni isolates from Danish broiler meat (n = 26), resis-
tance to ciprofloxacin (15%) and tetracycline (12%) were 
observed at similar levels as in 2013. Also, levels of antimi-
crobial resistance were comparable between C. jejuni isolated 
63DANMAP 2014
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from Danish broilers and Danish broiler meat (Figure 6.3), and 
macrolide (erythromycin) resistance has remained at a very low 
level for a decade. 
From  2002 to 2011, a steady increase in resistance to cip-
rofloxacin was observed in C. jejuni isolates from broilers and 
Danish broiler meat; even after 2009 where the poultry indus-
try stopped using fluoroquinolones in the broiler production. 
However, during the last five years, resistance to ciprofloxacin 
has fluctuated between 15% and 29% (Figure 6.3).
The consumption of antimicrobial agents in broilers is generally 
low, but tetracycline has been one of the most commonly used 
antimicrobial agents in Danish broilers over the last five years. 
Over the past two years their consumption of tetracycline, as 
well as broad spectrum penicillins and macrolide has increased 
considerably. However, this is not reflected in the resistance 
patterns in isolates from broilers or broiler meat (Figure 6.3). 
6.2.2 C. jejuni from imported meat
In C. jejuni isolates from imported broiler meat (n = 45), the 
levels of resistance to tetracycline (64%) and nalidixic acid 
(76%) remained high (Table 6.4), and resistance to ciprofloxa-
cin (82%) increased markedly compared with 2013. Compared 
to the Danish broiler meat, the occurrence of fully sensitive 
isolates (11%) was much lower in the imported meat. Almost 
all isolates resistant to ciprofloxacin (n = 37) was also resistant 
to nalidixic acid (n = 34), and often also to tetracycline (n = 
25). Nine percent of the C. jejuni isolates were multi-resistant 
in 2014.
Over the past five years, the level of resistance to tetracycline 
and ciprofloxacin has generally been higher in isolates from 
imported broiler meat compared with Danish broiler meat. This 
corresponds with the data reported by EFSA, where Denmark 
has reported the lowest proportions of resistance among  
C. jejuni isolates from broiler meat [EU Summary Report 2013, 
ECDC/EFSA 2014].
6.2.3 C. jejuni in cattle 
In C. jejuni isolates from cattle (n = 110), we observed moder-
ate levels of resistance to ciprofloxacin (22%) and nalidixic 
acid (24%), whereas resistance to tetracycline (4%), erythro-
mycin (1%) and streptomycin (1%) was low (Table 6.4). 
The majority (75%) of isolates was fully sensitive to the six 
compounds included in the test panel, none were multi-resis-
tant. Among the resistant isolates (n = 28) almost all (n = 24) 
were co-resistant to ciprofloxacin and nalidixic acid.
Despite continued low consumption of fluoroquinolones in 
cattle, resistance to fluoroquinolones (ciprofloxacin) among C. 
jejuni from cattle has remained at a moderate level (16 - 21%) 
since 2006. It has been discussed [DANMAP 2007] that clonal 
spread, particularly between farms, could be an explanation 
for the observed resistance to fluoroquinolones. Initially, 
fluoroquinolone-resistant C. jejuni isolates came from cattle 
farms in Southern Jutland, but has now spread to other parts 
of Denmark.
Resistance to tetracycline generally increased from 2005 to 
2010; however, this trend was discontinued in 2011 and in 
2014 the level of tetracycline resistance is comparable to 
2006-2009 (Figure 6.4).
6.2.4 C. jejuni in humans
In 2014, Campylobacter continued to be the most frequent 
cause of bacterial intestinal infections in Denmark. A total of 
3,782 human laboratory confirmed cases of campylobacte-
riosis were reported (67.1 per 100,000 inhabitants) [Annual 
report on Zoonoses in Denmark 2014].
A random selection of the Campylobacter isolated from stool 
samples in three geographical regions were submitted to SSI 
for species identification and susceptibility testing. In 2014, 
237 C. jejuni isolates were susceptibility tested. Among the 
tested isolates, 20% were from travel-associated cases and 
34% were domestically acquired and 46% were of unknown 
Table 6.4. Resistance (%) in Campylobacter jejuni from animals, meat of Danish and  
imported origin and human cases(a), Denmark
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 
three or more of the five antimicrobial classes (see Table 9.2). 
a) An isolate is categorised as ‘domestic sporadic’ if the patient did not travel outside Denmark one week prior to the onset of disease.
Cattle Broilers Broiler meat Humans
Antimicrobial agent Danish
%
Danish
%
Danish
%
Import
%
Domestically 
acquired
%
Travel
abroad
%
Total 
%
Tetracycline 4 12 12 64 21 66 28
Erythromycin 1 1 0 2 5 2 3
Streptomycin 1 5 0 7 8 9 6
Gentamicin 0 0 0 0 1 6 3
Ciprofloxacin 22 18 15 82 35 81 46
Nalidixic acid 24 18 15 76 35 81 46
Fully sensitive 75 74 81 11 60 17 51
Multi-resistant 0 1 0 9 8 11 6
Number of isolates 110 165 26 45 80 47 237
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origin. As in previous years, SSI collected information on travel 
history through phone interviews. Patients were asked about 
the date of disease onset and whether they had travelled 
abroad within a seven-day period prior to the onset of disease. 
Furthermore, patients who had been abroad were asked about 
their destinations. Cases were categorised as “domestically 
acquired” if the patients had not travelled within the week 
prior to the onset of disease.
Among the domestically acquired infections, 60% were fully 
sensitive to all the antimicrobial agents tested, while the 
percentage of fully sensitive isolates was much lower among 
isolates from travel associated cases (17%, Table 6.4). All 
multi-resistant isolates (6% of all cases) were co-resistant to 
ciprofloxacin and nalidixic acid as well as tetracycline (except 
one isolate). All isolates resistant to gentamicin or erythro-
mycin were multi-resistant, except for one isolate resistant to 
erythromycin only.  
The occurrence of resistance to ciprofloxacin and tetracycline 
continued  to be significantly higher in travel-associated C. je-
juni isolates (81% and 66%, respectively) compared to isolates 
from domestically acquired infections (35% and 21%, respec-
tively, Table 6.4 and Figure 6.3). 
Ciprofloxacin or other fluoroquinolones are often used for 
empiric treatment of adults with severe bacterial gastroenteri-
tis, and the level of resistance to these antimicrobial agents is 
therefore of major importance. In Denmark, fluoroquinolones 
are rarely used in animal husbandry since the implementation 
of legal restrictions in 2002-2003 [DANMAP 2010]. Travelling 
to, or eating meat from countries where fluoroquinolone re-
strictions are not implemented can be associated with a higher 
risk of acquiring infection with ciprofloxacin-resistant C. jejuni.
Birgitte Borck Høg, Helle Korsgaard 
and Eva Møller Nielsen
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Figure 6.3. Resistance (%) in Campylobacter jejuni from broilers, broiler meat and human cases(a), Denmark     
     
Note: The number of isolates varies between years (broilers: n = 41–165, Danish broiler meat: n = 26–70, imported broiler meat: n = 26–70, 
domestic human cases: n = 42–104 and travel-associated human cases: n = 24–78). 
a) An isolate was categorised as ‘domestic’ if the patient did not travel outside Denmark one week prior to the onset of the disease.  
Note: The number of isolates varies between years (n = 41–110).
Figure 6.4. Resistance (%) in Campylobacter jejuni from cattle, 
Denmark    
16/09/15      6.2  Figure    6.4  DANMAP2014  -­  cattle  -­C.  jejuni_Graphicco.xlsx
Figure  6.4.  Resistance  (%)  in  Campylobacter  jejuni  
from  cattle,  Denmark
Note:  The  number  of  isolates  varies  between  years  (n  =  41–110)
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05/10/15      6.2  Figure  6.3  DANMAP2014  -­  Cj  farm-­to-­fork_bibo.xlsx
Figure  6.3.  Resistance  (%)  in  Campylobacter  jejuni   from  broilers,  broiler  meat  and  human  cases(a),  Denmark  
Note:  The  number  of  isolates  varies  between  years  (broilers:  n  =  41–165,  Danish  broiler  meat:  n  =  26–70,  imported  broiler  meat:  n  =  26–70,  domestic  
human  cases:  n  =  42–104  and  travel-­associated  human  cases:  n  =  24–78)
a)  An  isolate  was  categorised  as  ‘domestic’  if  the  patient  did  not  travel  outside  Denmark  one  week  prior  to  the  onset  of  the  disease
DANMAP  2014
0
10
20
30
40
50
60
70
80
90
100
10 11 12 13 14 10 11 12 13 14 10 11 12 13 14 10 11 12 13 14 10 11 12 13 14
%
  re
si
st
an
t  
is
ol
at
es
Tetracycline Erythromycin Ciprofloxacin
Broilers Broiler  meat
Danish
Broiler  meat
Imported
Human
Travel   abroad
Human
Domestic
65DANMAP 2014
7RESISTANCE IN INDICATOR BACTERIA
RESISTANCE IN  
INDICATOR BACTERIA
7
DANMAP 2014 66
RESISTANCE IN INDICATOR BACTERIA7.
7. Resistance in indicator bacteria
Indicator bacteria (Enterococcus faecalis, Enterococcus fae-
cium and Escherichia coli) have been included in the DANMAP 
programme since 1995. Enterococci are included to monitor 
resistance in Gram-positive bacteria and E. coli as representa-
tive of Gram-negative bacteria. These bacteria were selected 
as indicators for occurrence of antimicrobial resistance in the 
different reservoirs through the food chain for several reasons: 
they are ubiquitous and present as major commensals in both 
the animal and human reservoirs, they can acquire antimicro-
bial resistance as a response to selective pressures, and finally 
they have the potential for transferring resistance to patho-
genic bacteria and can cause infection in humans.
7.1 Enterococci
 
For Enterococci, DANMAP 2014 includes randomly collected 
Enterococcus isolates from healthy pigs and broilers at slaugh-
ter (E. faecalis only) and from domestic fresh broiler meat, pork 
and beef sold at wholesale and retail outlets (both E. faecalis 
and E. faecium). In addition, enterococci from imported broiler 
meat, beef and pork (E. faecalis) were included. We included 
only one isolate per farm or meat sample, and data are pre-
sented in the report where a sufficient number of isolates from 
a given source were obtained (>15). For details on methodol-
ogy, see Chapter 9, Materials and Methods.
An isolate is considered multi-resistant if resistant to three or 
more of the ten included antimicrobial classes and fully sensi-
tive if susceptible to all ten classes included in this survey, 
(Table 9.2). Please note that resistance to streptogramins 
(Quinupristin/dalfopristin) is not included in the definition 
of multi-resistance or fully sensitive isolates. In 2014, the 
panels used for resistance testing were changed. For Entero-
coccus; kanamycin, penicillin, salinomycin and streptomycin 
were excluded, whereas the new panel requested by EFSA 
includes daptomycin. Thus, 2014 calculations of fully sensitive 
and multi-resistant isolates cannot be directly compared with 
results from previous years. 
The MIC distributions and occurrence of resistance among E. 
faecium and E. faecalis are presented in the web annex (Tables 
A7.1 - A7.3).
7.1.1 E. faecalis from broilers and domestic-produced 
broiler meat
In E. faecalis isolates from broilers (n = 100), 49% of the 
isolates were tetracycline resistant followed by erythromycin 
(27%) and chloramphenicol (2%). The occurrence of resistance 
to tetracycline has increased over the last five years, and 
the level in 2014 is comparable to or higher than what was 
observed in 2001-2007 (27 - 46%). Only one isolate (1%) 
Figure 7.1. Resistance (%) in Enterococcus faecalis from animals and meat of Danish and imported origin, Denmark
Note: The number of isolates varies between years (broilers: n = 86–114, Danish broiler meat: n = 34–75, imported broiler meat: n = 
69–104, Pigs: n = 109–157, Danish pork: n = 84–150 and imported pork: n = 45–140).
16/09/15      7.1  Figure  7.1  DANMAP2014  -­    E  faecalis  farm-­retail_Graphicco.xlsx
Figure  7.1.  Resistance  (%)  in  Enterococcus  faecalis   from  animals  and  meat  of  Danish  and  imported  origin,  
Denmark
Note:  The  number  of  isolates  var es  between  years  (broilers:  n  =  86–114,  Danish  broiler  meat:  n  =  34–75,  imported  broiler  meat:  n  =  69–104,  Pigs:  n  =  
109–157,  Danish  pork:  n  =  84–150  and  imported  pork:  n  =  45–140)
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was multi-resistant, while 42% were susceptible to all ten 
antimicrobial classes included in the multi-resistance defini-
tion (Table 7.1). The multi-resistant isolate was resistant to 
erythromycin, tetracycline and tigecycline.
The levels of resistance in E. faecalis isolates from domestic 
broiler meat were comparable to E. faecalis isolates from 
broilers (Figure 7.1). Only four isolates (8%) were multi-
resistant and all of these were resistant to tetracycline and 
erythromycin.
7.1.2 E. faecalis from pigs and domestic-produced pork
A very high occurrence of resistance to tetracycline (83%) 
and moderate to high occurence of resistance to erythromycin 
(49%) and chloramphenicol (24%) was found in E. faecalis 
isolates from pigs (n = 142). Resistance to fluoroquinolones 
(ciprofloxacin) was observed in one isolate (1%) from pigs. The 
levels of resistance were comparable with those from 2013 
(Figure 7.1). All the chloramphenicol- (n = 34) and gentamicin- 
(n = 12) resistant isolates from pigs were resistant to tetracy-
cline, and all but one chloramphenicol- and tetracycline-resis-
tant isolate were resistant to erythromycin. Almost all (97%) 
isolates that were resistant to erythromycin (n = 70) were also 
resistant to tetracycline. In 2014, 26% of the isolates from 
pigs were multi-resistant (Table 7.1) and 15% were fully sensi-
tive to the ten antimicrobial classes included. 
A total of 88% of the E. faecalis isolates from Danish pork (n 
= 109) were fully sensitive to all ten antimicrobial classes 
tested (Table 7.1). The highest occurrence of resistance was 
seen for tetracycline (12%) followed by erythromycin (8%), 
and chloramphenicol (4%). Resistance to fluoroquinolones 
(ciprofloxacin) was not observed in isolates from Danish pork. 
Resistance to tetracycline remained at the same level as in 
2013, at a significantly lower level than in isolates from pigs 
where tetracycline resistance has been 80 - 90% over the last 
ten years. Resistance to chloramphenicol and erythromycin are 
also much lower in isolates from Danish pork compared with 
isolates from pigs. 
7.1.3 E. faecalis from domestic-produced beef 
In E. faecalis from domestic beef (n = 57), 14% of the isolates 
were resistant to tetracycline and 2% resistant to erythromy-
cin and gentamicin. Most of the isolates (86%) were fully sen-
sitive to the ten antimicrobial classes, and only one isolate was 
multi-resistant (Table 7.1). Levels of antimicrobial resistances 
were comparable with those from 2013. 
7.1.4 E. faecalis from imported meat 
Resistance to erythromycin was lower in isolates from import-
ed broiler meat in 2014 (n = 74) compared with 2013 (Figure 
7.1). As in previous years, erythromycin resistance remained 
higher in E. faecalis from imported meat than in isolates from 
Danish broiler meat. None of the isolates from imported broiler 
meat were multi-resistant, whereas 8% of the isolates from 
Danish broiler meat were multi-resistant (Table 7.1). 
Compared with Danish pork, E. faecalis isolates from imported 
pork (n = 105) were more frequently resistant to tetracycline, 
whereas resistance levels to all other antimicrobial agents 
were comparable. A total of 47% of the E. faecalis isolates 
from imported pork were fully sensitive to the ten antimicro-
bial classes compared with 88% in isolates from Danish pork. 
All resistant isolates from imported pork were resistant to tet-
racycline, and the occurrence of tetracycline-resistant isolates 
has increased over the last five years. In isolates from both 
domestic and imported pork, 5% were multi-resistant (all were 
resistant to tetracycline and erythromycin, Table 7.1).
The levels of resistance in E. faecalis isolates in Danish and im-
ported beef (n = 42) were comparable, except for tetracycline 
and chloramphenicol where isolates from imported beef was 
more resistant (Table 7.1). Resistance to tetracycline (31%), 
erythromycin (12%) and chloramphenicol (10%) was detected 
in isolates from imported beef. Ten percent (10%) of the tested 
isolates from imported beef were multi-resistant compared 
with 2% among isolates from Danish beef. Overall, 69% of the 
tested isolates from imported beef were susceptible to the ten 
antimicrobial classes compared with 86% in Danish-produced 
beef.
Figure 7.2. Resistance (%) in Enterococcus faecium from Danish 
and imported broiler meat, Denmark
Note: The number of isolates varies between years (Danish broiler 
meat: n = 66–145, imported broiler meat: n = 64–107).   
QD = Quinupristin/dalfopristin.
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Note:  The  number  of  isolates  varies  between  years  (Danish  broiler  meat:  n  =  
66–145,  imported  broiler  meat:  n  =  64–107).    
QD  =  Quinupristin/dalfopristin.
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Table 7.1. Resistance (%) among Enterococcus faecalis from animals and meat of Danish and imported origin, Denmark
Note: An isolate is considered multi-resistant if resistant to three or more of the ten antimicrobial classes, and fully sensitive if susceptible to 
eleven antimicrobial agents included in the test panels (see table 9.2).
Antimicrobial agent
Broilers Broiler meat Beef Pigs Pork
Danish Danish Imported Danish Imported Danish Danish Imported
% % % % % % % %
Tetracycline 49 35 51 14 31 83 12 53
Tigecycline 1 0 0 0 0 0 0 0
Chloramphenicol 2 6 1 0 10 24 4 3
Ampicillin 0 0 0 0 0 0 0 0
Erythromycin 27 19 38 2 12 49 8 5
Gentamicin 0 0 0 2 5 8 2 2
Ciprofloxacin 0 2 1 0 0 1 0 0
Vancomycin 0 0 0 0 0 0 0 0
Teicoplanin 0 0 0 0 0 0 0 0
Linezolid 0 0 0 0 0 0 0 0
Daptomycin 0 0 0 0 0 2 0 0
Fully sensitive 42 65 41 86 69 15 88 47
Multi-resistant 1 8 0 2 10 26 5 5
Number of isolates 100 48 74 57 42 142 109 105
DANMAP 2014
Table 7.2. Resistance (%) among Enterococcus faecium from meat of Danish and imported origin, Denmark
Note: An isolate is considered multi-resistant if resistant to three or more of the ten antimicrobial classes, and fully sensitive if susceptible to 
eleven of the twelve antimicrobial agents included in the test panels (excluding quinupristin/dalfopristin, see table 9.2).
DANMAP 2014
Antimicrobial agent
Broiler meat Beef Pork
Danish
%
Imported
%
Danish 
%
Imported
%
Danish 
%
Tetracycline 10 42 6 10 9
Tigecycline 0 0 0 0 0
Chloramphenicol 0 0 0 0 0
Ampicillin 3 16 0 0 4
Erythromycin 9 51 0 5 0
Quinupristin/dalfopristin 2 4 0 0 0
Gentamicin 0 4 0 0 0
Ciprofloxacin 0 5 3 5 0
Vancomycin 0 0 0 0 0
Teicoplanin 0 0 0 0 0
Linezolid 0 0 0 0 0
Daptomycin 0 2 0 0 0
Fully sensitive 82 31 91 90 91
Multi-resistant 1 10 0 0 0
Number of isolates 96 81 35 21 23
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7.1.5 E. faecium from domestic-produced broiler meat, 
beef and pork 
In E. faecium isolates from Danish broiler meat (n = 96), resis-
tance was observed to tetracycline (10%), erythromycin (9%) 
and ampicillin (3%); and over the last five years, resistance to 
erythromycin has decreased. Only one isolate was multi-re-
sistant (resistant to tetracycline, erythromycin and ampicillin), 
while 82% were susceptible to the ten antimicrobial classes 
included (Table 7.2). Note that resistance to quinupristin/dalfo-
pristin is not included in the estimation of multi-resistant and 
fully sensitive E. faecium isolates.
In E. faecium isolates recovered from Danish pork (n = 23), 
resistance was observed to only tetracycline (9%) and ampicil-
lin (4%) (Table 7.2). No multi-resistant isolates were detected, 
and 91% of the tested isolates were fully susceptible to the 
ten antimicrobial classes included. 
In E. faecium from Danish beef (n = 35), few isolates were 
resistant to tetracycline (6%) and ciprofloxacin (3%). No iso-
lates were multi-resistant, while 91% of tested isolates were 
susceptible to the ten antimicrobial classes.
7.1.6 E. faecium from imported meat
As in 2013, resistance to tetracycline, ampicillin, erythromycin 
and ciprofloxacin was significantly more frequent in E. fae-
cium from imported broiler meat (n = 81) than in isolates from 
Danish broiler meat (n = 96, Table 7.2 and Figure 7.2). Overall, 
10% of the E. faecium isolates from imported broiler meat 
were multi-resistant; all were resistant to both tetracycline and 
erythromycin. 
Low levels of resistance were found in E. faecium from im-
ported beef, comparable to the finding in isolates from Danish 
beef. 
All levels of resistance in E. faecium from the different types of 
meat investigated in 2014 were comparable to levels in 2013.
7.1.7 One Health perspective
Occurrence of antimicrobial resistance in enterococci isolated 
from production animals and food are used as indicators for 
prevalence of antimicrobial resistance in reservoirs in the 
food chain from farm to consumer. Changes in occurrences of 
antimicrobial resistance in enterococci from production animals 
are thought to be directly related to the use of antimicrobial 
agents.
Apart from tetracycline, significantly higher resistance to chlor-
amphenicol and erythromycin was found among E. faecalis 
isolated from pigs when compared with broilers, reflecting the 
higher usage of antimicrobials in pigs. All of these antimicro-
bial agents are used for human treatment (though chloram-
phenicol for eye infections only).
As in previous years, the occurrence of antimicrobial resistance 
in E. faecalis from Danish pork is much lower than from Danish 
pig. This is not observed among E. faecalis from broiler meat, 
where we find equal levels of resistance in broilers and broiler 
meat. This may indicate that enterococcal populations in live 
animals and on pork constitute different sub-populations. 
Pork cuts for sampling are collected from wholesale and retail 
outlets. It is possible that enterococci on these products may 
reflect the processing environment rather than direct contami-
nation of the meat during slaughter and dressing. In contrast, 
the cutting of broilers is done in slaughter plants, which may 
explain why the enterococcal populations from live broilers and 
from broiler meat appear more similar. 
The tendency that imported meat (both for E. faecalis and E. 
faecium) contains isolates with higher levels of resistance is 
generally seen for broiler meat, beef and pork. All multi-resis-
tant enterococci were tetracycline and erythromycin resistant 
no matter what reservoir they were isolated from, indicating 
a close physical connection between these two antimicrobial 
resistance mechanisms. Furthermore, in all reservoirs, isolates 
that were tetracycline and erythromycin resistant was found 
in higher numbers than multi-resistant isolates, indicating 
that additional resistance mechanism(s) may be added to this 
structure.
Lars Bogø Jensen, Tina Birk and Helle Korsgaard
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7.2 Indicator Escherichia coli
 
For indicator E. coli, DANMAP 2014 includes randomly collected 
isolates from healthy pigs, broilers and cattle at slaughter and 
from fresh broiler meat, beef and pork sold at wholesale and 
retail outlets (domestic and imported meat). We included only 
one isolate per farm or meat sample, and present only data 
where a sufficient number of isolates were obtained (>15). For 
details on methodology see Chapter 9, Materials and Methods.
The MIC distributions and occurrence of resistance among E. 
coli are presented in the web annex (Tables A7.4 and A7.5). 
Textbox 7.1 presents data for E. coli isolated after selective 
enrichment with 3rd generation cephalosporins (ceftrioxone) 
examined for carbapenemase and ESBL resistance genes.  
In 2014, the panel of tested antimicrobials was changed. For 
E. coli; apramycin, ceftiofur, florfenicol, neomycin, streptomy-
cin and spectinomycin have been excluded, whereas the new 
panel requested by EFSA includes ceftazidime, meropenem 
and tigecycline. An E. coli isolate is considered fully sensitive if 
susceptible to all 13 antimicrobial agents included in the new 
test panel, and multi-resistant if resistant to 3 or more of the 
11 antimicrobial classes (Table 9.2). Thus, 2014 calculations of 
fully sensitive and multi-resistance isolates cannot be directly 
compared with results from previous years.
7.2.1 Indicator E. coli from broilers and domestic-
produced broiler meat 
Among the E. coli isolates from broilers (n = 191), a significant 
increase in resistance to gentamicin (from none to 3%) and na-
lidixic acid (3% to 11%) was observed compared with observa-
tions from 2013 and 2012; while reduced resistance was seen 
for tetracycline (15% to 6%), ampicillin (26% to 14%), trim-
ethoprim (19% to 7%) and sulfonamide (26% to 13%)(Table 
7.3). Gentamicin-resistant isolates were only found in broilers 
tested during 2014 (n = 6).
In contrast, the use of antimicrobial agents in the broiler 
production has increased since 2012. This increase applies 
to several therapeutic groups e.g. tetracycline, penicillins (not 
beta-lactamase sensitive), sulfonamides and trimethoprim 
(Table 4.1); a trend not reflected in the reduced resistance 
observed in broiler isolates in 2014. 
We found 3% of the E. coli broiler isolates resistant to nalidixic 
acid and 6% resistant to ciprofloxacin. From 2003 to 2007, 
fluoroquinolone consumption in poultry was significantly 
higher than for the other production animals in Denmark, be-
cause antimicrobial agents approved for poultry were limited 
to amoxicillin and fluoroquinolones. However, fluoroquinolones 
have not been used in the broiler production for the last five 
years.
Table 7.3. Resistance (%) among Escherichia coli from animals and meat of Danish and imported origin, Denmark
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 
three or more of the eleven antimicrobial classes (see Table 9.2).         
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Antimicrobial agent
Broilers Broiler meat Cattle Beef Pigs Pork
Danish
%
Danish
%
Imported
%
Danish
%
Danish
%
Imported
%
Danish
%
Danish
%
Imported
%
Tetracycline 6 12 39 12 11 9 37 36 39
Tigecycline 0 0 0 0 0 0 0 0 0
Chloramphenicol 0 1 5 5 4 0 2 5 5
Ampicillin 14 19 51 8 11 9 33 36 32
Cefotaxime 0 1 3 0 4 0 0 0 0
Ceftazidime 0 1 2 0 2 0 0 0 0
Meropenem 0 0 0 0 0 0 0 0 0
Trimethoprim 7 14 30 2 4 9 24 30 20
Sulfonamide 13 20 38 12 9 9 34 37 32
Gentamicin 3 2 2 0 0 0 1 3 5
Ciprofloxacin 12 5 39 0 4 0 0 0 5
Nalidixic acid 11 4 36 0 2 0 0 0 5
Colistin 0 0 1 0 0 0 0 0 0
Fully sensitive 70 70 24 86 83 84 43 48 48
Multi-resistant 7 13 39 7 7 9 25 29 25
Number of isolates 191 135 160 136 46 32 209 73 44
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In E. coli isolates (n = 135) from Danish broiler meat, 20% of 
the isolates were resistant to sulfonamide followed by ampicil-
lin (19%) and trimethoprim (14%). Occurrence of resistance 
to ciprofloxacin and nalidixic acid remained at a low level (5% 
and 4%, respectively), and generally, levels of resistance were 
comparable with the levels observed in 2013. 
Higher levels of resistance to tetracycline (12%) and trim-
ethoprim (14%) was found in E. coli from Danish broiler meat 
than in isolates from Danish broilers, while lower prevalence 
was found for the quinolones (nalidixic acid and ciprofloxacin) 
(Table 7.3).
Among E. coli isolates from Danish broilers and broiler meat, 
70% of the tested isolates were fully sensitive to all tested 
antimicrobials, while 7% and 13%, respectively, were multi-
resistant. Among the multi-resistant isolates, all of these were 
resistant to sulfonamide (n = 31), 93% resistant to ampicillin  
(n = 29) and around 50% to tetracycline (n = 16). 
Resistance to 3rd generation cephalosporins (ceftiofur and ce-
fotaxime) was not found in broiler isolates recovered using the 
non-selective method, but from 1 - 2% of the E. coli isolates 
from Danish broiler meat. Based on a more sensitive selective 
enrichment method, ESBL-producing E. coli was recovered from 
9% of the tested samples of Danish broiler meat (n = 137, see 
Textbox 7.1). None of the isolates showed any indication of 
carbapenemase (meropenem) resistance.
7.2.2 Indicator E. coli from cattle and domestic-produced 
beef 
In E.coli isolated from cattle (n = 136), 12% of the isolates 
were resistant to tetracycline and sulfonamide, followed by 
ampicillin (8%) (Table 7.3). Occurrences of resistance were 
comparable with levels in 2013. 
As in isolates from cattle, resistance in E. coli isolates from 
Danish beef (n = 46) was low, and at the same level as in 
2013. One isolate from Danish beef was resistant to cipro-
floxacin. Among the isolates from cattle and Danish beef, 7% 
were multi-resistant, while 86% and 83% were fully sensitive, 
respectively (Table 7.3). Among the multi-resistant isolates, all 
were resistant to ampicillin and sulfonamide (n = 12); and 83% 
to tetracycline (n = 10).
None of the isolates from cattle and only two isolates from 
Danish beef were resistant to 3rd generation cephalosporins 
(ceftiofur and cefotaxime). No ESBL-producing E. coli was 
recovered from the tested samples of Danish beef (n = 121) 
using the selective enrichment method (see Textbox 7.1). 
None of the isolates showed any indication of carbapenemase 
(meropenem) resistance.
7.2.3. Indicator E. coli from pigs and domestic-produced 
pork 
In E.coli from pigs (n = 209), 37% of the isolates were resistant 
to tetracycline followed by sulfonamides (34%) and ampicillin 
Figure 7.3. Resistance (%) in Escherichia coli from animals and meat of Danish and imported origin, Denmark 
Note: The number of isolates varies between years (broilers: n = 115-191, Danish broiler meat: n = 116–197, imported broiler meat: n =136–177, 
pigs: n = 146–209, Danish pork: n = 68–93 and imported pork: n = 30–53). Isolates are not tested for resistance to streptomycin in 2014.
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Figure  7.3.  Resistance  (%)  in  Escherichia  coli   from  animals  and  meat  of  Danish  and  imported  origin,  Denmark
Note:  The  number  of  isolates  varies  between  years  (broilers:  n  =  115-­191,  Danish  broiler  meat:  n  =  116–197,  imported  broiler  meat:  n  =136–177,  pigs:  n  =  
146–209,  Danish  pork:  n  =  68–93  and  imported  pork:  n  =  30–53).  Isolates  are  not  tested  for  resistance  to  streptomycin  in  2014
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(33%) (Table 7.3). The resistance levels were comparable to 
those observed in 2013, and the trend analysis over the pe-
riod 2010-2014 shows an increasing occurrence of resistance 
to ampicillin from 23% in 2010 to 34% in 2014 (Figure 7.3). 
In the E. coli isolates from Danish pork (n = 73), 37% were 
resistant to sulfonamide followed by tetracycline (36%) and 
ampicillin (36%). Generally, levels of resistance were compa-
rable to 2013 (Figure 7.3 and Table 7.3). 
Among the isolates from pigs and Danish pork, 25% and 29% 
of the isolates were multi-resistant while 43% and 48% were 
fully susceptible to all tested antimicrobials, respectively. 
Among the multi-resistant isolates from pigs and Danish pork 
(n = 74), almost all were resistant to ampicillin (n = 73) and 
sulfonamide (n = 72); and 70% to tetracycline (n = 52).
Quinolone resistance was not detected among isolates from 
pigs or Danish pork reflecting the low usage due to a voluntary 
ban by the industry in 2001. Furthermore, no resistance to 3rd 
generation cephalosporins (ceftiofur and cefotaxime) was de-
tected in 2014 using non-selective methods. Based on a more 
sensitive selective enrichment method, ESBL-producing E. coli 
was recovered from one of the tested samples of Danish pork 
(n = 182, see Textbox 7.1). None of the isolates showed any 
indication of carbapenemase (meropenem) resistance.
7.2.4 Indicator E. coli from imported meat
In E. coli from imported broiler meat (n = 160), 51% of the 
isolates were resistant to ampicillin followed by 38 - 39% 
resistance to tetracycline, sulfonamide and ciprofloxacin. 
Five isolates (3%) were resistant to 3rd generation cephalo-
sporins.  A significant reduction in prevalence of resistance 
to tetracycline, ampicillin, cefotaxime and sulfonamide was 
detected when comparing results from 2014 with 2013 
(Figure 7.3). Compared with Danish broiler meat, E. coli isolates 
from imported broiler meat had higher levels of resistance to 
tetracycline, ampicillin, trimethoprim, sulfonamide, nalidixic 
acid and ciprofloxacin. Furthermore, a higher proportion of the 
isolates from imported broiler meat were multi-resistant (39%), 
and less were fully sensitive (24%) to all tested antimicrobials, 
compared with the isolates from Danish broiler meat (Table 
7.3). Among the multi-resistant isolates from imported broiler 
meat (n = 62), 87% were resistant to sulfonamide (n = 54), 
85% to ampicillin (n = 53), while 63% (n = 39) were resistant 
to tetracycline. 
In E. coli from imported beef (n = 32), 9% of the isolates 
were resistant to tetracycline, ampicillin, sulfonamide and/
or trimethoprim. These levels are comparable with 2013 and 
the findings in Danish beef. No resistance to nalidixic acid and 
ciprofloxacin was observed. Three isolates were multi-resistant 
(9%), all of them were resistant to ampicillin, sulfonamide and 
trimethoprim, while one isolate was also resistant to tetracy-
cline (Table 7.3). 
In E. coli isolates from imported pork (n = 44), 39% of the 
isolates were resistant to tetracycline followed by ampicillin 
(32%) and sulfonamide (32%). Two isolates were resistant 
to nalidixic acid and ciprofloxacin. No changes in resistance 
levels were observed from 2014 to 2013, and resistance in 
imported pork is comparable to Danish pork (Table 7.3). Among 
isolates from imported pork, 25% were multi-resistant while 
48% were fully susceptible to all tested antimicrobials. Among 
the multi-resistant isolates (n = 8), all isolates were resistant 
to sulfonamide, while seven were resistant to tetracycline and 
ampicillin.
Resistance to 3rd generation cephalosporins (ceftiofur and 
cefotaxime) was only found in isolates from imported broiler 
meat (3%). Based on a more sensitive selective enrichment 
method, ESBL-producing E. coli was recovered from 25% of 
the tested samples of imported broiler meat (n = 167), but not 
from the tested samples of imported beef (n = 87) and pork 
(n = 163) (see Textbox 7.1). None of the isolates showed any 
indication of carbapenemase (meropenem) resistance.
7.2.5 One Health perspective 
We use E. coli as an indicator organism for antimicrobial resis-
tance because it is a commensal in both mammals and birds 
and commonly present on raw meat. Using phenotypic resis-
tance as a marker, our data indicate that E. coli in slaughter 
animals and in the derived meat constitute overlapping bacte-
rial populations (Table 7.3). Therefore, meat has the potential 
to act as a vehicle transferring antimicrobial resistance from 
food animals to humans. 
Transfer of genes coding for resistance to antimicrobial agents 
that are critically important in human medicine such as 3rd 
generation cephalosporins is of major concern, as is the trans-
mission through food of E. coli resistant to gentamicin and 
fluoroquinolones. Resistance to fluoroquinolones is generally 
low in Danish animals (only detected in broilers), but higher 
in imported meats, in particular imported broiler meat (Figure 
7.3). Resistance to fluoroquinolones (ciprofloxacin) was detect-
ed in E. coli from Danish beef, but at low levels. A significant 
reduction in ciprofloxacin resistance was seen when compar-
ing isolates from broilers with isolates from Danish broiler 
meat. Resistance to cephalosporins is presently increasing 
internationally in the animal reservoir, causing great concern 
both nationally and internationally. Cephalosporin resistance 
commonly resides on mobile genetic elements, e.g. plasmids, 
and therefore may be transferred between bacteria, in addition 
to clonal spread of E. coli strains. No resistance to cephalospo-
rins was detected using the DANMAP setup in isolates from 
broilers, pigs or cattle in 2014, but it was found in low levels in 
Danish broiler meat and Danish beef. 
The study of ESBL /AmpC in fresh meat available in Danish 
retail (Textbox 7.1) and among patients with ESBL-producing 
E. coli blood stream infections (textbox 8.1) shows that in 
Denmark consumption of meat may currently be considered an 
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insignificant source for the human infections. Only for one of 
the 241 human isolates could an isolate with matching ESBL 
gene and MLST type be identified among the typed isolates 
from meat.
Multi-resistance is of importance because high levels of resis-
tance decrease the number of first choice antibiotics available 
for treatment of infections in humans and because it increases 
the risk of selection of antimicrobial resistance. As an ex-
ample, if resistance to fluoroquinolone (chromosomal) or ESBL 
(plasmid) develops, the risk of co-selection through use of “old 
antimicrobial agents” (such as tetracycline, sulfonamide and 
penicillin) in the same bacterium increases with the occurrence 
of multi-resistance. Resistance to these antimicrobial agents 
is common in E. coli from Danish pigs and pork, as well as from 
imported broiler meat, where we also observed high levels 
(25%-29%) of multi-resistance (Table 7.3).
With co-resistance to critically important antimicrobial agents, 
the risk of maintenance and spread of the critically important 
antimicrobial resistance through use of another class of antimi-
crobial agents increases markedly, in particular when resis-
tance determinants are located on mobile genetic elements. 
High levels of resistance and multi-resistance contribute to a 
reduced number of antimicrobial agents available for use in hu-
man medicine, thus limiting the solutions for treating human 
illness, see section 8.1 regarding human E. coli infections.
Lars Bogø Jensen, Tina Birk and Helle Korsgaard
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Textbox 7.1
Reduced occurrence of ESBL-producing Escherichia coli in meat 
from Danish retail and comparison to isolates from human 
bloodstream infections
Background: Extended spectrum beta-lactamase (ESBL)-producing bacteria is one of the fastest emerging resistance prob-
lems worldwide in both humans and production animals. Lately, several studies have found similar ESBL genes, plasmids and 
clones of E. coli isolates from animals, meat and human infections, suggesting a zoonotic link. Furthermore, the occurrence of 
carbapenemase-producing Enterobacteriaceae (CPE) is an even greater threat in human medicine, since carbapenems are the 
last line antimicrobial agents for treatment of infections caused by multidrug-resistant Gram-negative bacteria. Carbapene-
mase-producing bacteria are currently almost exclusively isolated from human cases, primarily in the non-zoonotic Klebsiella 
pneumoniae, but carbapenemase resistant E. coli  have recently been discovered in pets, pigs and rivers [Woodford et al, 2014 
J Antimicrob Chemother 69:287-291]. To date no carbapenemase resistant bacteria has been found in the Danish surveillance 
of food or food producing animals.
ESBL and carbapenem resistance can be driven by usage of cephalosporins and/or carbapenems as well as antimicrobial usage 
in general, through co-selection. In July 2010, the use of cephalosporins in the Danish pig production was discontinued, but it 
is still used for systemic and intramammary treatment in cattle (Table 4.2). Cephalosporins have not been used in the Danish 
broiler production for at least a decade, but were before May 2012 used in the foreign production of grandparent animals of 
the Danish broilers [DANMAP 2012]. At present, carbapenems are not licensed for use in food-producing animals in Denmark 
or other parts of the world [EFSA Journal 2013;11(12):3501].
The aim of this study was to investigate the occurrence of carbapenemase- and ESBL-producing E. coli in fresh meat at retail 
and investigate if there was a clonal relationship between the ESBL-producing E. coli from retail meat and strains from human 
bloodstream infections (see section 10, for definition of ESBL).
Materials and methods: During January through December 2014, samples of broiler meat (Danish: n = 150, imported: n 
= 167), beef (Danish: n = 121, imported: n = 87) and pork (Danish: n = 182, imported: n = 163) were collected randomly at 
wholesale and retail outlets in all regions of Denmark. ESBL-producing E. coli were isolated from 5 g of meat after culturing 
in selective McConkey media enriched with ceftriaxone (1 µg/ml). Whole genome sequencing (WGS) was used to describe the 
genetic background for ESBL- and carbapenem-resistance. The reads were assembled de novo prior to prediction of genes, and 
the web-server ResFinder (www.genomicepidemiology.org.) was used to identify acquired ESBL and CPE genes in the WGS 
data. In isolates where no genes were detected, the sequences were investigated for up-regulation of chromosomal AmpC by 
use of CLCbio Genomic Workbench v8. The multi locus sequence typing was determined using the web server: www.genomi-
cepidemiology.org (version 1.7).
ESBL-producing E. coli isolates from meat and from human bloodstream infections obtained during 2014 (see Textbox 8.1) 
were compared for clonal relationship by whole-genome-based SNPs analysis, if they had the same ESBL gene and belonged 
to the same sequence types (STs).
Results: None of the isolates from Danish or imported meat contained any known carbapenemase genes.
Ceftriaxone resistant E. coli was found in 9% of Danish broiler meat and 25% of imported broiler meat samples. As in previous 
years, the occurrences were generally low (0-1%) in the Danish and imported beef and pork; only one sample from Danish pork 
contained ceftriaxone resistant E. coli (CTX-M-1) in 2014.
The occurrence of ESBL-producing E. coli in Danish broiler meat has decreased significantly, since the highest occurrence was 
detected in 2011 (44% in 2011, 25% in 2013 and 9% in 2014, Figure 1). The decrease was mainly due to a reduction in the 
occurrence of CMY-2 (Table 1). A significantly lower level of ESBL-producing E. coli was also observed in imported broiler meat 
from 2013 to 2014 (52% to 25%, Figure 1), where most of the reduction was due to less samples containing CMY-2, but also 
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CTX-M-1 and SHV-12 were found less frequently. The ESBL occurrence was significantly higher in imported meat than in 
broiler meat produced in Denmark. 
As in previous years, the most common ESBL enzymes in Danish and imported broiler meat were CTX-M-1 and CMY-2 (Table 1). 
More than one ESBL enzyme were detected in isolates from two samples of Danish broiler meat (CTX-M-1 and CMY-2; CTX-M-1 
and SHV-28) and in one sample of imported broiler meat (CTX-M-1 and CMY-2).
The 27 CTX-M-1 producing E. coli isolates from broiler meat and the one from pork belonged to 19 sequence types (STs). The 
14 CMY-2 producing isolates from broiler meat belonged to 11 STs. The two E. coli isolates from broiler meat co-producing 
CTX-M-1 and CMY-2 both belonged to two STs also detected among the broiler E.coli isolates producing CTX-M-1 only. The four 
SHV-12 producing E.coli isolates from broiler meat belonged to four different STs.
Similar combination of ESBL geno-types and STs were detected from human bloodstream E. coli isolates and E.coli isolates 
from imported broiler meat on five occasions; CTX-M-1 belonging to ST23, ST117 and ST131 (4 meat samples in total) and 
CMY-2 ST38 (1 meat isolate). Two highly similar isolates (ST23 containing CTM-X-1) were found from a sample of imported 
broiler meat and in a human bloodstream infection (11 SNPs were detected between the two isolates). Whereas the human 
and the meat isolates belonging to ST23, ST38 and ST131 did not have similar SNP-profiles. Thus, we only detected one case 
(ST23, CTX-X-1), with a possible transfer of an ESBL-producing E. coli between broiler meat and humans. 
Discussion and conclusion: 
The decreasing occurrence of ESBL-producing E. coli in Danish broiler meat continued in 2014 and for the first time a signifi-
cant reduction was also observed in imported broiler meat. The reductions are, most likely a result of the discontinued use of 
3rd generation cephalosporins in the top of the breeding pyramids in the country producing the grandparents. This has led to 
Danish Import
Enzyme 2009 2010 2011 2012(1) 2013 2014(1) 2009 2010 2011 2012(1) 2013(1) 2014(1)
CMY-2 50 81 95 88 83 23 48 37 62 36 38 33
CTX-M-1 50 19 5 11 14 77 25 44 23 40 32 45
CTX-M-14 - - - - - - - - - 2 - -
CTX-M-2 - - - - - - 3 3 - - - -
HV-28 - - - - - - - - - 1 - -
SHV-1 - - - - - - - - - - 1 -
SHV-12 - - - - 3 - 16 10 12 19 18 10
SHV-2a - - - - - - - 1 - - - -
TEM-11 - - - - - - - - - - 1 -
TEM-116 - - - 1 - - - - - - 1 -
TEM-20 - - - - - - 1 - - - - -
TEM-30 - - - - - - - - - 1 3 -
TEM-52 - - - - - - 1 4 1 - 3 -
TEM-52B - - - - - - - - - - - 5
Unknown - - - - - - 4 2 1 2 3 -
AmpC upregulation - - - - - - 1 - - - - 7
Total number of :
Enzymes 4 16 58 76 36 13 69 113 73 116 97 42
Meat samples 121 187 132 206 146 150 193 226 152 178 172 167
Table 1. Distribution (%) of ESBL enzymes detected in E. coli isolates from broiler meat, Denmark DANMAP 2014
Note: Proportion of total number of enzymes.  
1) In some isolates more than one enzyme was detected: CTX-M-1 and CMY-2, SHV-12, -28 or TEM-11, -30;  CMY-2 and SHV-12 or TEM-30, 
-52, -116; SHV-12 and TEM-30.
 
DANMAP 2014 76
RESISTANCE IN INDICATOR BACTERIA7.
a reduction in imported parent flocks harbouring ESBL genes. A significant reduction in ESBL-producing E. coli from broilers 
was also observed in Sweden, where the poultry production uses the same suppliers as Denmark [SWEDRES-SWARM 2014]. 
The reduction in imported broiler meat may be explained by a general reduction in antimicrobial consumption in EU countries 
exporting broiler meat to Denmark.
CTX-M-15, CTX-M-14, CTX-M-27 are the major enzymes detected among the ESBL-producing E. coli isolates from human 
bloodstream infections, whereas CTX-M-1 (4%) and CMY-2-variants (7%) are detected to a lesser extent (Textbox 8. 1). None 
of the isolates from Danish or imported meat contained any known carbapenemase gene. Therefore, we conclude that pres-
ently fresh meat available at the Danish market seems to be a minor source for the human ESBL-producing bacteria causing 
bloodstream infections, and not a source for carbapenemase producing bacteria causing human infections in Denmark. 
However, two highly similar E. coli isolates were detected; one from human bloodstream infection and the other from imported 
broiler meat – indicating a possible zoonotic transmission, which is in accordance with a previous report [Leverstein-van Hall et 
al. 2011. Clin. Microbiol.Infect. 17:873–880].
 
Besides clonal spread of ESBL-producing bacteria, genes encoding ESBL-production can be transferred horizontal by plasmid 
transfer between the animal reservoir and human reservoir. Recently, similar plasmids with genes encoding ESBL-production 
have been detected from broilers and humans in the Netherlands. [de Been et al. 2014 PLOS Genetics 10:12]. However, plas-
mid comparison was not investigated in the present study, but will be investigated in the future.
In summary, the investigation of bloodstream isolates from human cases of septicaemia allows us, for the first 
time, to assess the impact of zoonotic transmission of ESBL resistance genes. Human blood stream infections 
with E. coli may be seen as a result of a filtering process, where the filters include required pathogenicity traits 
in the bacterium and decreased resistance to invasion by the patient. The results show that humans and ani-
mals do share resistance genes and strain types. However, based on this relatively small sample from meat it is 
only a minority of ESBL E. coli bacteremias in humans that are caused by strains of possible animal origin. 
Further monitoring and larger studies are needed to investigate and quantify the zoonotic link between car-
bapenemase and/or ESBL-producing E. coli from meat/animals and human infections.
Helle Korsgaard, Henrik Hasman, Yvonne Agersø, Lars Bogø Jensen, Marc Stegger, Robert Skov and Anette M. Hammerum 
For further information: Anette Hammerum, ama@ssi.dk, Lars Bogø Jensen, lboj@food.dtu.dk
continued ... Textbox 7.1
Figure 1. Occurrence (%) of samples with ESBL-producing Escherichia coli in meat, Denmark DANMAP 2014 
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8. Resistance in human clinical bacteria
8.1 Escherichia coli
 
Escherichia coli is part of the normal intestinal flora in both 
humans and animals but also one of the most common causes 
of infections. In humans, E. coli is the most frequent cause of 
community- and hospital-acquired urinary tract infections and 
of bacteremia. E.coli also accounts for the majority of travel-re-
lated diarrhea. It further might cause meningitis in newborns. 
For E. coli, DANMAP 2014 includes data on resistance referred 
from 10 out of 11 Departments of Clinical Microbiology (DCM), 
representing 95% of the Danish population. These data cover 
all blood and urinary isolates from hospitals and for some DCM 
a selected number of urinary isolates from the primary health 
sector. Total numbers of isolates are shown in Table 8.1.
Blood isolates from hospital patients 
DANMAP received data on the antimicrobial susceptibility of 
approximately 4,500 E. coli isolates from blood (Table 8.1 and 
Figure 8.1). 
The total number of E.coli isolates from blood has been rising 
in recent years, (from 3,426 in 2010 to 4,492 in 2014). (Figure 
8.1). Similar increases have been observed in the number of 
positive bloodisolates for other bacteria. This increase might 
be explained by a rise in the amount of blood cultures taken at 
hospitals at admission but changes in blood culturing systems 
as well as the introduction of new blood culturing bottles 
might also play a role.  
In 2014, ampicillin resistance was 45%, which has been 
unchanged since 2007. For piperacillin/tazobactam the resis-
tance increased to 5%; resistance had been stable at 4% since 
surveillance was begun in 2009. 
For cephalosporins the resistance to 2nd generation cepha-
losporins (cefuroxime) was 8.5% and resistance to 3rd gen-
eration 7%, both decreasing slightly compared to 2013. This 
puts Denmark back among the other Scandinavian countries 
and the Netherlands in the EARS-Net data, which reported 
resistance for 3rd generation cephalosporins in 5 - 7% of their 
strains. For most other European countries, the occurrence of 
resistance reported in 2013 was higher, ranging from 10% and 
up [EARS-Net 2013].
The occurrence of ciprofloxacin resistance remained stable at 
12%. This is among the lowest reported resistances in Europe 
[EARS-Net 2013]. Historically ciprofloxacin resistance has 
been rising in Denmark until 2009 (15%) and has since shown 
a slow decrease. 
Aminoglycoside (gentamicin) resistance remained with 7% at 
the same level as reported in 2012 and 2013. Until 2012, the  
resistance to gentamicin slowly increased with about 0.5 - 1% 
a year. Most European Countries had resistance levels of 5 to 
10% [EARS-Net 2013].
No carbapenem (meropenem) resistant E. coli blood isolates 
were reported in 2014. However reporting only covers the 
first E.coli isolate per patient per year. Three carbapenemase 
producing blood isolates were referred to and confirmed at the 
reference laboratory at Statens Serum Institut. 
In the 10-year period from 2005 to 2014, resistance in E. coli 
blood isolates has altogether increased steadily, the increase 
being most pronounced from 2006 to 2011. Since then, a 
slight stagnation was observed or, for a few antimicrobial 
agents (cephalosporins and ciprofloxacin), even a decrease. 
This development parallels the trends in total antimicrobial 
consumption, which showed pronounced increase for both 
drugs til 2010 and for cefuroxim a drop in consumption from 
2013 to 2014 of 0,6 DID ( 5%) (Figure 5.1).
Figure 8.1. Resistance (%) in Escherichia coli blood isolates from 
humans, Denmark       
  
Note: The number (n) in parentheses represents the number of isolates 
tested for susceptibility in 2014. 
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Urine isolates from hospital patients 
DANMAP received data on the antimicrobial susceptibility of 
approximately 44,000 E. coli isolates from hospital patients 
with a urinary tract infection (Table 8.1 and Figure 8.2). 
For these isolates bigger variations showed in the chosen 
test panel: all 10 DCM performed susceptibility testing for 
mecillinam and ciprofloxacin and almost all tested for ampicil-
lin, piperacillin/tazobactam, gentamicin, cefuroxime and 3rd 
generation cephalosporins (most often cefpodoxim). Only five 
DCM tested for sulfamethizole. Routine testing for merope-
nem in hospital urines was performed at six DCM, the other 
DCM performed testing only on selected strains, thus referring 
fewer data to DANMAP. 
Ampicillin resistance was 42%, aminoglycoside (gentamicin) 
resistance was slightly higher and sulfonamide resistance was 
32%, which are at the same levels as in 2013.
Resistance to 2nd generation cephalosporin (cefuroxime) 
(7%) was sligthly higher than in 2013 (6%) and 3rd genera-
tion cephalosporin resistance (6%) was at the same level as in 
2013.
The occurrence of ciprofloxacin resistance was slightly lower 
than in 2013 (11% vs 12%), still the same development as in 
blood isolates was observed with a steep increase in resis-
tance  from 5% in 2005 to 13% in 2011 and since a slower 
decrease.
In 2014, one carbapenem (meropenem) intermediate  resistant 
E.coli strain from hospital urine was reported. 
Urine isolates from primary health care 
DANMAP received data on the antimicrobial susceptibility of 
approximately 50,000 E. coli isolates from urinary tract infec-
tion in patients from primary health care (Table 8.1 and  
Figure 8.3).
In Denmark culturing and susceptibility testing of urines from 
primary health care varies substantially between the differ-
ent regions. Many GP´s perform local testing and only urines 
from patients with known resistance problems are sent to the 
DCM at the regional hospital. Thus the amount of culturing and 
susceptibility testing performed at the different DCM will vary 
accordingly. As for hospital urines less than half of the DCM 
test for sulfamethizole, the same applies also to meropenem 
and piperacillin/tazobactam. All DCM test for mecillinam and 
3rd generation cephalosporins (cefpodoxime), most test for 
ampicillin and ciprofloxacin. 
Figure 8.2. Resistance (%) in Escherichia coli urine isolates from 
humans in hospitals, Denmark     
     
Note: The number (n) in parentheses represents the number of isolates 
tested for susceptibility in 2014.
Table 8.1. Resistance (%) in Escherichia coli isolates from humans, Denmark DANMAP 2014
*) An asterisk indicates a significant increase from 2013 to 2014.  
#) A number sign indicates a significant decrease from 2013 to 2014. 
a) Tested 3rd generation cephalosporins were ceftazidime, ceftriaxone, cefpodoxime and cefotaxime.   
Substance Blood isolates, hospitals Urine isolates, hospitals Urine isolates, primary health care
% % %
Ampicillin 45 42 39
Mecillinam 8 7 5 #
Piperacillin/tazobactam 5 * 4 #
Sulfonamide 32 32
Gentamicin 7 5
Ciprofloxacin 12 11 9 #
Cefuroxime 9 7 *
3rd generation cephalosporins(a) 7 6 4
Meropenem <1 <1 <1
Max. number of isolates tested 4,492 43,986 49,745
  Figure  8.2.  Resistance  (%)  in  Escherichia  coli  urine  isolates  from  humans  in  hospitals,  Denmark  
Note:  The  number  (n)  in  parentheses  represents  the  number  of  isolates  
tested  for  susceptibility  in  2014
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The occurrence of ampicillin resistance was 39% and sulfon-
amide resistance was 32%, both levels were similar to levels 
reported in 2013. Ampicillin resistance has been at the same 
level for the last 20 years, while sulfonamide resistance has 
decreased since 2009 (38%). 
The occurrence of resistance to 3rd generation cephalosporin 
was 4%, at the same level as reported in 2013. 
Resistance to ciprofloxacin was 9%, which continued the slight 
decrease observed for the past four years ( 11% in 2011). As 
for hospital urines and blood isolates, the resistance had been 
increasing from 2005 to 2011, which paralleled the increas-
ing consumption of fluoroquinolones during the same period 
(Table 5.1).
In 2014, two carbapenem (meropenem) resistant and one 
intermediate resistant strain were reported from E. coli urine 
isolates from primary health care. Routine meropenem testing 
was performed at three DCM, most DCM performing only on 
selected strains.
Results for mecillinam resistance
Mecillinam resistance was 8% for blood isolates, which was 
lower than resistance reported in previous years. Mecillinam is 
among the most used penicillins in Denmark and the con-
sumption of pivmecillinam in the primary sector has increased 
with 34% for the last decade (Figure 5.6, table 5.1). Detailed 
comparison of the reported resistance levels for mecillinam 
revealed great differences between laboratories but also for 
some individual laboratories over time. These differences are 
due to differences in reporting and change of breakpoints over 
time. Results for mecillinam resistance for 2014 are shown in 
Table 5.1, but results from the former years are not reported 
owing to the mentioned methodological and interpretational 
difficulties. This issue is now under consideration in the 
DANRES group.
Figure 8.3. Resistance (%) in Escherichia coli urine isolates from 
humans in primary health care, Denmark    
 
Note: The number (n) in parentheses represents the number of 
isolates tested for susceptibility in 2014.   
 
  Figure  8.3.  Resistance  (%)  in  Escherichia  coli  urine  
isolates  from  humans  in  primary  health  care,  Denmark  
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8.2 Klebsiella pneumoniae
 
Klebsiella pneumoniae is part of the normal intestinal flora in 
humans but also the cause of urinary tract-, respiratory tract-, 
and bloodstream infections. Many of these infections are 
hospital acquired and can be life threatening, especially if the 
strains are resistant to antimicrobial agents. 
For K. pneumoniae, DANMAP 2014 includes data on resistance 
referred from 10 out of 11 Departments of Clinical Microbiol-
ogy (DCM), representing 95% of the Danish population. (Table 
8.2).
Blood isolates from hospital patients 
Statens Serum Institut has since 2006 received data on the 
antimicrobial susceptibility of K. pneumoniae isolates from 
blood, and following a sudden increase in resistance (due to 
an outbreak with the so called epi-K.pn.in 2007) data were in-
cluded in the DANMAP report from 2008 and onwards. In 2014 
DANMAP received information on 943 K.pneumoniae.  (Table 
8.2 and Figure 8.4).
In general, the level of antimicrobial resistance has decreased, 
since it peaked in 2009. Piperacillin/tazobactam is the only 
antimicrobial with slowly increasing resistance since its first 
registration in the DANMAP report 2010 (Figure 8.4). This 
is in concordance with an increased use of this drug due to 
changes in the Danish antibiotic policy: increased use of beta-
lactams is thus recommended to reduce the consumption of 
 cephalosporins.
Resistance to 2nd generation cephalosporins (cefuroxime) was 
12% and resistance to 3rd generation cephalosporins was 8%. 
The resistance to 3rd generation cephalosporins is the highest 
reported level among the Nordic countries (which in 2013 
were reported below 5%), but remains lower than the occur-
rence reported by most other European countries. [EARS-Net 
2013]. 
In 2014, three carbapenem (meropenem) resistant and one 
intermediate K. pneumoniae blood isolate were reported.  
These data cover the first K. pneumoniae isolate registered per 
patient per year. In addition to these a fourth carbapenemase 
producing blood isolate were referred to and confirmed at the 
reference laboratory at Statens Serum Institut. 
Ciprofloxacin resistance was slightly lower than the previous 
year (9% in 2013, 7% in 2014), and resistance to aminoglyco-
side (gentamicin) remained unchanged from the year before 
(5%).
Compared to data reported to the EARS-Net 2013 report, the 
level of resistance to ciprofloxacin was higher than the levels 
reported from the other Nordic countries (< 5%) but levelled 
with resistance reported from the United Kingdom (9%) and 
the Netherlands (6%). Whereas the level of resistance to 
aminoglycosides was the same as in the other Nordic countries 
and lower than most countries reporting to EARS-Net [EARS-
Net 2013].
Resistance to mecillinam was 8%, at the same level as in 
2013. As for E.coli, data on percentages of resistance to mecil-
linam differ in time and geographically, which is related to 
variations in testing as well as interpreting rules and guide-
lines. Data for mecillinam resistance are presented in Table 8.2, 
but not shown in the figures. 
Urine isolates from hospital patients 
DANMAP received data on the antimicrobial susceptibility of 
6,349 K. pneumoniae isolates from hospital patients with a 
urinary tract infection (Table 8.2 and Figure 8.5).
Resistance to mecillinam (10%), sulfonamide (19%), gentami-
cin (4%), 2nd generation cephalosporins (cefuroxime) (9%), 3rd 
generation cephalosporins (7%) and ciprofloxacin (8%) was at 
the same level as reported in 2013.
In 2014, carbapenem (meropenem) resistance was reported in 
seven and intermediate resistance in five K. pneumoniae urine 
isolates from hospitalised patients. Not all DCM performed 
routine susceptibility testing for meropenem, thus the number 
of these strains represent a selected population. 
Note:  The  number  (n)  in  parentheses  represents  the  number  of  isolates  
tested  for  susceptibility  in  2014.  
  Figure  8.4.  Resistance  (%)  in  Klebsiella  pneumoniae  blood  
isolates  from  humans,  Denmark  
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Urine isolates from primary health care 
DANMAP received data on the antimicrobial susceptibility of 
 approximately 4,100 K. pneumoniae isolates from urinary tract 
infection in patients from primary health care. (Table 8.2 and 
Figure 8.6)
In 2014, resistance to 3rd generation cephalosporins was 5%, 
which is a slight decrease from the level reported in 2013 
(6%). 
Resistance to ciprofloxacin was 7%, which is similar to the 
levels reported in 2013. Resistance to mecillinam was 9% and 
 sulfonamide resistance decreased from 22% in 2013 to 17% 
in 2014.
In 2014, three carbapenem (meropenem) resistant and one 
intermediate resistant K. pneumoniae urine isolates from 
patients in primary health care were reported. As for the 
hospital urines this number represents a selected population.
Ute Wolff Sönksen and Stefan S. Olsen 
*) An asterisk indicates a significant increase from 2013 to 2014.
#) A number sign indicates a significant decrease from 2013 to 2014.
a) Tested 3rd generation cephalosporins were ceftazidime, ceftriaxone, cefpodoxime or cefotaxime.
DANMAP 2014Table 8.2. Resistance (%) in Klebsiella pneumoniae isolates from humans, Denmark
Substance
Blood isolates, hospitals Urine isolates, hospitals Urine isolates, primary healthcare
% % %
Mecillinam 8 10 9 #
Piperacillin/tazobactam 8 6 *
Sulfonamide 19 17 #
Gentamicin 5 4
Ciprofloxacin 7 8 7
Cefuroxime 12 9
3rd generation cephalosporins (a) 8 7 5
Meropenem <1 <1 <1
Max. number of isolates tested 943 6349 4105
Note:  The  number  (n)  in  parentheses  represents  the  number  of  isolates  
tested  for  susceptibility  in  2014
  Figure  8.6.  Resistance  (%)  in  Klebsiella  pneumoniae  urine  
isolates  from  humans  in  primary  health  care,  Denmark  
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  Figure  8.5.  Resistance  (%)  in  Klebsiella  pneumoniae  urine  
isolates  from  humans  in  hospitals,  Denmark  
Note:  The  number  (n)  in  parentheses  represents  the  number  of  isolates  
tested  for  susceptibility  in  2014
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Figure 8.5. Resistance (%) in Klebsiella pneumoniae urine 
isolates from humans in hospitals, Denmark
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8.3 Pseudomonas aeruginosa
 
Pseudomonas aeruginosa is an opportunistic pathogen of 
immunocompromised individuals. The case fatality rate is high 
for P. aeruginosa infections in patients suffering from cancer, 
cystic fibrosis and burns. P. aeruginosa typically infects the 
pulmonary tract, urinary tract, burns, wounds, and also causes 
bloodstream infections. It is among the most frequent colo- 
nizers of medical devices (e.g. indwelling catheters). P. aeru-
ginosa is intrinsically resistant to the majority of antimicrobial 
agents. The antimicrobial classes which can be used for treat-
ment include some fluoroquinolones (primarily ciprofloxacin), 
aminoglycosides (e.g. gentamicin, tobramycin and amikacin), 
some beta-lactams (piperacillin/tazobactam, ceftazidime, and 
carbapenems) and colistin.
P. aeruginosa blood isolates obtained  
from hospitalised patients
For P. aeruginosa, DANMAP 2014 includes data from 10 out of 
11 Departments of Clinical Microbiology (DCM), representing 
95% of the Danish population. DANMAP received data on the 
antimicrobial susceptibility of 388 P. aeruginosa isolates from 
blood. Resistance to all the tested antimicrobial agents was 
not significantly different from the level in 2013, except for 
gentamicin which decreased from 2013 ( 5%) to 2014 ( 2%), 
(Figure 8.7). The occurrence of resistance to fluoroquinolones, 
carbapenems, ceftazidime and piperacillin/tazobactam was 
at the same level or lower reported to EARS-Net 2013 by the 
Nordic countries [EARS-Net 2013].
Meropenem resistance was observed for 4% (n = 17) of the P. 
aeruginosa isolates in 2014. A Danish study of P. aeruginosa 
carbapenem non-susceptible isolates from 2011 showed that 
carbapenemases were present in a minority of the isolates 
(7%) [Hansen et al.2014 Microb.Drug Res. 20: 22-9]. As in 
previous years, putative carbapenemase producing  P. aerugi-
nosa isolates were sent  on  a voluntary basis from the DCM 
to SSI for national surveillance on carbapenemase producing 
bacteria, including not only isolates from bloodstream infec-
tions but also from other origins. In 2014, six VIM-producing P. 
aeruginosa isolates were detected from six patients. Further-
more, two NDM-producing P. aeruginosa were detected from 
two patients. [Textbox 8.2].
Anette M. Hammerum, Katrin G. Kuhn and Stefan S. Olsen
Note:  The  number  (n)  in  parentheses  represents  the  number  of  isolates  tested  for  susceptibility  in  2014
Figure  8.7.  Resistance  (%)  in  Pseudomonas  aeruginosa  blood  isolates  from  humans,  Denmark  
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Figure 8.7. Resistance (%) in Pseudomonas aeruginosa blood 
isolates from humans, Denmark     
 
Note: The number (n) in parentheses represents the number of isolates 
tested for susceptibility in 2014.
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Textbox 8.1 
Characterization of ESBL/AmpC-producing and carbapenemase-
producing Escherichia coli from bloodstream infections, 2014 
Denmark 
 
Background: Third-Generation cephalosporin-resistant Escherichia coli (3GC-R Ec) is increasing in Europe [EARS-Net report, 
2013]. The extended-spectrum cephalosporin-resistance in E. coli can be due to production of extended-spectrum beta-
lactamases (ESBLs), plasmid-mediated AmpC (pAmpCs) or constitutive overexpression of the chromosomal ampC gene due to 
mutations within the promoter/attenuator region.  
The worldwide spread of ESBL-producing E. coli is in part due to the spread of the pandemic clone O25b:-ST131. Evidently, 
this clone is strongly related to the presence of antimicrobial resistance genes, including CTX-M-15 and other ESBL enzymes, 
as well as virulence factors. 
Before 2007, the occurrence of 3GC-R Ec was low among E. coli isolated from bloodstream infections in Danish patients. How-
ever, the rate of resistance among invasive E. coli in Denmark has increased from 2.5% in 2006 to 7.0% in 2014. 
Carbapenemase-producing E. coli are also of concern (see Textbox 8.2 Carbapenemase-producing bacteria in Denmark, 2014). 
The aim of the present study was to characterize ESBL (including pAmpC) and carbapenemase-producing E. coli from blood-
stream infections according to genes and Multilocus sequence types (MLSTs).
Material and Methods: During January 2014 through December 2014, 11 out of 12 Danish departments of clinical microbi-
ology collected all their 3GC-R Ec (reported as ceftazidime, ceftriaxone, cefpodoxime or cefotaxime resistance) from blood-
stream infections. Furthermore, meropenem non-susceptible E. coli from bloodstream infections were included in the study. 
Only one isolate per patient was included in the study. The isolates were sent to Statens Serum Institut for further character-
ization.  Genomic DNA was extracted from the isolates (DNeasy Blood and Tissue Kit, QIAGEN, Copenhagen, Denmark). Frag-
ment libraries were constructed using the Nextera Kit (Illumina, Little Chesterford, United Kingdom) followed by 251-bp paired 
end sequencing (MiSeq, Illumina) according to the manufacturer’s instructions. The paired-end Illumina data was assembled 
using CLC bio’s Genomic Workbench 7.5.
The ResFinder web server, (www.genomicepidemiology.org, version 2.1) were used to identify acquired ESBL (including plas-
mid AmpCs) and carbapenemase genes from the assembled WGS data. 
The MLST web server (www.genomicepidemiology.org, version 1.7) was used for detection of MLST-profiles. For isolates with 
no ESBL genes detected, the sequences were investigated for mutations presumed to up-regulate chromosomal AmpC by the 
use of CLCbio Genomic Workbench.
Results: Whole genome sequence data were obtained from 261 E. coli isolates. Genes encoding ESBL production (including 
pAmpCs) and/or carbapenemase production were detected in 245 isolates. Sixteen isolates were hyper AmpC producers only; 
these isolates were not investigated further. The distribution of the 245 isolates with genes encoding ESBL and carbapen-
emase production in relation to the five Danish regions is shown in Table 1.
Demographic data was available for 240 of the 245 patients with ESBL/carbapenemase producing E. coli. One hundred-
twenty-seven (53%) of the patients were men and the average age at diagnosis was 70 years (ranging from below one to 97 
years). Twenty-seven patients (11%; 15 women and 12 men) of the 240 patients, died within 30 days of diagnosis (average 
age at death 75 years; ranging from 47 to 97 years).
Among the 245 isolates, 21 different ESBLs (including pAmpCs) and carbapenemases were detected (Table 2).  CTX-M-15 
dominated (49%) followed by CTX-M-14, CTX-M-27 and CTX-M-101. Different variants of CMY were detected in 16 (7%) iso-
lates. Three isolates produced carbapenemases; one OXA-48 (from a patient initially hospitalized in Turkey) and two OXA-181 
(from two patients with no recent history of travel abroad). In several isolates more than one gene encoding ESBLs and/or 
carbapenemases were detected (Table 2).
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The 245 isolates belonged to 51 different MLSTs. ST131 was the most common sequence type (ST), 124 (51%) of the isolates 
belonged to this type. Other major types were ST38 (7%), ST69 (4%), ST405 (5%) and ST648 (3%), whereas the rest of the 
isolates belonged to STs, which only were detected in 1 - 5 isolates (<1 - 2% per type) (Table 3). 
Among the 124 isolates belonging to ST131, CTX-M-15 (64 %) was most common, followed by CTX-M-27 (17%), CTX-M-101 
(10%) and CTX-M-14 (6%). The two isolates with OXA-181 and CMY-2 belonged to ST410, whereas the isolates with OXA-48 
belonged to ST443.
Conclusion: As in previous Danish studies of ESBL-producing E. coli from bloodstream infections, most of the isolates pro-
duced a CTX-M enzyme, most often CTX-M-15 [DANMAP 2009, DANMAP 2011, Hansen et al. Microb. Drug Res. 2014]. Plasmid 
mediated AmpC (CMY) was only present in a minor part of the isolates. 
As in the study by Hansen et al. the worldwide disseminated CTX-M-15 ST131 was strongly represented in this study, but 
the Danish isolates belonged to other international STs (e.g., ST38, ST69, ST405 and 648) related to spread of ESBLs too. The 
finding of three E. coli isolates with OXA-48 group enzymes from bloodstream infection is worrying.
Anette M. Hammerum, Lotte Jakobsen, Jenny D. Knudsen, Dennis S. Hansen, Leif P. Andersen, Bent L. Røder, Ulrik S. Justesen, Ute 
Sønksen, Claus Østergaard, Helga Schumacher, Mikala Wang, Jurgita Samulioniene, Katrin G. Kuhn and Frank Hansen 
For further information: Anette M. Hammerum (ama@ssi.dk)
Table 1. Distribution of 245 ESBL and Carbapenemase 
producing E. coli from bloodstream infections, 2014
Region       Numbers
The Capital Region of Denmark 110
The Zealand Region 27
Region of Southern Denmark 43
Central Denmark Region 43
North Denmark Region   22
Total numbers     245
Table 2. ESBL enzymes and carbapenemases detected  
in 245 E. coli from bloodstream infections, 2014 
 
Enzyme Numbers %
CTX-M-1 10 4%
CTX-M-14(1) 38 16%
CTX-M-14a(1) 5 2%
CTX-M-15(1) 121 49%
CTX-M-27 25 10%
CTX-M-55 8 3%
CTX-M-101 12 5%
Other ESBL enzymes 8 3%
CMY variants(1) 16 7%
OXA-48-group(1) 3 1%
DANMAP 2014
DANMAP 2014
DANMAP 2014
(1) In some isolates more than one enzyme was detected.
Table 3. Distribution of MLSTs among the 245 E. coli from 
bloodstream infections, 2014  
MLST Numbers of isolates %
ST12 5 2%
ST38 18 7%
ST69 10 4%
ST95 5 2%
ST131 124 51%
ST405 13 5%
ST648 7 3%
Other STs (1) 63 26%
(1) less than 5 isolates per ST  
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Textbox 8.2
Carbapenemase-producing bacteria in Denmark, 2014
 
Background: Carbapenems comprise one of the only classes of antimicrobial agents that can be used for treatment of 
infections with multi-resistant Gram-negatives like Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa and 
Acinetobacter baumannii. Treatment options for infections with carbapenem-resistant bacteria are often none or suboptimal. 
Resistance can be caused by the presence of various carbapenemases of which the most frequently occurring are K. pneu-
moniae carbapenemase (KPC), Oxacillinase (OXA), Verona integron-encoded metallo-β-lactamase (VIM), and New Delhi metallo-
β-lactamase (NDM), and Imipenemase (IMP).
In recent years, Danish Departments of Clinical Microbiology (DCM) have on a voluntary basis submitted carbapenem resistant 
isolates for verification and genotyping to the Antimicrobial Resistance Reference Laboratory at Statens Serum Institut. The 
present textbox describes carbapenemase-producing Enterobacteriaceae (CPE), carbapenemase-producing P. aeruginosa and 
Acinetobacter ssp. 
Figure 1. Numbers of carbapenemase-producing Enterobacteriaceae (CPE)
DANMAP  2014
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harboured  different  carbapenemases.
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During 2014, 55 carbapenemase producing bacteria were detected from 48 patients. More than one isolate from the same pa-
tient were included, if the isolates belonged to different bacterial species and/or if the isolates harboured different carbapen-
emases. Six of the isolates were from bloodstream infections. Thirty (65%) of the patients were men and the average age at 
diagnosis was 63 years (ranging from one to 97 years). Thirteen patients (28%) (nine men and four women), died within 30 
days of diagnosis (average age at death 68 years; ranging from 17 to 97 years). In many cases, the sources of the carbapen-
emase-producing bacteria were unknown or related to spread between patients in Denmark, which was different compared to 
the previous years, where most of the cases were related to travel abroad.  
 
Enterobacteriaceae: In 2014, 35 CPE (from 29 patients) were detected compared to 19 in 2013 and 20 CPE during 2008–
2012 (Figure 1). Twenty-two of the 35 CPE isolates harboured OXA-48-like genes. Twelve NDM-producing isolates and one 
KPC-producing isolate were detected 
The NDM-1 producing C. freundii outbreak, which started in 2012 in the North Denmark Region, continued in 2013 and 2014. 
Until the end of 2014, six patients were involved in this outbreak. None of these patients had a prior history of travel noted in 
their hospital records. The origin of the NDM-1 producing C. freundii was unknown. 
During 2014, NDM-5 producing K. pneumoniae were detected from three patients at a hospital in the Capital Region of Den-
mark. The isolates had highly similar SNP-profiles, indicating a possible spread between the patients or a common origin. None 
of the patients had travelled recently, and the origin of the NDM-5 producing K. pneumoniae was unknown.
Acinetobacter spp: The number of carbapenemases-producing Acinetobacter spp was the same level as in 2013. Nine OXA-
23 producing A. baumannii isolates were detected in 2014. Furthermore, one OXA-40-like producing A. baumannii, one OXA-
58-like producing A. baumannii and one NDM-1 producing A. Acinetobacter pittii were detected. NDM-1 producing A. pittii are 
rare and the origin of this isolate was unknown. 
P. aeruginosa: In 2014, six VIM-producing P. aeruginosa isolates were detected from six patients. Furthermore, two NDM-
producing P. aeruginosa were detected from two patients. 
Conclusion: The occurrence of carbapenemase-producing bacteria in Denmark is increasing, a trend worrisome to patients and 
clinicians. Especially the spread of CPE is of concern, since Enterobacteriaceae can be carried in the intestine for a long time 
without any symptoms of infections, which makes outbreak control difficult.    
Anette M. Hammerum, Frank Hansen, Katrin G. Kuhn and Lotte Jakobsen 
For further information: Anette M. Hammerum (ama@ssi.dk)
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8.4 Streptococci, including pneumoccci
 
Streptococci include Streptococcus pneumoniae (pneumococci), 
beta-haemolytic streptococci (BHS), and non-haemolytic strep-
tococci (NHS). The prevalence of asymptomatic carriership of 
pneumococci in the nasopharynx varies with age. NHS are part 
of the normal commensal flora of the upper respiratory tract, 
mouth, skin, and intestine in humans.
Pneumococci may cause common and less severe infections 
such as otitis media, sinusitis, pneumonia, and invasive infec-
tions such as bacteraemia, meningitis, and endocarditis.
BHS of group A cause tonsillitis, otitis media, wound infections, 
but also more severe infections: e.g., bacteraemia, necrotiz-
ing myo-fasciitis, and rarely meningitis. BHS of group B may 
be present in the vaginal flora of 20-25% of women in the 
child-bearing age and may therefore cause meningitis and 
septicaemia in the newborn. Such infections may also occur in 
elderly or immuno-compromised patients. BHS of groups C and 
G predominantly cause soft-tissue infections and sometimes 
bacteraemia. Approximately 10% of humans are asymptomatic 
throat carriers of BHS of any group. NHS may cause invasive 
infections, e.g. endocarditis. 
This report presents data on resistance in non-duplicate inva-
sive isolates (i.e., from blood or cerebrospinal fluid) of pneumo-
cocci and BHS submitted to the Neisseria and Streptococcus 
Reference laboratory. Isolates are received from all DCMs in 
Denmark  Non-invasive isolates are infrequently received but 
are not included in this report. There is no surveillance of NHS.  
Infections with pneumococci and BHS are usually treated with 
penicillins or macrolides. All invasive non-duplicate Streptococ-
cus pneumoniae and group A, B, C and G BHS were therefore 
tested for susceptibility to penicillin and erythromycin. More-
over, the group A, B, C and G BHS were tested for susceptibility 
to clindamycin and for inducible clindamycin resistance. 
Streptococcus pneumoniae
Susceptibility testing was performed on 722 isolates of S. 
pneumoniae (Figure 8.8).
For penicillin, 40 (5.5%) isolates were non-susceptible (resis-
tant and intermediary resistant) in 2014 compared to 6.3% in 
2013 (Figure 8.8). The 40 isolates belonged to 13 different 
serotypes and the most commonly found penicillin non-suscep-
tible serotypes were type 15A (n = 14), 19A (n = 5), 24F (n = 
4) and 23B (n = 4). One of the 40 isolates  (type 19F) was fully 
resistant to penicillin.
Regarding erythromycin,  47 (6.5%) isolates were non-sus-
ceptible in 2014 compared to 5.1% in 2013 (Figure 8.8). The 
47 isolates belonged to 11 different serotypes and the most 
commonly found erythromycin non-susceptible serotypes were 
type 15A (n = 15), 24F (n = 14) and 33F (n = 6). 
Non-susceptibility to penicillin or erythromycin or both was 
more frequent for some serotypes than for others. This was 
the case for serotype 9V (3 of 3 received isolates), 15A (15 of 
27 received isolates) and 23B (4 of 10 received isolates).
The levels of erythromycin and penicillin non-susceptibility in 
Denmark were similar to the levels reported in 2013 to EARS-
Net by the neighboring countries Norway, Sweden, Germany, 
and the United Kingdom. Many other European countries 
reported considerably higher levels of resistance in 2013 
[EARS-Net 2013].
Beta-haemolytic streptococci
Group A streptococci
All 149 isolates of group A streptococci (Streptococcus pyo-
genes) were sensitive to penicillin. Erythromycin resistance 
was detected in one isolate (0.7%) as compared to five isolates 
in 2013 (3.0% of 167). This isolate was also resistant to 
clindamycin (0.7%). In total, 99.3% of the isolates were sensi-
tive to both penicillin, erythromycin, and clindamycin.
Figure 8.8. Nonsusceptibility (%) in Streptococcus pneumoniae 
blood and spinal fluid isolates from humans, Denmark
Figure  8.8.  Nonsusceptibility  (%)  in  Streptococcus  
pneumoniae   blood  and  spinal  fluid  isolates  from  humans,  
Denmark
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Group B, C and G streptococci 
All 139 isolates of group B streptococci (Streptococcus agalac-
tiae) were sensitive to penicillin. Erythromycin resistance was 
detected in 31 isolates (22%) as compared to 22 in 2013 (17% 
of 129). 16 isolates (11%) were resistant to clindamycin and 
additionally four isolates (2.9%) showed inducible resistance 
to clindamycin.. In total, 77% of the isolates were sensitive to 
both penicillin, erythromycin, and clindamycin.
All 80 isolates of group C streptococci (Streptococcus equi-
similis and S. zooepidemicus) were sensitive to penicillin. 
Erythromycin resistance was detected in three isolates (3.8%) 
the same number as in 2013 (4.5% of 66). Three isolates 
(3.8%) were resistant to clindamycin and additionally one 
isolate (1.3%) showed inducible resistance to clindamycin. In 
total, 95% of the isolates were sensitive to both erythromycin, 
clindamycin and penicillin.
All 188 isolates of group G streptococci were sensitive to 
penicillin. Erythromycin resistance was detected in 19 isolates 
(10.1%) as compared to 16 in 2013 (10.4% of 154). Three 
isolates (1.6%) were resistant to clindamycin and additionally 
13 (6.9%) showed inducible resistance to clindamycin. In total, 
89.9% of the isolates were sensitive to both penicillin, erythro-
mycin, and clindamycin.
Tine Dalby and Steen Hoffmann
8.5 Enterococci
 
Enterococci are part of the normal intestinal flora of both 
humans and animals but might also cause infections. Impor-
tant clinical infections caused by Enterococcus species include 
urinary tract infections, bacteraemia and bacterial endocarditis. 
These infections can be life-threatening in humans, especially 
in hospitalized patients. The naturally high level of antimicrobi-
al resistance found in enterococci makes infections difficult to 
treat. Antimicrobial therapy for serious enterococcal infections 
requires the use of synergistic combinations of a cell-wall-
active agent such as penicillin (ampicillin) with an aminoglyco-
side (gentamicin) or a glycopeptide (vancomycin).
For E. faecalis and E. faecium, data from 10 of the 11 DCM 
were obtained, representing 95% of the Danish population.
Enterococcus faecium and Enterococcus faecalis blood 
isolates obtained from hospitalised patients 
DANMAP received data on the antimicrobial susceptibility 
of 738 E. faecium isolates and 598 E. faecalis isolates from 
blood.
As in previous years, most of the E. faecium isolates from 
bloodstream infections were ampicillin resistant. Treatment 
with fluoroquinolones, cephalosporins or carbapenems has 
been described as a risk factor for development of an E. 
faecium infection. An increasing consumption of these anti-
microbial agents has been observed in hospitals in Denmark 
during the last decade. The antimicrobial selection pressure in 
a hospital environment might be a reason for the high level of 
ampicillin resistant E. faecium as a cause of bloodstream infec-
tions. In 2014, 94% of the E. faecium isolates were resistant 
to ampicillin.
Only one of the DCMs (Aalborg) tested all enterococcal blood 
isolates for high-level gentamicin resistance (HLGR). Among 
the tested E. faecalis isolates, 30% were HLGR, whereas 68% 
of the tested E. faecium isolates were HLGR. The level of HLGR 
E. faecalis and HLGR E. faecium was similar to or higher than 
the level detected in many European countries reporting to 
EARS-Net in 2013 [EARS-Net 2013].
In 2014, vancomycin resistance was detected in 4.3% of the 
E. faecium isolates and 0.2% of the E. faecalis isolates from 
bloodstream infections. The E. faecium bloodstream isolates 
were part of outbreaks with vancomycin resistant (vanA) 
E. faecium, which is described in Textbox 8.3.. The level of 
vancomycin resistant E. faecium was above or at the same 
level reported to EARS-Net 2013 by the other Nordic countries 
[EARS-Net 2013].
Anette M. Hammerum, Katrin G. Kuhn and Stefan S. Olsen
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Textbox 8.3
Continued increase in occurrence of clinical vancomycin resistant 
enterococci in Danish hospitals in 2014
Background: Enterococcus faecalis and Enterococcus faecium are commensal bacteria in the intestine of humans. E. faecalis and 
E. faecium can also cause urinary tract infections (UTI) and fatal infections like sepsis and endocarditis, especially among older 
patients. Enterococci are intrinsically resistant to a number of first-line antimicrobial agents including cephalosporins. Therefore, 
therapy of enterococcal infections may be difficult. Severe enterococcal infections are primarily treated with vancomycin, but 
recently an increase in the occurrence of vancomycin resistant enterococci (VRE) has been observed in Denmark and internation-
ally. Many of the VRE are also resistant to ampicillin and gentamicin limiting the treatment possibilities. Newer antibiotics such as 
linezolid and daptomycin can be used for treatment of VRE, but both antimicrobial agents have many side effects. 
Surveillance of VRE: Since 2005, Danish Departments of Clinical Microbiology (DCM) have on a voluntary basis, submitted 
VRE for species identification, genotyping (vanA, vanB and vanC) and surveillance to the Antimicrobial Resistance Reference 
Laboratory at Statens Serum Institut. 
From 2005 through 2009, the occurrence of clinical VRE in Denmark has been low (<30 isolates) (Figure 1). However, in 2010 
and 2011 outbreaks occurred at hospital wards in the Central Denmark Region [DANMAP 2010 and DANMAP 2011] causing 
an increase in the number of clinical vanA E. faecium. In 2013, a steep increase in vanA E. faecium was observed. They were 
primarily detected at hospitals in the Capital Region, but also from The Zealand Region and the Central Denmark Region. VRE 
was detected in the two other regions of Denmark too, but to a much lower extent. Typing of VRE isolates from 2012 and 
2013 showed spread of several vanA E. faecium clones both inside hospitals and between hospitals [Pinholt et al. 2015, J. 
Antimicrobial. Chemother, 70:2474-82]. In 2014, a further increase in VRE was observed to a total of 303 isolates. Most of the 
VRE were vanA E. faecium, which increased from 231 clinical vanA E. faecium in 2013 to 297 in 2014 (Figure 1). Phylogenetic 
analysis of the whole genome sequences of the vanA E. faecium isolates obtained from blood  and sent to the reference labo-
ratory (n = 32) demonstrated the same clonal types on several hospitals. These isolates belonged to sequence types, which 
previously have been detected from clinical VRE outbreaks internationally (ST80, ST117, ST192 and ST203).
Conclusion: The continued increase in number and transmission of vanA E. faecium in 2014 in Denmark is worrying. VRE can 
be carried in the intestine for a long period without any symptoms of infection and likewise persist in the hospital environ-
ment, which makes infection control difficult but should include proper cleaning, good hand hygiene, screening for VRE and 
isolation of patients. 
Lotte Jakobsen and Anette M. Hammerum. For further information: Anette M. Hammerum (ama@ssi.dk) 
Figure 1. Numbers of vancomycin resistant Enterococcus faecium and Enterococcus faecalis isolates from clinical 
samples and van genes, Denmark  
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8.6 Staphylococcus aureus
 
Staphylococcus aureus is part of the normal flora of the skin 
and mucosa in approximately 50% of humans. Some people 
only carry S. aureus intermittently whereas others carry S. au-
reus for longer time. However, in addition S. aureus also causes 
infections ranging from superficial skin infections i.e. impetigo 
and boils to invasive infections such as post-operative wound 
infections, infections related to intravenous catheters and 
prosthetic devices, bacteraemia, osteomyelitis, endocarditis 
and septic arthritis.
In Denmark, a voluntary surveillance programme of all S. 
aureus bacteraemia cases was established in 1957. Labora-
tory and clinical notification of Methicillin-resistant S. aureus 
(MRSA) has existed since November 2006. At SSI, all isolates 
are typed by spa typing, susceptibility testing is performed 
for 20 antimicrobials and the presence of the gene lukF-PV is 
determined.  LukF-PV codes for a cytotoxin (Panton-Valentine 
leucocidin, PVL) which has been closely linked to skin abscess-
es and the very rare condition of severe necrotizing pneu-
monia. PVL is found both in MSSA and MRSA, for MRSA PVL 
has been closely associated with community acquired MRSA 
strains. In addition demographic and epidemiological informa-
tion is registered. Based on the epidemiogical information each 
case is classified with respect to possible place of acquisition: 
hospital (HA), community (CA), healthcare-associated with a 
community onset (HACO), import (IMP) and livestock-associat-
ed MRSA (CC398). For CA and HACO classification is separated 
into known and not known exposure.
Surveillance of bacteraemia 
In 2014, 1,964 S. aureus bacteraemia cases corresponding to 
34.9 cases per 100,000 inhabitants were reported from the 
Departments of Clinical Microbiology (DCM) in Denmark. For the 
second year the number of cases was higher than in the previ-
ous  years (approximately 1,500 annual cases). This may to 
some extent reflect underreporting in previous years. Fifty-six 
(2.9%) of the bacteraemia cases were caused by MRSA. This 
is a steep increase compared to the levels in previous years 
(30 cases, 1.7 % in 2013), but still very low compared to most 
other countries participating in EARS-Net [EARS-Net 2013]. 
Eight of the 56 MRSA cases were caused by CC398 (4 MRSA 
CC398 in 2013). Four hundred and thirty seven (22%) pa-
tients died within thirty days of the onset of bacteraemia. The 
mortality for the MRSA bacteraemia cases was 21% (n=12). 
Antimicrobial resistance in S. aureus bacteraemia isolates from 
2005–2014 is presented in Table 8.3. The highest frequency 
of resistance to other than penicillin, was observed for fusidic 
acid (15%), erythromycin (8%), clindamycin (8%) and norfloxa-
cin (6%). Susceptibility to all tested antimicrobial agents was 
at the same level as in 2013, but resistance to erythromycin, 
clindamycin, fusidic acid and norfloxacin has increased steadily 
since 2005 (Table 8.3). Resistance to at least 1, 2 or 3 other 
antimicrobial agents in addition to penicillin was demonstrated 
in 29%, 16% and 9% of the cases, respectively. Typing dem-
onstrated 545 different spa types distributed in 28 different 
CC groups (the ten most prevalent spa types are presented in 
Table 8.4). PVL was demonstrated in 21 (1%) cases of which 
six were MRSA. The 21 PVL containing isolates were distrib-
uted over 18 different spa types and 10 different CC groups.
Surveillance of methicillin-resistant S. aureus 
In 2014, 2,965 new MRSA cases were detected (52.7 per 
100,000 inhabitants). This was the highest number of cases 
observed in Denmark (Figure 8.9). A case was defined as 
a person found positive for the first time with a specific 
MRSA strain regardless whether the patient was infected or 
colonised only. MRSA isolates carry either the mecA or more 
uncommonly, the mecC gene.
In 2014, the number of new MRSA cases increased by 42% 
compared to 2013 (n=2,092) and was almost five times as 
high as in 2007 (n=663). CC398 cases increased substantially 
and constituted 43% (n=1,277) of new MRSA cases in 2014 
(Table 8.5). The increase was for a large part due to changes in 
screening procedures for patients admitted to hospitals, which 
from December 2012 included contact to pigs as a risk factor 
for acquisition of MRSA.   
MRSA isolates carrying mecC were demonstrated in 53 cases 
(1.8%) in 2014 (9 in 2009, 21 in 2010, 37 in 2011, 24 in 2012 
and 41 in 2013). Thirty-six of the cases (68%) had infections 
at the time of diagnosis. Only one possible livestock contact 
was registered for the 53 mecC cases.
The total number of cases and the number of cases presenting 
with infection according to epidemiological classification are 
shown in Table 8.5. Most of the cases (86%) were acquired in 
Denmark. At the time of diagnosis, 38% (n=1,115) of cases had 
infection, which was lower than in 2013 (45%) due to a much 
lower fraction of infections among CC398 cases (n=240, 19%). 
The epidemiological classification of MRSA infections 2007–
2014 is shown in Figure 8.10. Despite the increasing total num-
ber of cases, the number of hospital acquired infections (n=49) 
and the number of healthcare-associated with community onset 
(HACO) infections (n=140) were at a stable very low level. The 
number of community-acquired (CA) infections continued the 
increasing trend in 2014 and was by far the largest group (n = 
456) while infections caused by CC398 increased in 2014 and 
was the second most prevalent (n=240) (Figure 8.10).
Molecular typing of the MRSA strains 
In total, spa typing revealed 291 different strain types of which 
210 types were associated with clinical infections. The 10 
dominating spa types isolated in 2014 are shown in Table 8.4. 
They constituted 67% of the total number of MRSA isolates. Ten 
spa types constituted 57% of the 1,115 clinical infections with 
MRSA. These most prevalent spa types causing clinical infections 
at time of presentation were t034/CC398 (n=179), t002/CC5 
(n=91), t008/CC8 (n=86), t019/CC30 (n=58), t127/CC1 (n=53), 
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Figure  8.9.  Number  of  MRSA  cases,  with  a  three  years  moving  average,  Denmark
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Table 8.3. Resistance (%) in isolates from S. aureus bacteraemia cases, Denmark
Antimicrobial agent
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
% % % % % % % % % %
Methicillin 1.6 1.4 0.6 1.3 1.6 1.4 1.4 1.2 1.7 2.9
Penicillin 78 80 78 77 77 75 77 74 76 77
Erythromycin 5 5 4 5 7 5 7 6 7 8
Clindamycin 4 4 3 4 6 4 6 6 6 8
Tetracycline 3 3 2 3 2 3 2 2 3 5
Fusidic acid 10 10 9 9 9 13 13 14 15 15
Rifampicin <1 <1 <1 <1 <1 <1 <1 <1 0 <1
Norfloxacin 3 2 1 2 2 3 4 4 5 6
Kanamycin 2 1 <1 1 1 1 <1 1 2 2
Linezolid nt nt nt 0 0 0 0 0 0 0
Mupirocin 0 0 <1 <1 <1 <1 <1 <1 <1 <1
Trimethoprim-sulfamethoxazole nt nt nt nt nt nt <1 1 1 1
Note: nt = not tested. In web annex table A8.1 the distribution of MICs and resistance for all tested antimicrobial agents are shown.
DANMAP 2014
Figure 8.9. Number of MRSA cases, with a three years moving average, Denmark
SAB MRSA
spa type CC group(a) No. of cases spa type CC group(a) No. of cases No. causing 
infections (%)
t127 CC1 103 t034 CC398 990 179 (18)
t230 CC45 100 t002 CC5 181 91 (50)
t002 CC5 88 t011 CC398 180 36 (20)
t084 CC15 66 t127 CC1 136 53 (39)
t012 CC30 66 t008 CC8 119 86 (72)
t091 CC7 63 t223 CC22 98 33 (34)
t015 CC45 51 t304 CC8 79 37 (47)
t008 CC8 46 t019 CC30 71 58 (82)
t701 CC8 35 t032 CC22 70 31 (44)
t065 CC45 33 t437 CC59 54 35 (65)
Table 8.4. The ten most prevalent spa types demonstrated in SAB and in MRSA cases, Denmark 2014  DANMAP 2014
a) CC = Clonal complex.
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t304/CC8 (n=37), t011/CC398 (n=36), t437/CC59 (n=35), t223/
CC22 (n=33) and t032/CC22 (n=31). The PVL encoding gene 
lukF-PV was demonstrated in 32% of the infections and in 7% of 
the asymptomatic carriers and most often in relation to isolates 
with spa types t008 (n=102), t019 (n=66), t002 (n=41), t437 
(n=40) and t044 (n=32).
Resistance among MRSA isolates 
Resistance is shown in Table 8.6 and is divided into two catego-
ries: CC398 and other. CC398 isolates were typically resistant 
to tetracycline (99%) and clindamycin (89%) with high levels of 
resistance to erythromycin and norfloxacin (41% and 28%, re-
spectively). Resistance to fusidic acid and kanamycin was higher 
among non-CC398 (17% vs 1% and 30% and 7%, respectively). 
Resistance to at least 1, 2 or 3 other antimicrobials in addition to 
β-lactam antibiotics (cefoxitin/penicillin) was demonstrated in 
70%, 58% and 38% of all of the cases, respectively.
Andreas Petersen, Robert L. Skov and Anders Rhod Larsen
Table 8.6. Resistance (%) in CC398 MRSA and  
other MRSA cases, Denmark
In web annex table A8.2 the distribution of MICs and resistance for all 
tested antimicrobials are shown.
Clonal complex CC398 % other CC % All cases %
Erythromycin 41 33 35
Clindamycin 89 23 33
Tetracycline 99 21 33
Fusidic acid 1 17 14
Rifampicin 0 <1 <1
Norfloxacin 28 27 27
Kanamycin 7 30 26
Linezolid 0 <1 <1
Mupirocin 0 <1 <1
Trimethoprim-
sulfamethoxazole
1 3 3
Number of tested 
isolates
316 1616 1932
DANMAP 2014
DANMAP 2014Table 8.5. Epidemiological classification of new MRSA cases, Denmark
Note: Numbers shown in bold are totals.
Epidemiologic classification Exposure No. of cases (% of total) No. (%) of cases with infections 
Imported (IMP) 411 (14) 230 (56)
Hospital-acquired (HA) 95 (3) 38 (40)
Healthcare associated, 
community onset (HACO)
187 (6)
      with known exposure 34 13 (38)
      without known exposure 153 125 (82)
Healthcare worker 50 (2) 13 (26)
Community-acquired (CA) 945 (32)
      with known exposure 478 86 (18)
      without known exposure 467 370 (79)
CC398 1277 (43) 240 (19)
Figure 8.10. Number of MRSA infections according to epidemiological classification, Denmark
Figure  8.10.  Number  of  MRSA  infections  according  to  epidemiological  classification,  Denmark
0
50
100
150
200
250
300
350
400
450
500
2007 2008 2009 2010 2011 2012 2013 2014
N
o.
  o
f  i
nf
ec
tio
ns
Imported   (IMP) Hospital-­acquired   (HA)
Health-­care   associated,   community  onset   (HACO) Community-­acquired   (CA)
CC398
DANMAP 2014
DANMAP 2014 94
RESISTANCE IN HUMAN CLINICAL BACTERIA8.
Textbox 8.4
Neisseria gonorrhoeae 2014
Background: Neisseria gonorrhoeae is the causative agent of the sexually transmitted infection gonorrhoea, which is usually 
located in the urethra in males and cervix in females. N. gonorrhoeae (gonococci) may sometimes be demonstrated in speci-
mens from the pharynx or rectum in either gender, although infections in these sites are generally asymptomatic. Complica-
tions of gonorrhoea include e.g. salpingitis, epididymitis, orchitis, and prostatitis. Further, conjunctivitis may occur in newborns 
after transmission from an infected mother during labour and rarely in adults following direct inoculation.
Methods: Through decades, all Departments of Clinical Microbiology in Denmark have submitted their isolates of gonococci to 
the Neisseria and Streptococcus Reference (NSR) laboratory at Statens Serum Institut for national surveillance of antimicrobial 
resistance. 
At the NSR laboratory ceftriaxone, ciprofloxacin and azithromycin MICs were determined using the Etest® on chocolate agar 
incubated at 35°C in 5% CO2. The breakpoints used were those defined by the EUCAST. Both fully and intermediary resistant 
isolates were categorized as resistant. Penicillinase production was tested for using the Nitrocephin assay.
As part of NSR’s participation in ECDC’s surveillance of sexually transmitted infections since 2009, approximately 110 gono-
coccus isolates are investigated per year for susceptibility to an expanded panel of antimicrobial agentsincluding cefixime and 
in selected years also spectinomycin, and gentamicin. The latter two drugs were not included on the 2014 survey.
Results and discussion: In 2014, 842 isolates were received. Most of the received isolates were from urethra or cervix, while 
clinicians only rarely obtain specimens from rectum and pharynx. Occasionally, the NSR laboratory receives strains isolated 
from other anatomical sites, such as conjunctivae, joint fluid, blood, Bartholin’s abscess, etc.
The annual number has increased considerably from 2011 through 2014, presumably because the widespread use of com-
bined PCR-testing for Chlamydia trachomatis and Neisseria gonorrhoeae has identified unexpected cases of gonorrhoea (fol-
lowed by culture), but possibly also due to an increasing incidence of gonorrhoeae.
The ciprofloxacin resistance rate was 46% in 2014, thus showing a steady decline since the peak of 75% in 2009 (Figure 1). 
The percentage of strains producing penicillinase was 11% in 2014. It has fluctuated between 22% in 2005 and 11% in 2014 
and 2013.
Ceftriaxone resistant gonococci (MIC > 0.125 mg/L) as well as ceftriaxone treatment failure in patients with gonorrhoea have 
occurred in several countries during recent years. No cases with such resistance have ever been reported from Denmark. Dur-
ing 2003 through 2009 the proportion of isolates with MIC ≥  0.008 mg/L gradually increased from 40% to nearly 75% (Figure 
2), but during recent years this shift has nearly reversed (44% in 2014). Thus, there is no evidence of emerging ceftriaxone 
resistance in Denmark.
In 2014, azithromycin resistance including intermediary resistance (MIC > 0.5 mg/L) in gonococci was 36% (Table 1). Several 
recent guidelines for the treatment of gonorrhoea recommend the combination of high dose ceftriaxone and azithromycin (1 g 
or 2 g).
Resistance against cefixime (MIC > 0.125 mg/L) was 6% in 2014, i.e. a decrease compared to 2013. Cefixime is an oral cepha-
losporin that has never been used in Denmark. 
Conclusions: The incidence of gonorrhoea seems to be increasing. Although resistance problems are so far not present in 
Denmark, the emerging ceftriaxone treatment failures in other countries underlines the importance of maintaining the central-
ised national surveillance of antimicrobial resistance in gonococci. 
Steen Hoffmann 
For further information: Steen Hoffmann (hof@ssi.dk)
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Figure 1. Ciprofloxacin resistance and penicillinase production in gonococci, Denmark, 2005-2014
Figure 2. Distribution of ceftriaxon MIC values (mg/L) in gonococci, Denmark, 2005-2014
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Textbox 8.5
Livestock associated methicillin-resistant Staphylococcus aureus 
(LA-MRSA) among humans in and in pig herds 2014
Background: Livestock associated methicillin resistant Staphylococcus aureus (LA-MRSA) was first recognized in 2005 and 
have since disseminated worldwide. In Europe, LA-MRSA primarily belongs to clonal complex 398 (CC398) and is especially 
associated with pigs from where it spreads to humans, primarily to persons with contact to pigs. 
Livestock associated MRSA in humans: The number of persons positive for MRSA CC398 continued to increase to 1277 
cases in 2014 (42 in 2009, 111 in 2010, 164 in 2011, 232 in 2012 and 643 in 2013). A significant part of the increase from 
2012 and onwards was associated with a change in the MRSA screening policy of patients admitted to hospital as contact to 
pigs was included as a risk factor requiring screening for MRSA in December 2012.  
[https://sundhedsstyrelsen.dk/en/health/infectious-diseases/mrsa/guidelines]. 
The most frequent spa types related to CC398 were t034 (n = 990), t011 (n= 180) and t571 (n = 20). The majority of CC398 
cases (1140, 89%) were in persons with documented close contact to pigs or in members of their household. This resembles 
the proportion from previous years. In actual numbers, cases without documented contact to livestock increased from 83 
cases in 2013 to 137 in 2014. The majority of these cases are from areas of high pig density and there is still no sign of sig-
nificant spread of CC398 to urban areas.
Two hundred and forty of the 1,277 CC398 cases (19%) presented with infections. This is considerably lower than for com-
munity acquired MRSA (CA-MRSA) in general, and reflects that the majority of cases are found through screening programmes. 
In 2014, eight bacteraemia cases were MRSA CC398. Two of the patients died within 30 days. The patients did not have any 
direct contact to pigs. 
MRSA in animals:  In 2014, a national survey was carried out to estimate the prevalence of LA-MRSA in Danish pig herds. 
Samples, consisting of five pools of five nasal swabs per herd were collected in 70 breeding herds and 205 randomly selected 
slaughter pig herds. All samples were collected at the farm. 
The results are shown in Table 1. The overall prevalence of MRSA was high in both breeding herds, 63 %, and slaughter pig 
herds, 68 %, which is a marked increase compared to previous surveys, where 16 % of the herds, tested at the farm were 
found positive for MRSA (DANMAP 2010 and 2011). Differences between regions were not significant.
 
Table 1: LA-MRSA in 275 Danish pig herds, Denmark
No. tested herds Prevalence
Breeding herds 70 63 %
Slaughter pigs – Denmark 205 68 %
Slaughter pigs – Jutland 147 70 %
Slaughter pigs – Funen 39 69 %
Slaughter pigs - Zealand 19 53 %
 
Conclusions: In 2014, a steep increase in CC398 cases was detected and CC398 continued to be the most common CC group 
among human MRSA cases. An increasing number of CC398 cases had no documented contact to pigs but lived in areas with 
high density of pigs. Likewise, an increase since 2010 in the percentage of infected pig herds was evident. 
Andreas Petersen, Anders Rhod Larsen, Karl Pedersen and Robert L. Skov 
For further information Robert L. Skov, E-mail: rsk@ssi.dk and Karl Pedersen, kape@vet.dtu.dk
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9. Materials and methods
9.1 General information
 
For the DANMAP 2014 report, population sizes and 
 geographical data were obtained from Statistics Denmark  
[www.dst.dk] and data on general practitioners from the 
 Danish Medical Association [www.laeger.dk].
The epidemiological unit for pigs and cattle was defined as 
the individual farm, meaning that only one isolate per bacterial 
species per farm was included in the report. The same epide-
miological unit was applied for broilers, except for Salmonella 
where the individual flock of broilers was defined as the epide-
miological unit. For food, the epidemiological unit was defined 
as the individual meat sample. For humans, the epidemiologi-
cal unit was defined as the individual patient and the first 
isolate per patient per year was included.
Unless stated specifically, all differences and temporal trends 
noted in the text are statistically significant (p<0.05) using either 
Chi-square tests or linear logistic regression (see Section 9.6.3).
9.2 Data on antimicrobial consumption
 
Antimicrobial agents used for humans and animals in Denmark 
are presented in Table 3.2.
9.2.1 Data on antimicrobial consumption in animals
Since 2001, consumption data presented in this report have 
been obtained from the national monitoring programme 
VetStat, which is a database hosted by the Danish Veterinary 
and Food Administration. Prior to 2001, data were based on 
national sales figures from the pharmaceutical industry.
Data registration
In Denmark, all therapeutic drugs are prescription-only and 
VetStat collects data on all medicines prescribed by veteri-
narians for use in animals, except in a few instances when 
medicines are prescribed on special license (i.e. medicines not 
approved for marketing in Denmark). In addition, data on con-
sumption of coccidiostatics as feed additives (non-prescription) 
and antimicrobial growth promoters (not in use since 2000) are 
collected by VetStat.
Until 2007, antimicrobial agents could only be purchased at 
the pharmacy or in medicated feed from the feed mills. From 
April 2007, the monopoly was suspended and private com-
panies (four in 2014) were permitted - on certain conditions 
identical conditions as for pharmacies - to sell prescribed vet-
erinary medical products for animals. In addition, price setting 
was liberalised, which allowed for discounts corresponding to 
lower administration costs related to sale of large quantities to 
the veterinarians.
The pharmacy or company either sells the medicines to veteri-
narians for own use in practice or for re-sale to farmers, or sells 
the medicines directly to the animal holder on presentation of 
a prescription. By law, the profit that veterinarians may make 
on the sale of medicine is very small (5%), thereby limiting the 
economic incentive to sell medicine.
In 2014, 93% of antimicrobial agents were purchased through 
pharmacies and the drug trading companies, while 4% were 
purchased from the feed mills. These percentages do not 
include prescribed zinc oxide from the feeding mills for the pig 
production. In cattle, the majority of antimicrobial agents are 
now purchased from pharmacies, whereas 10 years ago where 
more than 80% of the antimicrobial agents used in cattle was 
purchased through the veterinarian. In aquaculture, more than 
80% is purchased through the feed mills.
Data on all sales of veterinary prescription medicine from the 
pharmacies, private companies, feed mills and veterinarians 
are sent electronically to VetStat. Veterinarians are required by 
law to report to VetStat all use and prescriptions for production 
animals (monthly submissions). For most veterinarians, the 
registration of data is linked to the writing of invoices. Howev-
er, errors in the veterinarians invoice system sometimes cause 
errors in amounts reported, and these data are not validated 
at entry to VetStat. The electronic registration of the sales at 
the pharmacies is linked to the billing process and stock ac-
counts at the pharmacy, which ensures a very high data quality 
regarding amounts and identity of drugs. Data are transferred 
daily from pharmacies to The Register of Medicinal Product 
Statistics at SSI and on to VetStat also daily. 
The VetStat database contains detailed information about 
source and consumption for each prescription item: date of 
sale, identity of prescribing veterinarian, source ID (identity 
of the pharmacy, feed mill, or veterinarian practice reporting), 
package identity code and amount, animal species, age-group, 
disease category and code for farm-identity (CHR - Danish 
Central Husbandry Register). The package code is a unique 
identifier, relating to all information on the medicinal product, 
such as active ingredient, content as number of unit doses (e.g. 
number of tablets), package size, and code of the antimicro-
bial agent in the Veterinary Anatomical Therapeutic Chemical 
(ATCvet) classification system.
Knowledge of the target animal species enables the presenta-
tion of consumption data in “defined animal daily doses” - a 
national veterinary equivalent to the international defined 
daily doses (DDDs) system applied in the human field  
[www.whocc.no]. 
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Methods 
In DANMAP we want to compare consumption of antimicrobials 
between different animal populations and between veterinary 
and human sectors. In order to do this we need to take into ac-
count the quantity of antimicrobials used, their potency, their 
formulation, the route of administration and – sometimes – the 
age of the animals in which they are used. We also need to 
know the size of the populations to which the antimicrobials 
are administered. 
In DANMAP 2014, we use defined animal daily doses (DADDs) 
that are harmonised so products with the same active com-
pound, strength and dispensing form all have the same 
dose, even if higher doses listed in the approved Summary 
of Product Characteristics (SPC). Thus the animal daily doses 
currently listed in the VetStat database (ADDs) and the DADDs 
used in DANMAP 2014 are not in full compliance; however 
adjustments of the VetStat ADDs are being implemented. See 
Textbox 9.1 for further description of this issue. DADDs are 
applied for estimation antimicrobial consumption in pigs and 
cattle, and listed in the web annex.
DADD - Defined animal daily dose 
DADD is the average maintenance dose per day for 
a drug used for its main indication in the appropriate 
animal species. The DADD is not defined at product 
level but for each antimicrobial agent, administration 
route and animal species and when appropriate, also 
age group. DADD has been specifically defined for use 
in DANMAP and does not always completely match the 
“prescribed daily dose” or the recommended dosage in 
the Summaries of Product Characteristics (SPC).
 
The basic principles for the DADD are similar to the principles 
previously described for the ADD. The designation of the DADD 
is based on the VetStat ADDs, but re-defined for each group 
of antimicrobial agents, i.e. for each combination of active 
compound, administration route, formulation, considering the 
following principles:
1. Minor inconsistencies, e.g. due to rounding of numbers, have 
been corrected;
2. Approved dosage for the most widely used antimicrobial 
products were given priority above dosage for products that 
are rarely used;
3. Approved dosage for older products within the group are 
maintained as the common DADD even if a new product is 
approved with a higher dosage;
4. In determining the dosage for a group with large variation 
between approved dosages of the products, the dosages 
in accordance with the dose given in ”The Veterinary 
 Formulary” [British Veterinary Association, 2005, 6th 
edition] are applied;
5. Dosages may vary within active compound and administra-
tion route, if different dosages have been approved for 
different age group/indication or formulation. 
When principle 2 and 3 are conflicting, principle 4 is applied.
Denominator
Trends in antimicrobial consumption in pigs are presented in 
DADD per 1,000 animals per day – DAPD. The number of ani-
mals in a population (in epidemiological terms: the population 
at risk) is represented by their live biomass. The biomass of a 
species is calculated, taking into account average live body-
weight and the average life-span in each age group. In 2014, 
DAPD calculations were carried out for pigs only.
DAPD - DADD per 1,000 animals per day 
The number of DADDs administered to a specific ani-
mal species during a year (in thousands) divided by the 
number of standard animals at risk per day. The number of 
standard animals at risk per day takes into account species 
differences in average body-mass and life-span. When rel-
evant, the numbers of DADDs and standard animals at risk 
are estimated for specific age groups, or simply as number 
of doses (DADDs) used to treat one kg of animal divided 
with the total estimated biomass (in tonnes). 
DAPD is a statistical measure, providing a rough esti-
mate of the proportion (in thousands) of animals treated 
daily with an average maintenance dose of a particular 
antimicrobial agent. For example, 10 DAPDs indicate 
that an estimated 1% of the population, on average, 
receives a certain treatment on a given day. The DAPD is 
also referred to as the treatment proportion. 
In principle, the metric DAPD is parallel to the metric 
used in pharmaco-epidemiology for the human sector, 
Defined daily dose per 1,000 inhabitants per day (DID), 
see Section 9.2.3.
 
Due to a relative high number of pigs exported around 30 kg 
weight (32% of pigs produced in 2014, Table 3.1), an adjusted 
measure of consumption per pig was calculated. The adjust-
ment is based on the assumption that pigs exported at 30 kg, 
on average, received the same amount of antimicrobial agents 
before export, as other pigs from farrowing to 30 kg.
Antimicrobial use per pig produced (adjusted) = [DADDs 
+DADDw + (1+Q)*DADDf] / (biomass-days-total+ Nw* 
5800(kg*days)), where DADDs = amount of antimicrobial 
agents used in sows; DADDw = amount of antimicrobial agents 
used in weaners; DADDf = amount of antimicrobial agents 
used in finishers; Q is the proportion of weaning pigs exported 
around 30 kg. Nw = number of pigs exported at 30 kg body-
weight, and Nw*5800 is the number of biomass days the 
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exported pigs would have contributed to the live biomass if 
not exported.
9.2.2 Estimation of live biomass of animals
The estimation of live biomass and thus the number of stan-
dard animals at risk per day depends on the available data 
sources for each species. 
Pig production. The estimation was based on the number of 
pigs produced, including exports at different ages [Statistics 
Denmark; Danish Agriculture and Food Council], productivity 
data for each year [Danish Agriculture and Food Council] and 
census data for breeding animals [Statistics Denmark]. The 
average weight and life span for the growing animals (piglets, 
weaners and finishers) were estimated from the productivity 
number. The estimation methods were developed in coopera-
tion with Danish Agriculture and Food Council. There are no 
statistics on average weight of breeding animals available, so 
an estimated average weight had to be assumed. However, the 
size of the breeding animals has probably increased over the 
last decade, but this could not be accounted for.
Cattle production. The live biomass of the cattle population is 
estimated from census data [Statistics Denmark] and the aver-
age live weight of the different age groups. The Danish cattle 
population is mainly dairy, particularly Holstein Friesian, but 
also other breeds such as Jersey and a small population of beef 
cattle. Most of the cattle slaughtered are dairy cows and bull 
calves of dairy origin. The average live weight was estimated 
for 10 different age and gender categories.
Turkey production. The live biomass is estimated based on 
the number of turkeys produced [Statistics Denmark; Danish 
Agriculture and Food Council] and an average live weight at 
slaughter of 21 kg for male turkeys and 11 kg for hens after 
an estimated average life span of 20 weeks and 15.5 weeks, 
respectively [Danish Agro; S. Astrup, personal communication]. 
The estimated mean live biomass per turkey is assumed to be 
half of the weight at slaughter.
Fur animals. The live biomass of mink is estimated from 
production data [Statistics Denmark, Kopenhagen Fur] and the 
average weight at pelting was 2.45 kg [Kopenhagen Fur]. The 
progeny live for approximately 7 months. The biomass for the 
breeding animals (female) was estimated based on census 
data and an assumed average live weight of 2 kg.
Pet animals. Only dogs and cats are taken into account, as the 
other population sizes are negligible in Denmark, and relatively 
rare in veterinary practice. The population is based on census 
Textbox 9.1  Revised method for calculating the ADD in Vetstat 
When Vetstat was introduced in 2000, the Animal Daily Doses (ADDs) was calculated based on the approved Summary of Product 
Characteristics (SPC).  The intention was that products with the same active compound, same strength and same dispensing form 
should have the same ADD. For products with dose ranges, the ADD was calculated as the average value. In cases where different 
indications required different doses, the ADD was calculated on the basis of the most frequent indication. These principles are similar 
to those used for antimicrobial products used for humans. Most products for veterinary use were registered through a national proce-
dure, making it possible to apply the principles described above. Furthermore, the ADDs used in Vetstat had no legislative implication 
at the time.
In 2011, an increasing number of veterinary products were registered by the central registration procedure by the European Medi-
cines Agency (EMA). In some cases, registration is based in information from studies carried out in in the other European countries, 
where the average doses for same indication are somewhat higher than in Denmark. As a consequence of this, several products came 
on the Denmark market with approved ADDs that were double up compared to similar products already on the market, but approved 
through the national procedure. This issue was addressed in DANMAP 2012.
In 2010 the yellow card was introduced [DANMAP 2010], and as a consequence of this, the ADDs defined in Vetstat became of con-
siderable legislative importance. Therefore, it was unacceptable if products with the same active compound, strength and dispensing 
form had different ADDs in Vetstat.  Consequently, it was decided that Vetstat, by announcement, should be able to regulate ADD on 
its own and not necessarily follow the approved SPC (BKG nr. 178 af26/2 2014). 
The following shows the principles for calculating ADD (only for pig and cattle). The main points are as follows:
• Products with same active compound, same strength and same dispensing form  should have same ADD
• If a product is brought on the market with two or more different strengths, the ADDs for each  strength are calculated proportionally.
• If one or more products with same active compound and dispensing form are approved for two or more indications and with differ-
ent doses, the ADD will be calculated on basis of the indication for which it is more frequently used.
 
The next step will be a parallel ADD (DDDA) based on the active ingredient. The DDDA will at this stage be used only for calculation of 
number of doses used of every active ingredient. This will not affect the yellow card system.  
For further information: Erik Jakobsen (erja@fvst.dk)
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data [Statistics Denmark, 2000] estimating 650,000 cats 
and 550,000 dogs. The number of dogs in Denmark has been 
relatively stable during the last ten years [Danish Dog regis-
ter, 2012]. The average live weight for cats and dogs were 
estimated to 4 kg and 20 kg, respectively (based on pedigree 
registration data).
Aquaculture. The estimation is based on data from the Danish 
AgriFish Agency (NaturErhvervstyrelsen) on produced amounts 
in each subtype of production, and information on the typical 
lifespan and entrance and exit body weights, and were calcu-
lated in cooperation with Danish Aquaculture [NH Henriksen, 
Danish Aquaculture]. 
9.2.3 Data on antimicrobial consumption in humans
Data on consumption of antibacterial agents in humans were 
obtained from The Register of Medical the Department of Data 
Delivery and Medicinal Product Statistics, at Statens Serum In-
stitut. The Register receives monthly reporting of consumption 
from all pharmacies in Denmark, including hospital pharmacies. 
Data from the primary health care sector have been collected 
since 1994, whereas data on consumption in hospitals are 
available from 1997.
Only somatic hospitals were included, when the consumption 
was measured by occupied bed-days and admissions. Data 
from private hospitals and clinics, psychiatric hospitals, special-
ised non-acute care clinics, rehabilitation centres and hospices 
were excluded from DANMAP (representing approximately 
3% of the antimicrobial consumption at hospitals and of the 
number of bed-days).
In the primary health care in Denmark, all antibacterial agents 
for human use are prescription-only medicines and are sold 
by pharmacies in defined packages. Each package is uniquely 
identified by a code, which can be related to package size, con-
tent as number of unit doses (e.g. number of tablets), content 
as number of Defined Daily Doses (DDDs), code of the antimi-
crobial agent in the Anatomical Therapeutic Chemical (ATC) 
classification system, and producer. In addition, the following 
information is collected for each transaction: social security 
number (CPR number) of the patient, code identifying the pre-
scribing physician, date and pharmacy of the transaction, and 
information regarding reimbursement of cost, if applicable. For 
hospital data we have information of the type of department 
and hospital but no information on the individual consumption 
level.
Before 2012 data from hospitals on certain infusion substanc-
es was obtained directly from the hospital pharmacies. From 
2013 onwards all data from hospitals are reported to and de-
livered by The Register of Medicinal Product Statistics at SSI:
The present report includes data on the consumption of “anti-
infectives for systemic use”, or group J01, of the 2014 update 
of the ATC classification, in primary health care and in hospitals 
as well as consumption of per oral and rectal preparations of 
metronidazole (P01AB01) and oral preparations of vancomycin 
(A07AA09). As recommended by the World Health Organiza-
tion (WHO), consumption of antibacterial agents in primary 
health care is expressed as DIDs, i.e. the number of DDDs per 
1,000 inhabitants per day (DDD/1,000 inhabitant-days). Con-
sumption in primary health care is also reported as a number of 
packages per 1,000 inhabitants. Consumption of antibacterial 
agents in hospitals is expressed as DIDs, for comparison with 
primary health care, and DBDs, the number of DDDs per 100 
occupied beds per day (DDD/100 occupied bed-days).
Since antimicrobial consumption expressed as DDD/100 
occupied bed-days does not necessarily reflect changes in 
hospital activity and production, consumption in hospitals is 
also presented as DAD (the number of DDDs per 100 admitted 
patients).
The number of occupied bed-days is calculated as the date 
of discharge minus the date of admission (minimum one day), 
and the number of admissions is calculated as one admission 
whenever a patient is admitted to one specific ward (one 
patient can be registered as admitted multiple times if trans-
ferred between wards during one hospital stay). Data on the 
number of occupied bed-days (or patient-days) and number of 
admissions in each hospital were obtained from the National 
Patient Registry at the National Board of Health [www.sst.dk].
9.3. Collection of bacterial isolates
 
9.3.1 Animals
Samples from healthy pigs and cattle and broilers were col-
lected for the DANMAP programme at slaughter by meat 
inspection staff or abattoir personnel. 
Salmonella. DANMAP 2014 only includes Salmonella isolates 
from caecum samples originating from random sampling of 
healthy pigs. Samples were sent for examination at the Dan-
ish Veterinary and Food Administrations (DVFA) laboratory in 
Ringsted. Serotyping was performed at DTU National Food 
Institute. Data from previous years also include isolates from 
the national Salmonella surveillance programme where the 
results of a serological surveillance at the slaughterhouses and 
in all breeding herds appoint risk herds to be further examined 
by microbiological analysis of pen-faecal samples.
No Salmonella data from layers, broilers and cattle are present-
ed in DANMAP 2014 due to a low number of isolates available 
from the national surveillance. Further details on the sam-
pling procedures and the findings of the Danish surveillance 
programs are presented in the Annual Report on Zoonoses in 
Denmark, 2014 [www.food.dtu.dk].
Campylobacter, indicator E. coli and enterococci. For broil-
ers, caecal samples were collected at slaughter throughout 
2014, covering 99.8% of all broilers slaughtered in Denmark 
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(Sampling according to Commission decision 2013/652/EU). 
From each flock, four intact caeca were pooled and sent for 
examination at the DVFA laboratory (Campylobacter and E. coli) 
and DTU National Food Institute (Enterococcus). From broilers, 
isolates of Campylobacter jejuni, indicator E. coli and Entero-
coccus faecalis were collected. 
Random sampling of healthy pigs (same caecum samples as for 
Salmonella) and cattle (rectum samples) were collected once a 
month throughout 2014. The slaughter plants included in the 
DANMAP programme accounted for 99% and 95% of the total 
number of pig and cattle slaughtered in Denmark during 2014, 
respectively. The number of pigs and cattle samples from 
each slaughter plant was proportional to the annual number 
of animals slaughtered at the plant. Samples were sent for 
examination at DTU National Food Institute. Indicator E. coli 
and Enterococcus faecium were isolated from pigs, whereas 
Campylobacter jejuni and indicator E. coli were isolated from 
cattle. 
9.3.2 Meat
Salmonella. The Salmonella isolates from Danish pork origi-
nated from the national Salmonella surveillance programme 
(carcass swabs taken at the slaughterhouse after cooling). 
Samples were sent for examination at the Industry laborato-
ries. Serotyping was performed at DTU National Food Institute. 
No Salmonella data from broiler meat and beef, as well as 
imported meat are presented in DANMAP 2014 due to a low 
number of isolates available from the national surveillance and 
control programmes.
Campylobacter. The Campylobacter jejuni isolates origi-
nated from the national control program: Intensified control 
of Salmonella and Campylobacter in fresh meat based on a 
case-by-case risk assessment. Sampling was carried out by 
the regional DVFA officers, and included Danish and imported 
fresh broiler meat ready for retail, e.g. located in cold stores, 
slaughterhouses, cutting and processing facilities, but also at 
catering companies or at border control posts. The Samples 
were examined at the DVFA laboratory. 
Indicator E. coli and enterococci. Approximately a thousand 
meat samples were collected at wholesale and retail outlets 
in all regions of Denmark throughout 2014. Samples were 
collected by the DVFA Food Control Offices during routine 
inspection or on specific request for the DANMAP programme 
and examined at the DVFA laboratory. Indicator E. coli, Entero-
coccus faecium and Enterococcus faecalis were isolated from 
Danish and imported broiler meat, beef and pork. 
9.3.3 Humans
S. Typhimurium and C. jejuni. Antimicrobial susceptibility 
was performed on human faecal isolates submitted to Statens 
Serum Institut (SSI). Campylobacter isolates were submitted 
from Departments of Clinical Microbiology (DCM) covering three 
geographical regions: Northern Jutland, Funen and Zealand. In-
formation on travel history was obtained for the patients. Sal-
monella isolates were submitted from all DCM in Denmark. Exact 
figures of the proportion tested and the sampling strategy for 
the different species can be found in Sections 6.1 and 6.2. 
Staphylococcus aureus. All blood isolates were referred to 
the Staphylococcus reference laboratory at SSI on a volun-
tary basis. In November 2006, methicillin-resistant S. aureus 
(MRSA) became a notifiable disease in Denmark and it became 
mandatory to submit all MRSA isolates to the reference labora-
tory.
Invasive Streptococcus pneumoniae, Streptococcus 
pyogenes (group A streptococci), group B, C and G strep-
tococci. Invasive pneumococcal disease is a notifiable disease 
in Denmark, and therefore all invasive isolates nationwide are 
sent to SSI for identification or confirmation as well as suscep-
tibility testing and typing. Invasive group A, B, C and G strepto-
coccal isolates are referred to SSI on a voluntary basis. Tradi-
tionally, only isolates from blood and spinal fluid are included 
in the DANMAP report.
E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, 
E. faecium and E. faecalis. Data were provided on all clini-
cal isolates recorded from either blood samples (E. coli, K. 
pneumoniae, P. aeruginosa, E. faecium and E. faecalis) or urine 
samples (E. coli and K. pneumoniae) submitted for susceptibil-
ity testing to the DCM at the following hospitals: Rigshospi-
talet, Hvidovre, Herlev, Region Zealand, Odense, Esbjerg, Vejle, 
Herning/Viborg, Aarhus and Aalborg.
No samples were collected from healthy humans.
9.4 Isolation and identification of bacteria
 
9.4.1 Animals
Salmonella from pigs was isolated according to the open 
reference methods for detection in foods, faeces and materials 
from primary animal production using MSRV [NMKL No. 187, 
2007] or Annex D, ISO 6579 [ISO6579:2002/Amd 1:2007]. 
Serotyping of suspect colonies by slide agglutination accord-
ing to the White-Kauffmann-Le Minor Scheme in combination 
with “The molecular approach developed by CDC [Fitzgerald et 
al. 2007. J Clin Microbiol. 45:3323-34;  McQuiston et al. 2011. J 
Clin Microbiol. 49: 565–573] . Only one isolate per herd of each 
serotype was selected.
Campylobacter. For samples from broilers, isolation was 
performed according to the guidelines for microbiological 
examination of food [NMKL No. 119, 2007]. Identification was 
performed by microscopy and by oxidase activity, catalase activ-
ity and the ability to hydrolyse indoxyl acetate and hippurate. 
For samples from cattle, selective enrichment in Preston broth 
at a ratio of 1:10 incubated in microaerophilic atmosphere for 24 
h at 41.5°C was performed followed by inoculation of 10 µl of 
the enrichment broth onto mCCD agar and incubated as above. 
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Campylobacter-like colonies were verified by microscopy and 
species identification of C. jejuni was performed by a real-time 
PCR assay [Mayr et al. 2010. J Food Prot. 72(2):241-50]. Only 
one C. jejuni isolate per broiler flock or cattle herd was selected.
Indicator E. coli. The material from pigs and cattle was inocu-
lated directly onto Drigalski agar (SSI Diagnostica, Denmark) 
and incubated o/n at 37°C. Yellow colonies were inoculated 
onto BBL CHROM agar Orientation Medium (Becton Dickinson, 
Germany) and red colonies were collected as E. coli after o/n in-
cubation at 37°C. For broilers, four caecum samples was pooled 
and added 10 ml of BPW, stomached 30 sec. followed by 
streaking (1 µl) onto violet red bile (RVG) agar and incubated 
for 24 h at 44°C. Presumptive E. coli was identified using TBX 
agar incubated o/n at 44°C. Only one E. coli isolate per broiler 
flock, pig or cattle herd was selected.
Indicator enterococci. An adequate amount of material 
suspended in 2 ml of sodium chloride (0.9%) was inoculated 
on Slanetz Bartley agar and incubated two days at 42°C. Three 
colonies resembling typical E. faecalis were sub-cultivated on 
blood agar. E. faecalis were identified by motility- and arginine 
dihydrolase tests and the ability to ferment mannitol, sorbitol, 
arabinose and raffinose. Only one E. faecalis isolate per broiler 
flock or pig herd was selected.
9.4.2 Meat
Salmonella was isolated according to the open reference 
methods issued by the NMKL [NMKL No. 187, 2007 or NMKL 
No. 71, 1999], the ISO 6579:2002 or alternative methods 
validated against the reference method according to ISO 
16140:2001. Serotyping of for Salmonella isolates from 
animals. Only one isolate per positive swab sample of each 
serotype was included.  
Campylobacter was isolated according to the guidelines for 
microbiological examination of food [NMKL No. 119, 2007). 
Identification was performed by microscopy and by oxidase 
activity, catalase activity and the ability to hydrolyse indoxyl 
acetate and hippurate. Only one C. jejuni isolate per batch of 
fresh meat was selected.
Indicator E. coli was isolated by adding 5 g of the sample 
to 45 ml of MacConkey- or laurylsulphate-broth, which was 
incubated o/n at 44°C, subsequently streaked onto violet red 
bile agar and incubated for 24 h at 44°C. Presumptive E. coli 
was identified using TBX agar TBX agar incubated o/n at 44°C. 
Only one E. coli isolate per meat sample was selected.
Indicator enterococci were isolated by adding 5 g of the 
sample to 45 ml azide dextrose broth, incubated o/n at 44°C 
and subsequently streaked onto Slanetz-Bartley agar and 
incubated 48 h at 44°C. Colonies typically for E. faecium and 
E. faecalis were identified by a real-time PCR assay. Only one 
isolate of of E. faecium and E. faecalis per meat sample was 
selected.
9.4.3 Humans
Salmonella isolates were serotyped by slide agglutination 
according to the Kauffman-White Scheme.
Campylobacter. Species identification was performed using a 
species-specific PCR assay [Klena et al. 2004. J Clin Microbiol. 
42: 5549–5557].
Staphylococcus aureus. Species confirmation and typing was 
performed by sequencing of the S. aureus specific spa gene 
[Harmsen et al. 41: 5442–5448, J Clin Microbiol., 2003]. Spa 
-negative isolates were confirmed as S. aureus by MALDI-TOF. 
Based on the spa type and known association with MLST 
typing, each isolate was assigned to a clonal complex (CC). 
For MRSA isolates, presence of the mecA or mecC methicillin 
resistance genes was confirmed by PCR [Larsen et al. 2008. 
Clin Microbiol Infect. 14: 611–614; Stegger et al. 2012. Clin 
Microbiol Infect. 18: 395–400]. For all isolates, presence of 
lukF-PV gene (PVL) was demonstrated by PCR [Larsen et al. 
2008. Clin Microbiol Infect. 14: 611–614; Stegger et al. 2012. 
Clin Microbiol Infect. 18: 395–400].
Invasive Streptococcus pneumoniae. Serotype identifica-
tion of invasive S. pneumoniae was performed by latex agglu-
tination (ImmuLex™ Pneumotest Kit, SSI Diagnostica, Hillerød, 
Denmark) and further with factor specific antisera by the 
Neufeld Quellung test (SSI Diagnostica, Hillerød, Denmark).  
Invasive Streptococcus pyogenes (group A streptococci), 
group B, C and G streptococci. Identification of groups were 
performed by latex agglutination (Streptococcal Grouping 
Reagent, Oxoid, Roskilde, Denmark).
9.5 Susceptibility testing
 
Antimicrobial susceptibility testing of Salmonella, Campylo-
bacter, indicator E. coli, Enterococcus and Staphylococcus au-
reus was performed as microbroth dilution MIC with Sensititre 
(Trek Diagnostic Systems Ltd., East Grinstead, UK). Inoculation 
and incubation procedures were in accordance with the CLSI 
guidelines [Clinical and Laboratory Standards Institute, USA] 
and the European standard ISO 20776-1:2006. 
The relevant quality control strains were used:  Staphylococcus 
aureus ATCC 29213, Escherichia coli ATCC 25922, Pseudo-
monas aeruginosa ATCC 27853, Enterococcus faecalis ATCC 
29212 and Campylobacter jejuni ATCC 33560.
Isolates from animals were susceptibility tested partly at DTU 
National Food Institute (pigs - E. coli and E. faecalis; cattle – E. 
coli and Campylobacter; poultry - E. faecalis) and the DVFA 
laboratory (poultry – E. coli and Campylobacter). Isolates from 
meat were generally tested at the DVFA laboratory, except 
for Salmonella from the surveillance of fresh meat that were 
tested at DTU National Food Institute.  Isolates were stored at 
-80°C until susceptibility testing. MIC-testing at DTU National 
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Food Institute and the DVFA laboratory in Ringsted is accred-
ited by DANAK (the national body for accreditation).
Salmonella, Campylobacter and Staphylococcus aureus isolates 
of human origin were tested at SSI. 
Table 9.1 presents the interpretation of MIC-values used for 
any combination of bacteria and antimicrobial agent. Since 
2007, data are interpreted by EUCAST epidemiological cut-off 
values (ECOFFs) with a few exceptions described in Table 9.1. 
The corresponding clinical breakpoints validated by EUCAST 
are presented both in Table 9.1 and in the MIC-distribution 
tables to visualize the impact of the use of ECOFFs contra 
clinical breakpoints. In general, if ECOFFs were re-validated and 
changed by EUCAST during the past year, all data presented 
from previous years were interpreted using the changed 
ECOFFs. Data from susceptibility testing of Staphylococcus 
aureus were interpreted using EUCAST clinical breakpoints. 
All MIC-distributions are presented in the web annex at www.
danmap.org. Each of the tables provides information on the 
Table 9.1. Interpretation criteriae for MIC-testing by EUCAST epidemiological cut-off values (blue fields) and  
the corresponding EUCAST clinical breakpoints (white fields)  DANMAP 2014
Note: * indicates EUCAST epidemiological cut-off values (ECOFFs) and EUCAST clinical breakpoints. ECOFFS marked in orange indicate 
antimicrobial agent included in the new EU test panels, not present in the DANMAP test panel used in previous years. The following compounds 
are not included in the EU test panels for Salmonella and E. coli: apramycin, ceftiofur, florfenicol, neomycin, streptomycin and spectinomycin (new 
compounds are ceftazidime, meropenem and tigecycline); for Enterococcus:  kanamycin, penicillin, salinomycin and streptomycin (new compound 
is daptomycin); for Campylobacter:  chloramphenicol. In addition, azithromycin is included in the EU test panel for Salmonella and E. coli but are 
not included in the DANMAP 2014 as no EUCAST ECOFFs were available. 
a) In 2014, only the Salmonella isolates from Danish pork were tested for susceptibility to apramycin, ceftiofur, florfenicol, neomycin, 
streptomycin and spectinomycin. 
b) The EUCAST ECOFF (>2) for colistin was applied for S. Typhimurium and other serotypes, except for S. Enteritidis and S. Dublin where ECOFF >8 
was applied according to investigations presented in DANMAP 2011. 
c) No current EUCAST ECOFF is available for sulfamethoxazole, so the previous cutoff (>256) was maintained. 
d) The EUCAST ECOFF (>1) was not applied for quinupristin/dalfopristin (tradename synercid) according to investigations presented in DANMAP 2006.
Antimicrobial agent Salmonella (a) E. coli E. faecium E. faecalis C. jejuni  
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
Ampicillin >8* >8* >8* >8* >4* >8* >4* >8*
Apramycin >16 >16
Cefotaxime >0,5* >2* >0,25* >2*
Ceftazidime >2* >0,5*
Ceftiofur >2* >1*
Chloramphenicol >16* >8* >16* >8* >32* >32*
Ciprofloxacin >0,064* >0.064* >0,064* >1* >4* >4* >4* >4* >0,5* >0.5*
Colistin >2*/8(b) >2* >2* >2*
Daptomycin >4* >4*
Erythromycin >4* >4* >4* >4*
Florfenicol >16* >16*
Gentamicin >2* >4* >2* >4* >32* >32* >2*
Linezolid >4* >4* >4* >4*
Meropenem >0,125* >8* >0,125* >8*
Nalidixic acid >16* >16* >16*
Neomycin >4* >8*
Quinupristin/dalfopristin >4(d) >4*
Spectinomycin >64
Streptomycin >16*
Sulfonamide >256(c) >64*
Teicoplanin >2* >2* >2* >2*
Tetracycline >8* >8* >4* >0.5* >4* >0.5* >1* >2*
Tigecycline >1* >2* >1* >2* >0,25* >0,25*
Trimethoprim >2* >4* >2* >4*
Vancomycin >4* >4* >4* >4*
Trimethoprim
Vancomycin
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number of isolates, the applied interpretation of MIC-values 
and the estimated level of resistance and confidence intervals.
Multi-resistance was defined as resistance to three or more 
of the antimicrobial classes listed in Table 9.2. Isolates were 
considered fully sensitive if susceptible to all the antimicrobial 
agents included in the test panels. 
Invasive Streptococcus pneumoniae from humans. Screen-
ing for penicillin- and erythromycin-resistant  S. pneumoniae  
was performed with 1 μg oxacillin discs and 15 μg erythromy-
cin discs (Oxoid, Roskilde, Denmark),  respectively, on Müller-
Hinton agar (Müller-Hinton plate, 5% blood, 20 mg beta-NAD, 
SSI Diagnostica, Hillerød, Denmark). Penicillin and erythromycin 
MICs were determined using STP6F plate, Sensititre (Trek Di-
agnostic Systems Ltd., East Grinstead, UK) as recommended by 
the manufacturer. All breakpoints used were as defined by the 
EUCAST. Both fully and intermediary resistant isolates were 
defined as resistant. 
Invasive Streptococcus pyogenes (group A), group B, C 
and G streptococci from humans. Screening for penicillin-,  
erythromycin- and clindamycin-resistant streptococci was 
performed with 1 unit penicillin G discs, 15 μg erythromycin 
discs and 2µg clindamycin discs (Oxoid, Roskilde, Denmark), 
respectively, on Müller-Hinton agar (Müller-Hinton plate, 5% 
blood, 20 mg beta-NAD, SSI Diagnostica, Hillerød, Denmark). 
Isolates were simultaneously tested for inducible clindamycin 
resistance. Non-sensitive streptococci were tested further 
with the respective E-tests (Biomérieux), either benzylpenicil-
lin, erythromycin or clindamycin on Müller-Hinton agar. The 
breakpoints used were as defined by the EUCAST. Both fully 
and intermediary resistant isolates were defined as resistant.
E. coli, K. pneumoniae, invasive P. aeruginosa, invasive E. 
faecium and E. faecalis from humans. The DCM performed 
either disk (Oxoid, Basingstoke, UK) or tablet (Neo-Sensitabs®, 
A/S Rosco) diffusion susceptibility testing on a number of media. 
Since 2013, all DCM have used breakpoints defined by EUCAST.
Data on antimicrobial resistance from private hospitals and 
clinics and from psychiatric hospitals were excluded. All sub-
mitting laboratories participate in national and international 
quality assurance collaborations such as the United Kingdom 
National External Quality Assessment Schemes (NEQAS).
9.6 Data handling
 
9.6.1 Animals and meat
The results from the analysis of the bacteria isolated and the 
susceptibility were harmonised and validated using SAS, and 
the isolate-based data were stored in a database contain-
Table 9. 2. Definitions of antimicrobial classes for calculation of multi-resistance (MR) in zoonotic and indicator bacteria, DANMAP  
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the panel for the selected bacterial species   
a) An isolates is considered multi-resistant if  resistant to three or more of the eleven antimicrobial classes   
b) An isolates is considered multi-resistant if  resistant to three or more of the five antimicrobial classes   
c) An isolates is considered multi-resistant if  resistant to three or more of the ten antimicrobial classes    
IMPORTANT:  The following compounds are not included in the EU test panels for Salmonella and E. coli: apramycin, ceftiofur, florfenicol, 
neomycin, streptomycin and spectinomycin (new compounds are ceftazidime, meropenem and tigecycline); for Enterococcus:  kanamycin, penicillin, 
salinomycin and streptomycin (new compound is daptomycin); for Campylobacter:  chloramphenicol. In addition, azithromycin is included in the EU 
test panel for Salmonella and E. coli but are not included in the DANMAP 2014 as no EUCAST ECOFFs were available. Thus calculations of multi-
resistance and and fully sensitive isolates in 2014 is not comparable to results presented in previous years DANMAP reports.  
 
Antimicrobial classes Salmonella and E. coli(a) Campylobacter(b) Enterococcus(c)
Tetracyclins Tetracycline Tetracycline Tetracycline
Phenicols Chloramphenicol Chloramphenicol
Penicillins Ampicillin Ampicillin 
Cephalosporins Cefotaxime and/or  ceftazidime
Carbapenems Meropenem
Sulfonamides Sulfonamides  
Trimethoprim Trimethoprim  
Aminoglycosides I Gentamicin Gentamicin   Gentamicin 
Aminoglycosides II Streptomycin 
Quinolones Ciprofloxacin and/or nalidixic acid  Ciprofloxacin and/or nalidixic acid  Ciprofloxacin
Polymycins Colistin 
Macrolides Erythromycin Erythromycin
Glycopeptids Vancomycin and/or teicoplanin 
Oxazolidinones Linezolid
Glycylcyclines Tigecycline  Tigecycline 
Lipopeptide Daptomycin
DANMAP 2014
DANMAP 2014 106
9. MATERIALS AND METHODS
ing all antimicrobial resistance data used for DANMAP and/or 
reported to EFSA since 2007. The Oracle database (9i Enter-
prise Edition®) is maintained at DTU National Food Institute. 
The susceptibility data were stored as continuous values as 
well as categorised as susceptible or resistant as defined by 
the relevant ECOFF. Each animal isolate was identified by the 
bacterial species, the subtype as applicable and by the date 
of sampling and species of animal. Information on the farm of 
origin was also recorded when available. For each meat isolate, 
information was available on food type, bacterial species, date 
and place of sampling, date of examination and country of 
origin was recorded whenever possible. Identification numbers 
were also included, which makes it possible to obtain further 
information about the isolate from the relevant authorities or 
laboratories. 
All handling and evaluation of results were carried out using 
SAS®Software, SAS Enterprise Guide 6.1.
9.6.2 Human  
Salmonella and Campylobacter. Data on Salmonella and 
Campylobacter infections are stored in the Danish Registry 
of Enteric Pathogens (SQL database) maintained by SSI. This 
register includes only one isolate per patient within a window 
of six months and includes data on susceptibility testing of 
gastrointestinal pathogens.
Staphylococcus aureus. For MRSA, data on the characteristics 
of the isolates and the clinical/epidemiological information 
were obtained from the Danish MRSA register at SSI (manda-
tory reportable). Patients were registered, regardless of coloni-
sation or clinical infection, the first time they were diagnosed 
with MRSA or when a new subtype was demonstrated. Based 
on the reported information,  MRSA cases were classified as  
colonization/active  screening  (i.e. surveillance samples to de-
tect nasal, throat, gut or skin colonization), imported infection 
(i.e. acquired outside Denmark), infection acquired in a Danish 
hospital, defined as diagnosed >48 hours after hospitalisation 
with no sign of infection at admittance (HA-MRSA) or infection 
diagnosed outside hospitals (community onset).
MRSA cases with community onset were further classified 
according to risk factors during the previous 12 months as 
either health-care associated with community onset (HACO) or 
community-acquired (CA). Health-care associated risk factors 
included prior hospitalizations, stay in long-term care facilities 
and being a health-care worker. Community risk factors includ-
ed known MRSA-positive household members or other close 
contacts. Due to the increasing numbers of cases belonging to 
CC398, this type was treated separately as both epidemiology 
and relevant exposure are different from other CA cases.
Streptococcus pneumoniae, Streptococcus pyogenes 
(group A streptococci), group B, C and G streptococci. 
Data on susceptibility testing of isolates were stored as MICs 
in a Microsoft® Access database linked to a SQL server at SSI. 
Analysis including selection of isolates from blood and spinal 
fluid samples and removal of duplicate isolates was performed 
in Microsoft® Access.
E. coli, K. pneumoniae, invasive P. aeruginosa, invasive 
E. faecium and invasive E. faecalis. Ten out of eleven DCM 
in Denmark provided data on resistance levels in E. coli, K. 
pneumoniae, invasive P. aeruginosa, invasive E. faecium and 
invasive E. faecalis isolates. Data were extracted from the fol-
lowing laboratory information systems:
• ADBakt (Autonik AB, Skoldinge, Sweden) for the DCM at 
Hvidovre, Herlev and Aalborg Hospitals.
• MADS (DCM Skejby Hospital, Aarhus, Denmark) for the DCM 
at Rigshospitalet, Slagelse/Region Zealand, Odense, Esbjerg, 
Vejle, Herning/Viborg, and Aarhus (Skejby) Hospitals.
 
Resistance data on the first isolate per patient per year were 
included. Generally, resistance data were excluded if suscep-
tibility to a certain antimicrobial agent was tested on only a 
selected number of isolates.
9.6.3 Statistical tests
Significance tests of differences between proportions of 
resistant isolates were calculated using SAS®Software, SAS 
Enterprise Guide 6.1 or StatCalc in EpiInfo™ v. 6. Difference 
in pair-wise comparisons were tested using Chi-square, or 
Fisher’s Exact Test when the number of samples is low. When 
appropriate, significance of temporal trends is tested using 
linear logistic regression using Proc LOGISTC procedure in SAS 
(Likelihood ratio test).
In the text, commented differences imply statistically signifi-
cant differences where p<0.05.
When comparing proportions between years, the EUCAST 
epidemiological cut-off values for 2014 were also used for 
interpretation of previous years MICs.
Annette Nygaard Jensen, Birgitte Borck Høg, 
Helle Korsgaard and Ute Wolff Sönksen
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List of abbreviations
AGP Antimicrobial growth promoter
ATC Anatomical Therapeutic Chemical Classification System
ATCvet Anatomical Therapeutic Chemical Classification System for veterinary medicines
CA Community-acquired
CC Clonal complex
CDI Clostridium difficile infections
CHR Central Husbandry Register
CI Confidence interval
CNS Central nervous system
COHA Community onset hospital-acquired
CPE Carbapenemase producing Enterobacteriaceae
CPO Carbapenemase producing organisms
CPR Danish Civil Registry, register for social security numbers
DAD Defined Daily Doses per 100 admissions
DADD Defined animal daily dose
DAPD Defined animal daily dose per 1,000 animals per day
DBD Defined Daily Doses per 100 occupied bed-days
DCM Department of Clinical Microbiology
DDD  Defined Daily Dose
DID  Defined Daily Doses per 1,000 inhabitants per day (DDD/1000 inhabitant days)
DTU  Technical University of Denmark
DVFA Danish Veterinary and Food Administration
EARS-Net The European Antimicrobial Resistance Surveillance Network
ECDC European Centre for Disease Prevention and Control
EFSA European Food Safety Authority 
ESBL Extended spectrum beta-lactamase 
GI Gastrointestinal
GP General practitioner
HAI  Hospital-acquired infections
HAIBA Hospital-acquired infections database
HLGR High-level gentamicin resistance 
HOHA Hospital onset hospital-acquired
MIC Minimum inhibitory concentration 
MRSA Methicillin-resistant Staphylococcus aureus 
N Number of samples
n  Number of isolates tested for antimicrobial susceptibility
OIE World Organisation for Animal Health
RFCA Regional Veterinary and Food Control Authorities
SSI Statens Serum Institut
VASC Veterinary advisory service contracts 
VMP Veterinary medicinal products 
VetStat Danish Register of Veterinary Medicines
VRE Vancomycin resistant enterococci
WGS Whole genome sequencing
WHO  World Health Organization
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Glossary
Anatomical Therapeutic Chemical (ATC) classification. 
International classification system for drug consumption stud-
ies. The ATC code identifies the therapeutic ingredient(s) of 
each drug for human use according to the organ or system on 
which it acts and its chemical, pharmacological and therapeutic 
properties. Antibacterials for systemic use are known as ATC 
group J01. The ATC classification is maintained by the WHO 
Collaborating Centre for Drug Statistics and Methodology (Oslo, 
Norway) (www.whocc.no/atcddd/indexdatabase/).
The ATC classification for veterinary medicinal products,
ATCvet, is based on the same main principles as the ATC 
classification system for medicines for human use and is also 
maintained by the WHO Collaborating Centre for Drug
Statistics and Methodology (www.whocc.no/atcvet/database/).
Antibacterial agents. Synthetic (chemotherapeutics) or natu-
ral (antibiotics) substances that destroy bacteria or suppress 
bacterial growth or reproduction [Source: Dorland’s Illustrated 
Medical Dictionary]. Antimycobacterial agents are not included. 
In the section of human consumption, ‘antibacterial agents’ are 
referred to as ‘antimicrobial agents’ (see below).
Antimicrobial agents. The term ‘antimicrobial agents’ covers 
antibacterial, antiviral, coccidiostatic and antimycotic agents. In 
the section on veterinary consumption, the broad term
‘antimicrobial agents’ is usually used because coccidiostats are 
included. Antiviral substances are not used in veterinary medi-
cine, and antimycotics are only registered for topical veterinary 
use and used mainly in companion animals. Antimycobacterial 
agents are not included. The term ’antibacterial agents’ is only 
used in the veterinary section for precision, to distinguish from 
use of coccidiostats as feed additives (poultry only). In the 
section of human consumption, the term ‘antimicrobial agents’ 
refers to all antibacterial agents for systemic use (J01 in the 
ATC system).
Broiler. A type of chicken raised specifically for meat 
production. In Denmark, the average weight after slaughter is 
1.66 kg.
Central Husbandry Register (CHR). This is a register of all 
Danish farms defined as geographical sites housing produc-
tion animals. It contains information concerning ownership, 
farm size, animal species, age groups, number of animals and 
production type. Each farm has a unique farm identity number 
(CHR-number).
Defined animal daily dose (DADD). DADD is the average 
maintenance dose per day for a drug used for its main indica-
tion in the appropriate animal species. DADD has been specifi-
cally defined for use in DANMAP and does not always com-
pletely match the “prescribed daily dose” or the recommended 
dosage in the Summaries of Product Characteristics (SPC). In 
contrast to the ADD previously used in DANMAP, the DADD 
not has been defined for each antimicrobial agent, administra-
tion route and animal species but at product level. In DANMAP 
2012, the DADD replaces the ADD (as defined in VetStat), 
which has been used since DANMAP 2003. For more details, 
see Chapter 10, Materials and Methods. The DADDs used in 
DANMAP 2012 are presented the web annex.
DADD per 1,000 animals per day (DAPD). Trends in vet-
erinary consumption, both within and across species, are 
presented in DAPD, allowing for comparison between sectors 
and adjusting for changes in live biomass. The estimated live 
biomass is expressed as the number of standard animals with 
an estimated average weight and lifetime. This may also be 
referred to as the ‘standard-animals-at-risk’ and takes into 
account species differences in body-mass and life-span. DAPD 
is a statistical measure, providing an estimate of the propor-
tion of animals (in thousands) treated daily with a particular 
antimicrobial agent. For example, 10 DAPDs indicate that an 
estimated 1% of the population, on average, receives a certain 
treatment on a given day (Section 4.3 and Chapter 10, Materi-
als and Methods).
Defined Daily Dose (DDD). This is the assumed average 
maintenance dose per day for a drug used for its main indica-
tion in adults. It should be emphasised that the Defined Daily 
Dose is a unit of measurement and does not necessarily reflect 
the recommended or prescribed daily dose. DDDs provide a 
fixed unit of measurement independent of price and formula-
tion, enabling the assessment of trends in drug consumption 
and to perform comparisons between population groups. The 
DDDs are defined and revised yearly by the WHO Collaborating 
Centre for Drug Statistics and Methodology (www.whocc.no/ 
atcddd/indexdatabase).
DDD per 1,000 inhabitants per day (DID). Consumption in 
both primary health care, hospital care and the overall total 
consumption is presented in DID, allowing for comparison 
between sectors and for illustration of the consumption in 
hospital care without taking account of hospital activity (dis-
charges). Data presented in DID provide a rough estimate of 
the proportion of the population within a defined area treated 
daily with certain drugs. For example, 10 DIDs indicates that
1% of the population on average gets a certain treatment 
daily. In figure presented as DDD/1,000 inhabitant-days.
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ESBL. In the DANMAP report, ‘ESBL’ describes the clinically 
important acquired beta-lactamases with activity against 
extended-spectrum cephalosporins; including the classical 
class A ESBLs (CTX-M, SHV, TEM), the plasmid-mediated AmpC 
and OXA-ESBLs [Giske et al. 2009. J. Antimicrob. Chemother. 
63: 1-4].
Finishers. Pigs from 30-100 kg live weight from after the 
weaner stage to time of slaughter.
Fully sensitive. An isolate will be referred to as fully sensitive 
if susceptible to all antimicrobial agents included in the test 
panel for the specific bacteria.
Intramammaria. Antimicrobial agents for local application in 
the mammary gland (udder) to treat mastitis.
Layer. A hen raised to produce eggs for consumption.
Minimum inhibitory concentration (MIC). This is the lowest 
concentration of antimicrobial agent in a given culture medium, 
e.g. broth or agar, below which growth of the bacteria is not 
inhibited.
Multi-resistant. A Salmonella, Campylobacter, Enterococcus 
or E. coli isolate is assumed multi-resistant if it is resistant 
to three or more of the antimicrobial classes. The number of 
antimicrobial classes and antimicrobial agent included therein 
depend on the test panel for each bacterium (See Table 10.3, 
Materials and methods).
Pet animals. Dogs, cats, birds, mice, guinea pigs and more 
exotic species kept at home for pleasure, rather than one kept 
for work or food. Horses are not included as pet animals. The 
live biomasses of Danish pets used for estimating veterinary 
consumption only include dogs and cat.
Piglet. The newborn pig is called a piglet from birth till they 
are permanently separated from the sow at 3-4 weeks of age. 
The weight of the piglet at weaning is approximately 7 kg.
Poultry. The major production species are fowl - Gallus gallus 
(broilers, layers, including breeding and rearing) and turkey. 
Regarding antimicrobial consumption, ‘poultry’ also includes 
domesticated ducks, geese, game birds and pigeons.
Sow. Any breeding female pig on the farm.
Weaner. Any pig of 7–30 kg live weight after it has been 
weaned.
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